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ABSTRACT
Targeting the cerebrovasculature in sepsis: A focus on the brain microvascular
endothelium
Divine C. Nwafor
The blood-brain barrier (BBB) is a critical interface between the systemic circulation and
the brain. It is a specialized multicellular unit composed of brain microvascular endothelial cells
(BMECs), pericytes, a basement membrane, and astrocytic end foot processes. BMECs are a
principal component of the BBB that provide the structural framework needed for the stringent
transport of molecules into the brain. BMEC dysfunction permits the trafficking of neurotoxins
from systemic circulation into the brain, which ultimately exacerbates BBB dysfunction and
neuroinflammation. Studies have shown that BBB dysfunction is a key determinant of cognitive
decline in sepsis. However, there are critical knowledge gaps that exist in understanding the
molecular and cellular mechanisms underpinning BMEC physiology and function as it relates to
the maintenance of BBB integrity.
A strategy for bridging this critical knowledge gap requires an examination of proteins
and enzymes localized to BMECs. Tissue-nonspecific alkaline phosphatase (TNAP) has been
historically used as a brain endothelial histological marker due to its abundant expression on
BMECs. Yet, the role of TNAP in BMECs remains unclear. The objective of this project was to
understand the function of BMEC TNAP at the BBB in normal physiology and sepsis. Our
central hypothesis is that BMEC TNAP is critical for maintenance of BBB integrity in
normal physiology and in sepsis through molecular mechanisms that preserve BMEC
structure and function. The studies presented in this dissertation demonstrated a novel antiinflammatory role for TNAP in cerebral microvessels. We also demonstrated that BMEC TNAP
plays an important role in maintaining paracellular barrier integrity during systemic inflammation
via cytoskeletal reorganization. Importantly, our data elucidated a molecular target (Rho-

associated protein kinase) through which loss of TNAP activity in cerebral microvessel in sepsis
could be mitigated. Finally, we utilized the cre-lox system to generate a genetic mouse model
with an endothelial VE-cadherin conditional knockout of the Alpl gene (VE-cKO). We showed
that VE-cKO mice exhibited whole brain size selectively increased BBB permeability that is
worsened in sepsis and stroke.
Collectively, this body of work demonstrated that TNAP activity in cerebral microvessel is
important for maintaining BBB integrity. These findings lay the groundwork needed to stimulate
the discovery of a therapeutic target whose activity can be manipulated to mitigate long-term
neurological dysfunction in sepsis. Moreover, our results will impact not only sepsis but will
improve the quality of life and medical outcomes in other neurodegenerative and inflammatory
diseases such as stroke and Alzheimer’s disease (AD).
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Note: Parts of this chapter include text and figures taken from the publications highlighted
above

1

I. Background
Sepsis is a debilitating systemic inflammatory process involving multiple organ systems
that is preceded by an infection. It is the 10th leading cause of death in the United States with an
annual financial burden for patients and survivors that exceeds $20 billion [1, 2]. Through
mechanisms that remain largely poorly understood, sepsis can induce acute and chronic
changes in the central nervous system (CNS), particularly at the blood-brain barrier (BBB) [3]. A
compromised CNS can lead to sepsis-associated encephalopathy (SAE), a well-characterized
state of cognitive impairment and neurological dysfunction often seen in the acute phase of
sepsis. Multiple pathways have been investigated for their contribution to the sepsis-associated
compromise of the BBB. This chapter integrates current clinical knowledge of sepsis with
mechanistic insights from both clinical studies and preclinical animal models of sepsis. The
overall goal of this chapter is to demonstrate how sepsis pathophysiology perturbs the integral
function of cells and proteins that comprise the BBB. We provide insights to uncover how a
compromised BBB may lead to SAE or permanent brain dysfunction in sepsis survivors. Finally,
we discuss how tissue-nonspecific alkaline phosphatase (TNAP), an enzyme localized to brain
microvascular endothelial cells (BMECs), may play an important role in maintaining endothelial
barrier integrity.

II. Sepsis Pathophysiology
A. Clinical sepsis presentation
The most current definition from the Sepsis-3 consortium describes sepsis as a lifethreatening organ dysfunction caused by a dysregulated host response to an infection [4]. The
most common precipitating sites for sepsis are the respiratory system, genitourinary system,
and the abdomen [5, 6]. Sepsis may present as a combination of various non-descript signs and
symptoms making early diagnosis difficult. For example, patients may present with fever, chills,
pain, delirium, increased heart rate, shortness of breath, diarrhea, and/or low blood pressure.
2

The diagnosis and management of sepsis has changed dramatically over thirty years. The
historical definition of sepsis was focused primarily on inflammation and incorrectly portrayed
sepsis as a sequential process that eventually ends in septic shock (Fig 1A). In 2016, Sepsis-2
criteria were revised to current Sespis-3 criteria to improve consistency in classification in
epidemiological and clinical trials. The revised Sepsis-3 classification shown in Fig. 1B focuses
on accelerated recognition and management of sepsis [4].
In recent years the focus in clinical treatment has shifted to severe sepsis and septic
shock, which has increased survival in hospitalized patients diagnosed with severe sepsis and
critically ill patients with septic shock who have a higher risk of multi-organ failure complications
and death [5]. This heterogeneous presentation of clinical sepsis makes disease management
and appropriate therapeutic interventions difficult. Some challenges associated with the
management of sepsis include late diagnoses, poor prognoses, inadequate therapeutics, and
post-sepsis complications. These challenges stem from late recognition and difficulties
associated with differentiation of sepsis from other illnesses in its early stage. In the later stages
of sepsis, recognition becomes easier, yet sepsis is more difficult to treat and often coincides
with multi-organ failure [5, 7, 8].
Most sepsis cases are hospital-acquired. Hospital-acquired sepsis cases are often
comorbid with prior injury, such as stroke, trauma, or post-surgery. Most cases of hospitalacquired sepsis are treated in the intensive care unit (ICU). However, ICU heterogeneity can
make sepsis more common in one ICU versus another. For example, there is a higher incidence
of sepsis in a trauma ICU as opposed to a surgical ICU [5]. Alternatively, a significant number of
sepsis patients are admitted to the hospital or directly to the ICU via the Emergency Department
[9]; the majority of these patients present with community-acquired sepsis from pneumonia or
complications from other comorbid conditions such as diabetes [10, 11]. In addition to the
patient setting, the development of sepsis often depends on several risk factors, such as age
where a proportionate relationship exists between increasing age and sepsis acquisition [12,
3

13]. Male gender, non-Caucasian ethnicity, and pre-existing conditions such as Alzheimer’s
disease (AD), human immunodeficiency virus, or cancer are also risk factors for sepsis
acquisition [5, 13-15].

B. Current experimental animal models of sepsis
Understanding the mechanisms involved in the pathophysiology of sepsis requires the
use of animal models that adequately reproduce several features of the human disorder
including both inflammation and infection. The most common animal models are: cecal ligation
and puncture (CLP), the colon ascendens stent peritonitis model (CASP), endotoxin injection,
and bacterial infusion [16]. The CLP model is regarded as the gold standard for human-like
sepsis progression in animal models [17]. Execution of this model necessitates leakage of
polymicrobial feces into the peritoneum after the cecum is punctured with a needle. Animals
typically show decreased cerebrovascular blood flow post-CLP surgery and disease severity is
modeled by controlling needle size and number of punctures (Fig. 2); however, a major
limitation of this model is the failure to maintain continuous fecal leakage due to abscess
formation and necrosis of the punctured bowel. Some investigators also administer antibiotics
either at the time of injury or at intervals post-injury. Although antibiotic administration is an
additional feature which mimics the treatment regimen in human patients, the use of different
antibiotic classes and dosing paradigms across laboratories may confound the interpretation of
findings when results are compared between laboratories [16, 18]. The CASP model is a newer
model recently introduced to counter the flaws of the CLP model [16, 19]. This model involves
the insertion of a stent at the ascending portion of the colon, allowing continual leakage of feces
into the peritoneum [16, 20]. Despite the resemblance to human-like sepsis progression, the
drawbacks to this model include animal variation in colon size, fecal content, and the volume of
feces that leaks into the peritoneum [16, 21]. Although these two models have provided
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remarkable insights to understanding the pathophysiology of sepsis, they fail to fully recapitulate
the comprehensive clinical progression of sepsis in humans [16].
Two alternative sepsis models involve injection or infusion of endotoxin or bacteria. The
endotoxin model typically involves injection of lipopolysaccharide (LPS) endotoxin, a component
of gram-negative bacterial cell walls which signals most commonly through toll-like receptor-4
(TLR4). Administration of LPS via different routes (i.e., intraperitoneal, intravenous, or
intracerebroventricular) initiates a cytokine storm that results in the release of tumor necrosis
factor alpha (TNF-a) and numerous Interleukins (IL-1, -6, and -10). Injection of LPS mimics
many classical signs and symptoms of sepsis-induced inflammation, thereby providing a basic
understanding of how inflammation activates the immune response in sepsis [16, 22]. One
major limitation of the LPS model is the lack of integration of the infection component. A second
limitation is that very large endotoxin doses are required in many rodent models to mimic the
pathological profile of the clinical sepsis picture observed in humans [23]. Bacterial injection is a
less widely used model involving infusion of a bacteria (usually Escherichia coli or
Staphylococcus aureus) to initiate both inflammation and infection [16, 24, 25]. Different
bacterial strains used for infection present a challenge in this model, as they will produce
different patterns of sepsis progression [26]. Thus, the characteristics of the sepsis model must
be considered when interpreting the effects of sepsis on the CNS and other organ systems. The
CLP model was utilized for a majority of the experiments discussed in this dissertation.

C. The CNS in sepsis: sickness behavior and sepsis-associated encephalopathy (SAE)
A critical role for the CNS in the pathophysiology of sepsis has emerged over the past
two decades. Several recent reviews address this topic in excellent detail [13, 27-30]. One
important contribution of the CNS is “sickness behavior”. Sickness behavior is a response seen
in sepsis characterized by fever, adaptive behavioral changes, and neuroimmune changes [31].
The response is governed primarily by systemic interactions with the vagus nerve (VN) and
5

circumventricular organs (CVOs). The VN is an important mediator of inflammation. Septic mice
that underwent a vagotomy (VGX) surgery exhibited an increase in the synthesis of
inflammatory cytokines compared to sepsis only mice [27, 32-34]. In contrast, stimulation of the
VN in septic animals resulted in an overall reduction in the synthesis of inflammatory cytokines,
leukocyte recruitment, and endothelial activation [34-36]. The VN also relays peripheral
information to the medullary autonomic nuclei while the CVOs allow passage of inflammatory
mediators, primarily cytokines, from the peripheral circulation into the brain parenchyma. These
inflammatory mediators activate the nucleus tractus solitarii (NTS) and locus coeruleus [37].
Activation of these brainstem areas relay signals to autonomic nuclei, behavioral, and
neuroendocrine centers [38, 39]. The summative effect can be observed as depression, social
withdrawal, increased heart rate, poor blood pressure control, or altered vigilance [18].
In addition to sickness behavior, patients with acute sepsis may have changes in brain
function that present as delirium, seizures, psychological disorders, abnormal motor
movements, and increased mortality [38, 40]. Changes in brain function are most commonly
manifested as delirium. While sepsis-associated delirium usually presents as decreased activity,
a hyperactive form associated with agitation may be seen in some patients [38]. Tools that can
be utilized to confirm sepsis-associated delirium include medical history, blood chemistry,
electrolyte balance, the ICU screening checklist, Confusion Assessment Method, and Glasgow
Coma Scale [38, 41]. Sickness behavior and/or delirium may progress to a more severe
phenotype, sepsis associated encephalopathy (SAE), which is regarded as a diagnosis of
exclusion [42]. It is characterized by impaired consciousness, seizures, delirium, coma, focal
cognitive deficits and alterations in electroencephalogram [43] patterns [44]. Patients with SAE
have increased mortality, long-term neurological decline, memory lapse, inattentiveness,
disorientation, and verbal difficulties [45].
Alterations in EEG wave patterns often predict SAE outcome, and EEG reactivity is
associated with mortality even at one-year post-severe sepsis [44, 46]. For example, a recent
6

study showed resting-state EEG changes in sepsis survivors at 6-24 months after hospital
discharge, including increased delta and sigma activity compared to control patients [47].
Changes in EEG frequencies can be associated with changes in brain function. For example,
slowing alpha activity with increased theta activity reflects cortical dysfunction and can occur in
patients with mild to moderate encephalopathy. Slowing of delta activity is often associated with
more severe neurocognitive decline and indicates impaired function in deeper brain structures,
such as the basal ganglia [44]. While evaluation of EEG can be sensitive for SAE diagnosis in
the absence of neurological examination abnormalities, it has poor specificity and can be
hampered by sedation and analgesia [45, 48].
Ischemia is another common complication of early sepsis due to drastic changes in
systemic blood pressure [40]. A number of human clinical studies support the premise of
decreased cerebral blood flow (CBF) in acute sepsis [49-52]. The abrupt change in blood
pressure with added sepsis-associated coagulopathy causes reduced blood flow to neurons.
The hippocampal region and watershed areas are affected more often than other brain regions
when this occurs. Autopsies in patients who died from septic shock revealed consistent
ischemic and hypoxic insults in areas particularly susceptible to low blood flow (e.g. amygdala,
frontal junctional cortex etc.) and in autonomic centers [53]. Furthermore, the autopsies of seven
delirious ICU patients in another study revealed pathological lesions in the hippocampus,
striatum, and pons triggered by ischemia or hypoxia [54]. The presence of ischemia in postmortem studies strongly suggest that vascular irregularities and alterations of CBF occur during
sepsis. Importantly, multiple clinical observations support the concept that, in the absence of
cerebrovascular occlusion (i.e., stroke), impaired cerebral autoregulation and hypotension may
be the primary drivers of tissue hypoxia and cerebral ischemia observed in sepsis patients [5557].
A recent study in rats conducted by Towner et al. showed that CBF in the thalamus and
cortex is significantly increased 24 hours post-LPS injection but significantly reduced six weeks
7

post-LPS injection when compared to saline controls [58]. Preceding human clinical studies also
support the decrease in CBF at 24 hours observed by Towner and colleagues, yet there
remains a paucity of literature on how sepsis may affect long-term CBF in human patients.
Overall, coincident alterations in cerebral blood and cardiovascular collapse in sepsis
emphasize the importance of fluid resuscitation as a crucial component of sepsis management.
The ideal type of fluid (colloid versus crystalloids) and ideal composition used to treat septic
patients remains controversial. Three clinical trials demonstrated that colloid use in sepsis
treatment failed to show a clear benefit [59-61]. In addition to the findings from this study, the
restricted accessibility, safety issues, and the expense of colloids shifted the debate towards
identifying the ideal crystalloid composition (e.g. Ringer’s lactate, Ringer acetate etc.) [62]. We
refer the reader to excellent reviews regarding optimal fluid therapeutic strategies in sepsis [6264].
The utilization of magnetic resonance imaging (MRI) in the diagnosis of SAE offers a
unique opportunity in capturing some of the morphologic, ischemic, and metabolic alterations
associated with sepsis. A summary of MRI findings in acute sepsis is shown in Table 1. In
particular, diffusion weighted imaging (DWI) and the apparent diffusion coefficient (ADC) are
two MRI modalities currently used in assessing BBB breakdown caused by vasogenic
(extracellular) or cytotoxic (intracellular) edema [65]. Cytotoxic edema typically caused by
ischemia, hypoxia, or vasogenic edema is the most consistently reported MRI change
associated with SAE [65-68]. Early detection of BBB breakdown by gadolinium (Gd) could
establish an adequate therapeutic window for current and future septic treatments, but human
studies are limited [69-71]. A recent study in rats revealed a significant increase in the infiltration
of Gd in the cortex, hippocampus, and thalamus 24 hours and 1-week post LPS injection [58].
Gd use may also cause a substantial risk of nephrogenic systemic fibrosis, a risk factor which
suggests that Gd-based imaging in the CNS should be evaluated on a case-by-case basis.
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Sedatives are often administered in the ICU when treating sepsis. A study conducted by
Qiao and colleagues in rats showed that the application dexmedetomidine and midazolam
improved survival, and reduced cytokine levels and splenic apoptosis in septic mice [72]. A
systematic review by Zamani et al. emphasized the importance of the kind of sedative used in
treating sepsis; the findings from this study revealed that dexmedetomidine improved short term
mortality when compared to other sedatives [73]. It is widely thought that the neuroprotective
effects of dexmedetomidine result from neuronal death prevention, suppression of inflammatory
cytokines, and the modulation of neurotransmitters released in the sympathetic nervous system
[73-76]. However, a limitation noted by Zamani et al. was the small sample size included in the
clinical studies. It is important to note that the tools used in the confirmation of sepsisassociated delirium are not helpful in ICU-sedated patients who may otherwise exhibit signs of
delirium [42].
Sepsis also affects long-term neurological outcomes. The greatest risk factor for longterm impairment is the duration of delirium in the acute phase of sepsis and the increased
ventricular to brain ratio as calculated by MRI [38, 40, 77, 78]. A seminal study published by
Iwashyna and colleagues suggested that up to 70% of sepsis survivors may exhibit lasting
neurological impairment, including alterations in mood, cognition, and motor function [79].
Cognitive, motor, and mood impairments are three of the most common long-term neurological
outcomes in septic patients [40]. Current evidence also suggests an increased susceptibility to
other neurodegenerative disorders such as stroke or AD post-sepsis insult [80]. Thus, patient
populations that are the most vulnerable to long-term neurologic decline post-sepsis are the
elderly and patients with preexisting neurodegenerative diseases [12, 13, 38, 80]. The
consequences of sepsis on both acute and chronic neurological outcomes demonstrates a
critical need to understand the mechanisms involved in SAE development. Harnessing this
knowledge will provide essential therapeutic avenues to limit SAE progression and protect
against long-term neurological impairment or dysfunction.
9

III. Mechanisms of Blood-Brain Barrier Dysfunction in Sepsis
A. Blood-brain barrier overview
This section will provide a brief overview of the cell biology and physiology of the BBB.
The BBB and other associated cell types within the neurovascular unit (NVU) are shown in
Figure 3 [38, 81]. The BBB is a highly-selective, dynamic, and semipermeable biological
interface between the brain parenchyma and cerebral circulation. Preservation of BBB integrity
protects normal brain function and is dependent on maintaining a precise cerebral homeostasis
driven, in large part, by ion and gas concentrations and nutrient availability. The BBB’s unique
structure is comprised of endothelial cells, astrocytes, pericytes, and a basal lamina. The
endothelial cells are joined by tight junctions (TJs), and surrounding pericytes and astrocytes,
which associate with the basal lamina to protect the brain parenchyma. Endothelial cells are
sealed or joined together by TJs which are comprised of occludin, claudin, and cadherin
proteins. Because paracellular movement of compounds around and between endothelial cells
is highly restricted, active transport is required to move polar solutes and nutrients across the
BBB into the brain parenchyma [82]. However, water, small gases, and small- to moderatelysized lipid-soluble compounds can enter the brain passively [83, 84].
Primary efflux transporters include permeability glycoprotein (P-gp) and breast cancer
resistance protein (BCRP), which actively pump compounds out of the brain and back into
circulation [82]. Often, these transporters further restrict the permeability of compounds and
drugs which may otherwise have the molecular characteristics to passively cross the BBB [85].
The concept of the NVU emphasizes the continual crosstalk and interactions between the BBB,
other resident CNS cells such as neurons, microglia, and oligodendrocytes, and peripheral
immune cells. The BBB-NVU crosstalk also forms a network in which all cells are under
constant surveillance and adapt their behavior in both healthy and disease states [86]. Readers
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are referred to these excellent in-depth reviews about the function and structure of the BBB and
NVU [83, 86-88].

B. Neuroinflammation, immune cell infiltration, and BBB permeability post-sepsis: A focus brain
microvascular endothelial cells (BMECs)
BMECs are a principal component of the BBB that provide the structural framework
needed for the stringent transportation of molecules into the brain, and maintenance of precise
cerebral homeostasis. A probable starting point of sepsis-induced brain dysfunction is the
initiation of brain endothelial cell damage followed by chronic neuroinflammation, but the
mechanism by which this occurs is not well understood [51]. Neuroinflammation is a response to
CNS disruption or dysfunction and it is typically found in many neurological disorders [89].
Current literature suggests neuroinflammation in sepsis begins when immune cells recognize
foreign pathogen associated molecular patterns (PAMPs) such as LPS, flagellin, fimbriae,
peptidoglycan, heat shock proteins, and DNA fragments, which are encoded as ‘danger signals’
to the host. Recognition of PAMPs causes release of pro-inflammatory cytokines in the
periphery [90]. Inflammatory mediators may enter the brain by numerous mechanisms that
include: transcellular diffusion, solute carrier proteins, receptor-mediated transcytosis, and
adsorptive transcytosis [91]. Many cytokines enter the brain through receptor-mediated
endocytosis on brain endothelial cells. For example, during inflammation TNF-a is upregulated
and its transportation from blood to brain parenchyma is increased, primarily through receptormediated endocytosis of its receptors, tumor necrosis factor receptor 1 (TNFR1) and tumor
necrosis factor receptor 2 (TNFR2) [92, 93]. Molecules originating in peripheral or CNS tissues
may activate the brain vascular endothelium and various leukocytes to produce hormones that
facilitate their entry into the brain. For example, Nishijima and colleagues observed that
prostaglandin E2 (PGE2) enhanced transport of serum insulin-like growth factor 1 across the
BBB [94].
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Cytokine production contributes to neuronal dysfunction in sepsis in addition to many
other neurological disorders. Cytokine infiltration enhances activation of brain endothelial cells
and microglia, which ultimately leads to loss of neuronal function. Activation of the brain
endothelium leads to enhanced activity of the coagulation cascade, microthrombi formation, and
ischemia, which, in turn, promotes increased BBB permeability, leukocyte infiltration and
neuroinflammation. This process triggers neuronal damage, apoptosis, and brain edema [95,
96]. Cytokine-mediated microglial activation occurs simultaneously with brain endothelial cell
activation. Although the normal microglial response is to phagocytose injured neuronal cells and
clear debris, sustained and dysregulated microglial activation is highly detrimental to specific
regions of the CNS. Thus, persistent microglial activation enhances the production of
inflammatory cytokines and reactive oxygen species (ROS), which perpetuates a vicious cycle
of increased BBB permeability coupled with neuronal damage and apoptosis [92, 95].
Collectively, neuronal apoptosis and microglial activation are two primary mechanisms that
increase the activity of inducible nitric oxide synthase (iNOS) activity and generation of nitric
oxide (NO). Neuronal apoptosis is further exacerbated due to neuron sensitivity from increased
levels of NO produced by activated microglia [97, 98]. Intriguingly, iNOS levels are elevated in
sepsis and are highest in deceased septic patients [99]. This increased iNOS activity could also
be responsible for the cardiovascular collapse seen in sepsis [53, 93, 99]. It is likely that this
cardiovascular collapse also affects the cerebral microcirculation and leads to subsequent
sepsis-associated brain dysfunction.
At the onset of inflammation, peripheral leukocytes migrate through the tightly regulated
BBB and enter myriad areas of the CNS including but not restricted to CSF, CP, meninges,
perivascular spaces, and eventually into cerebral parenchymal tissues [89]. Transcellular
migration of leukocytes across the BBB during inflammation is a multi-step process. These
steps are: (i) rolling: weak adhesions between brain endothelial cell selectins and leukocytes
(e.g. neutrophils, monocytes, macrophages etc.); (ii) activation: G-coupled receptor activation
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on leukocytes via chemokines results in an increased expression of adhesion molecules of their
cell surfaces; (iii) arrest: interactions between adhesion molecules on the brain endothelial cells
and adhesion molecules on leukocytes; (iv) crawling: preferred site for transmigration is sought
out by the leukocyte as it crawls along the brain endothelial cells; (v) transmigration: crossing of
the leukocytes in between adjacent brain endothelial cells and into the brain parenchyma [100].
This multi-step process of leukocyte migration has been implicated in many neurological
diseases like multiple sclerosis (MS), stroke, and life-threatening infections like sepsis [100102].
The infiltration of immune cells from the periphery into the brain is a central indication
that other components of the brain endothelial cell (TJ proteins, actin cytoskeleton etc.) may be
dysfunctional depending on the disease context. Loss of BBB integrity is well documented in
neuropathologies like the MS and stroke [103]. Rochfort et al. and others have shown reduced
expression of TJ proteins (occludin and claudin-5) and an upregulation of metalloproteinases
(MMPs) in human brain microvascular endothelial cells after treatment with the serum of MS
patients [104-107]. Furthermore, the reorganization of brain endothelium actin cytoskeleton via
pro-inflammatory cytokines in MS patients contributes to the decreased expression of TJ
proteins [108, 109]. Likewise, oxidative stress on brain endothelial cells during the ischemic and
reperfusion phases in stroke may also cause BBB dysfunction. Stroke oxygen-glucose
deprivation in vitro and in vivo middle cerebral artery occlusion (MCAO) experiments conducted
by Liu et al. showed that brain endothelial TJ proteins are decreased and redistributed
alongside an associated increase MMP-2 [110].
Sepsis, particularly Gram-negative sepsis, has been shown to upregulate caveolin-1 in
brain endothelial cells [111]. Increased caveolin-1 has recently been shown to increase the
amount of peripheral immune infiltration into the brain [112]. The mechanisms by which this
occurs are not completely understood, but new preclinical studies have shed light on some
prevailing theories. Wu and colleagues found that caveolin-1 facilitates T-cell trafficking into the
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CNS via brain endothelial cell increased expression of intercellular adhesion molecule-1 (ICAM1) [113]. Caveolin-1 causes acid sphingomyelinase to interact with ICAM-1 increasing the
binding affinity for peripheral immune cells [114]. Once activated, ICAM-1 facilitates peripheral
immune cell diapedesis into the brain. This process occurs via Src phosphorylation in brain
endothelial cells and a subsequent conformational change to ICAM-1, which directly induces
transcellular migration [115]. During sepsis, this entire process is enhanced. After entering the
brain, T-cells are recruited towards damaged glia via cytokine release. Recent evidence
suggests that IL-17A aids this migration process [116]. Additionally, T-cells are helped by
astrocytes to re-cross the leaky BBB and carry information about the status of the brain to the
rest of the body [117]. It is postulated that peripheral immune cells also release cytokines that
maintain the leakiness of the BBB as they exit the brain. When and how long this cross-talk
between microglia and peripheral immune cells persist remains to be elucidated. The feedback
loop, however, has been implemented in non-autonomous neuronal death [118].
Future studies are warranted to further characterize the brain/immune communication
network and, in particular, where the peripheral immune cells ultimately reside after exiting the
brain. Collectively, these mechanisms represent the complicated and multi-factorial
mechanisms of sepsis at the level of the BBB. More importantly these studies emphasize a role
for BMECs as a therapeutic target to treat many neurological conditions. An integrated overview
of the brain and peripheral mechanisms found in sepsis is shown in Figure 4.

IV: A Putative Role Tissue-nonspecific Alkaline Phosphatase (TNAP) in BMECs
The identification of unexplored membrane proteins may be key to better understanding
the specific barrier functions of the BBB in disease states such as sepsis. In turn, this
knowledge may provide novel therapeutic targets for intervention. One potential therapeutic
target localized primarily to the surface of brain endothelial cells is the non-specific isoform of
alkaline phosphatase (AP), also known as TNAP. Tissue-nonspecific alkaline phosphatase
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(TNAP) is one of many proteins localized to BMECs, and is highly abundant in human and
rodent cerebral microvessels [119]. There are four alkaline phosphatase (AP) isoenzymes and
they include: TNAP, germ cell alkaline phosphatase (GCAP), intestinal alkaline phosphatase
(IAP), and placental alkaline phosphatase [120]. TNAP is expressed in bone, liver, intestine,
kidney, and brain while the other three AP isoenzymes are expressed in the tissues which they
are aptly named after [121].
TNAP is bound to the plasma membranes of cells via a glycosylphosphatidylinositol
(GPI) moiety, and functions as an ectoenzyme [122-124]. Known substrates for TNAP under
healthy conditions include: inorganic pyrophosphates (PPi), vitamin B6, adenosine triphosphate
(ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), and
phosphoethanolamine (PEA) [125, 126]. A role for TNAP in bone is well documented from
earlier studies showing that defective TNAP activity in bone led to hypophosphatasia in humans
and rodents [127-129]. The observed defect in TNAP function demonstrates a role for TNAP in
skeletal mineralization, and resulted from an accumulation of PPi and osteopontin (OPN) which
blocks hydroxyapatite crystal formation – a key inorganic constituent required for bone formation
[130, 131]. Furthermore, patients who demonstrated clinical hypophosphatasia also presented
with seizures [132]. Later studies, revealed that the seizures resulted from failure to transport
vitamin B6 across the BBB. TNAP’s inability to hydrolyze vitamin B6 in the periphery decreased
the availability of pyridoxal, a hydrolyzed form of vitamin B6 which is able to cross the BBB but
not vitamin B6; thus, this creates a deficiency of vitamin B6 in the brain which is important for
synthesis of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter [133, 134].
Despite the presumed role of TNAP in peripheral and CNS health from these elegant studies,
it’s role in cerebral microvessels remained vastly unexplored.
There are two different TNAP isoforms, so-called bone and liver TNAP isoforms. The
bone-type TNAP transcript is expressed in the BMECs of human and mouse [135]. During
development, mouse TNAP activity in cerebral microvessels is delayed and not seen until post15

natal day 10 compared to rat and primate TNAP activity which is seen as early as embryonic
day 15 [135], and at 28 weeks of gestation in humans [136]. Also, TNAP enzymatic activity in
the brain parenchyma compared to cerebral microvessels differs from one species to another.
For example, TNAP activity is weaker in the brain parenchyma compared to cerebral
microvessels in humans, monkeys, rodents, guinea pigs, and cats [137-140]; however, in
rabbits, frogs, and chickens, TNAP activity is stronger in the brain parenchyma but weaker in
cerebral microvessels [137, 141]. Furthermore, differences between TNAP activity expression in
peripheral vessels compared to cerebral microvessels have been elucidated. A comparative
study assessing the expression of TNAP in BMECs compared to peripheral endothelial cells
from the aorta showed that BMECs express a significant amount of TNAP activity compared to
peripheral endothelial cells [142]. In addition, Vorbrodt et al. showed that TNAP in the
endothelial cells of the liver sinusoids was absent, however, skeletal endothelial cells revealed a
strong TNAP activity that was discontinuous or irregularly scattered across the plasma
membrane compared to brain endothelial cells which showed a continuous and uniform layer of
strong TNAP expression [143]. Such species-to-species or cell developmental differences need
to be taken into account when elucidating the function of BMEC TNAP in animal models prior to
translating these findings to human BMEC TNAP function. Despite the high expression of TNAP
on cerebral microvessels, the role of TNAP in the brain microvascular endothelium remained
unclear. This dissertation aims to demonstrate a role for TNAP in maintaining barrier integrity in
health and in sepsis.

V. Models and Tools to Study TNAP: Advantages and Disadvantages
One of the many challenges to elucidating the role of TNAP in health and disease has
been the creation of appropriate pharmacological and genetic tools. Although TNAP is present
in all mammals and most tissues, its gene (ALPL in humans, Alpl or Akp2 in mice) transcription
varies slightly [135]. In the first of its 12 exons, the 5’-untranslated region (UTR) contains either
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exon 1A or 1B by alternative transcription initiation [144]. Exon 1A is preferentially driven in
osteoblasts, while exon 1B is more often initiated by the liver and kidney [145-147]. Using
marmosets, brain TNAP has been shown to use the same promotor as bone, however exon 1B
is preferentially transcribed by mouse neurons [135]. TNAP activity is also important during
mouse embryo development; it is the predominant AP expressed in 7 to 14 day-old embryos
and primordial germ cells [148]. As of January 2021, there are 411 mutations reported in the
ALPL gene mutations database (http://alplmutationdatabase.hypophosphatasie.com/), the
majority of which are pathogenic. Dramatic depletion of TNAP activity, clinically referred to as
hypophosphatasia (HPP), results in neurological symptoms, including epilepsy [130, 133, 149].
Conversely, abnormally high levels of TNAP activity can also result in seizures and neurological
dysfunction [150-152]. This presents an interesting dynamic where TNAP activity levels must be
sustained within a certain range in order to maintain homeostasis.

A. TNAP mouse models
A recent review describes several models for HPP where the TNAP gene is either
genetically or chemically depleted [153]. Readers are referred to this review which covers indepth genetically modified mice for evaluation of TNAP function [154]. TNAP knock-out (Alpl-/-)
mice life expectancy is short, averaging 3-5 weeks [133, 155]; therefore, they cannot be used
for adult studies of HPP or to elucidate the function of TNAP in brain microvessels. Some
researchers opt to use adult heterozygous transgenic mice (Alpl+/-) to explore the consequences
of reduced TNAP activity [156-158]. Injection of a recombinant mineral-targeted TNAP lentivirus
into neonatal mice has been shown to increase AP levels up to 60 days and reduces
craniosynostosis [159, 160]. Due to the wide expression of TNAP in various cell types, TNAPexpressing cells can also be targeted using the Cre-Lox system. For example, using mice with
tamoxifen-inducible inactivation of transforming growth factor ß (TGF-ß) in TNAP-expressing
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cells (Tnapcre; Tgfßr2fl/fl), researchers have shown that TNAP mitigates TGF-ß-dependent
cardiac and skeletal muscle fibrosis through inactivation of SMAD2/3 transcription factors [161].
Conditional TNAP overexpression has been achieved using an HprtALPL knock-in mouse,
which is described in [162]. Briefly, this model contains a floxed “stop cassette” and human
ALPL cDNA is inserted into the hypoxanthine phosphoribosyltransferase (Hprt) locus on the X
chromosome. Cross-breeding of the HprtALPL with Cre-expressing mice results in deletion of the
stop cassette and constitutive ALPL expression within the target cell type. Because of the
nature of this X-linked system, both homozygous (HprtALPL/ALPL) and heterozygous (HprtALPL/-)
females are considered to be over-expressors, however HprtALPL/- females typically show a
milder phenotype. Female TagIn-Cre+/-; HprtALPL/- mice showed a much milder medial vascular
calcification (MVC) phenotype compared to male hemizygous TagIn-Cre+/-; HprtALPL/Y mice,
however the effects in female TagIn-Cre+/-; HprtALPL/ALPL mice were not described [162].
Creation of Alplfl/fl mice was first described here [163]; a floxed Alpl allele allows for conditional
knockout of TNAP when crossed with Cre recombinase transgenic mice. Breeding of the
appropriate combinations of Cre and Alplfl/fl animals after three generations will result in 50% of
the offspring as TNAP-cKO mice and 50% as Alplfl/fl littermate controls.

B. Pharmaceutical tools to study TNAP
There are several commercially available TNAP inhibitors currently on the market. Lhomoarginine (hArg) and levamisole are two of the oldest inhibitors, however these are not very
selective and offer weak binding to TNAP and are known to cause neurological side effects
[164, 165]. In 2019, researchers showed that hArg had no effect on TNAP levels in TNAPoverexpressing mice, however, it did offer some protection from myocardial remodeling through
mechanisms unrelated to TNAP inhibition [166]. Although levamisole has been used in several
studies to help identify the role that TNAP plays in health and disease [119, 167, 168], it is a
reversible inhibitor, so cells treated with this drug rapidly regain TNAP activity [169]. Due to their
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lack of specificity and negative effects of pan-AP inhibitors such as levamisole, Dr. Jose Luis
Millan and collaborators sought to develop a better inhibitor for TNAP. Using high-throughput
screening they identified several small molecule Aryl Sulfonamides as potent and selective
TNAP inhibitors [170]. So far, one of these inhibitors is commercially available for purchase from
Millipore Sigma, 2,5-Dimethoxy-N-(quinoline-3-yl) benzenesulfonamide or MLS-0038949,
primarily for cell structure applications. Further modifications of the previous TNAP inhibitor has
resulted in the development of a second inhibitor more suitable for in vivo applications, SBI-425
[171]. SBI-425 has been used in several studies related to vascular calcification [162, 172, 173]
and by our own lab to identify its applicability for studying TNAP’s role in the brain; however, we
demonstrated that the SBI-425 inhibitor is unable to cross the healthy BBB [174].

VI. Project Objectives and Aims
BMECs are a principal component of the BBB that provide the structural framework
needed for the stringent transportation of molecules into the brain, and maintenance of precise
cerebral homeostasis. BMEC dysfunction permits the trafficking of neurotoxins, bacteria, and
inflammatory cells from systemic circulation into the brain, which ultimately exacerbates BBB
dysfunction and neuroinflammation. Recent studies have shown that BBB dysfunction is a key
determinant of cognitive decline [79, 175-177]. Yet, therapies that mitigate BBB dysfunction and
improve cognitive outcomes in neurogenerative and inflammatory disease conditions are limited
because of the critical knowledge gap that exists in understanding the molecular and cellular
mechanisms underpinning BMEC physiology and function as it relates to the maintenance of
BBB integrity.
A strategy for bridging this critical knowledge gap requires an examination of protein and
enzymes localized to BMECs, and evaluating their role in preserving BBB integrity. TNAP has
been historically used as a brain endothelial histological marker due to its abundant expression
on BMECs. Yet, the role of TNAP in BMECs remains unclear. The objective of this dissertation
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is to elucidate the role played by BMEC TNAP in preserving BBB integrity in normal physiology
and in sepsis. Taken together, we will test the central hypothesis that BMEC TNAP is critical
for maintenance of BBB integrity in normal physiology and in sepsis through molecular
mechanisms that preserve BMEC structure and function. We will test our central hypothesis
via the following 3 specific aims:

Aim 1: Establish a role for brain microvascular TNAP in early and late sepsis (covered in
Chapter 2). Decades of studies have shown that cerebral microvessels are abundantly rich in
the AP isoenzyme known as TNAP [124, 178, 179]. Yet, TNAP’s role on the cerebral
microvessels remains to be elucidated [119]. The objective of this aim is to demonstrate a role
for TNAP in sepsis, and provide insights to how loss of brain microvascular TNAP couples
sepsis-associated BBB dysfunction and neuroinflammation.

Aim 2: Elucidate the molecular mechanisms through which BMEC TNAP maintains
barrier integrity (covered in Chapter 3). Preliminary evidence from earlier TNAP studies have
demonstrated that TNAP is able to hydrolyze nucleotides (ATP, AMP, ADP), inorganic
pyrophosphates (PPi), vitamin B6, and PEA [125, 126]. However, these targets are not specific
to brain endothelial cells and represent upstream pathways through which TNAP operates. The
objective of this aim is to elucidate downstream molecular targets of BMEC TNAP that could be
therapeutically advantageous towards the treatment of sepsis and prevention of long-term
cognitive impairment.

Aim 3: Determine the impact of BMEC TNAP conditional loss on BBB integrity in health
and sepsis (covered in Chapter 4). Other cell types that comprise the BBB such as astrocyte
end-feet processes and pericytes have been shown to express TNAP activity [180-182]. The
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objective of this aim is to examine whether the conditional loss of BMEC TNAP in vivo is
capable of inducing BBB dysfunction in health and sepsis.

The expected outcome of this work will produce a comprehensive understanding of the
role played by BMEC TNAP activity in preserving BBB integrity in normal physiology and in the
setting of sepsis-induced neurological impairment. The results will have a positive impact
because they lay the groundwork needed to stimulate the discovery of a potential therapeutic
target whose activity can be manipulated during injury to mitigate long-term neurological
dysfunction in sepsis, or alternatively, as a tool to increase the permeability of the BBB for
temporary delivery of drugs to the brain.

VII. Conclusion
The heterogeneous presentation and causes of sepsis are profoundly linked to its
variable clinical outcomes. Chronic neurological impairment is an increasingly common yet
poorly understood clinical outcome. Understanding the mechanistic determinants of BBB
integrity during sepsis is critically important for sepsis diagnosis and implementation of
treatment options to ensure a positive prognosis. Importantly, long-term prognosis in sepsis
survivors is linked to both transient and permanent alterations in BBB permeability and function.
Thus, targeting the BBB should be incorporated as part of a short- and long-term therapeutic
strategy in all sepsis patients. The development of therapies that inhibit BBB dysfunction and
stimulate normal BBB function will limit mortality, suppress neuroinflammation, and improve
neurological outcomes in sepsis survivors. Taken together, the identification of cellular and
molecular mechanisms that preserve BBB function in the face of sepsis will provide valuable
therapeutic targets to treat numerous inflammatory disorders that target both the brain and the
periphery—ranging from AD and stroke to diabetes and cardiovascular disease.
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Figures
Figure 1

A.

• Response is manifested by 2 out of the following 4:
- Temperature > 38°C (100.4°F) or < 36°C (96.8°F)
- Heart rate > 90 beats/min
- Respiratory rate >20 breaths/min or Paco2 <32
mmHg
Systemic
- White blood cell count >12,000/μL, <4000/μL or
inflammatory
response syndrome >10% immature (bands) forms

B.

Clinical history indicates infection

qSOFA ≥ 2 of the following variables:
• Change in mental status
• systolic blood pressure ≤100 mmHg
• Respiratory rate ≥22/min

Yes

• Systemic response to an infection defined by 2 or
more systemic inflammatory response syndrome
(SIRS) criteria as a result of an infection

No

Sepsis still
suspected?

Yes

Assess for evidence of organ dysfunction using SOFA

Sepsis

No

• Sepsis accompanied by organ dysfunction,
hypoperfusion or hypotension
Severe sepsis

SOFA ≥ 2 of the following variables:
• PaO2/FiO2 ratio
• Glasgow Coma Scale
• Mean arterial pressure (MAP)
• Vasopressor administration
• Serum creatinine or urine output
• Bilirubin
• Platelet count

Yes
• Sepsis induced hypotension that fails to correct with
fluid resuscitation. Systolic blood pressure <90
mmHg or mean arterial pressure <70mmHg

Patient has sepsis

Septic shock

• Presence of multiple altered organ dysfunction

Despite Fluid resuscitation,
1. Vasopressors required to maintain MAP ≥65 mmHg
AND
2. Serum lactate level >2mmol/L

Multiple organ
dysfunction

Yes
Patient has septic shock
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No

No

Monitor patient and reevaluate
for sepsis if clinically suspected

Figure 2
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Figure 1: Comparison of past and present guidelines for diagnosis of sepsis and septic
shock. (A) Past guidelines stressed that the diagnosis and progression of sepsis from a
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systemic inflammatory response to multiple organ dysfunction was sequential rather than
multifactorial. (B) The current guidelines for defining sepsis and septic shock stress that multiple
linked considerations are necessary for an accurate diagnosis. Both past and present guidelines
involve a clinical screening tool for patients likely to have sepsis that includes a clinical
characterization of the severity of the disease. Clinicians have traditionally used a sequential
organ failure assessment (SOFA) system to categorize the severity of organ dysfunction in
sepsis, which associates a higher SOFA score with increased mortality [4, 183]. New sepsis
guidelines employ a quick SOFA (qSOFA) score, which is a modified version of the SOFA score
that includes altered mental status, a systolic blood pressure £ 100 mg Hg, and a respiratory
rate ³ 22/min. Patients with a qSOFA ³ 2 have an overall in-hospital mortality risk greater than
10% [4, 184]. If warranted, further clinical analysis can be completed using other SOFA criteria
[4]. Figure is adapted from Singer et al. [4].
Figure 2: Relative cerebrovascular blood flow post-sepsis. Male C57BL/6J mice were
subjected to two different CLP severity models of sepsis (22 gauge: severe sepsis; 20 gauge:
septic shock). Relative blood flow was measured 12 h post-sepsis using a laser speckle
instrument. As expected, the septic shock mice demonstrated reduced cerebrovascular blood
flow compared to the severe sepsis and sham mice. This diagram illustrates the impact of
sepsis on the cerebrovasculature.
Figure 3 Key cellular components of the blood-brain barrier. The schematic illustrates the
relationships between cells that comprise the BBB. Neurons and microglia are also included as
part of the neurovascular unit, a conceptual framework that describes the interactions with the
BBB, resident brain cells, and peripheral immune cells.
Figure 4: Complex neuroinflammatory processes disrupt the blood brain barrier (BBB)
and lead to cognitive impairment in sepsis. Sepsis begins with systemic infection that
evokes an exaggerated host immune response from the recognition of pathogen-associated
molecular patterns (PAMPs) [90]. This exaggerated immune response involves a cascade of
events, including disrupted blood flow, immune cell infiltration, and increased BBB permeability,
which may ultimately result in cognitive dysfunction [95-97].
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Tables
Table 1: MRI imaging studies in patients with sepsis
Publications

Subject

Acute MRI Findings

[185]

Adult Human

T2-weighted hypersensitivity with altered DWI
showing ring enhancement

[186]

Adult Human

Multiple ischemic strokes with predominant white
matter lesions

[187]

Adult Human

Bilateral diffuse hyperintense areas in the white
matter of the cortex and cerebellum

[188]

Pediatric

Restricted diffusion in the basal ganglia and

Human

subcortical white matter of frontal and occipital
lobes; Brain edema was also present

[189]

Adult Human

White matter hyperintensities (WMH)

[190]

Rodent

Accumulation of vasogenic edema fluid at the base
of the brain
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[191]

Adult Human

Atrophy, WMH, edema, and localized bilateral
hemorrhage in the cortex and subcortical structures

[57]

Adult Human

Leukoencephalopathy and ischemic stroke

[192]

Adult Human

Acute abnormal hypointensity of the white matter
and edema; Subacute WMH

[58]

Rodent

Increased MRI intensities in the cortex, perirhinal
cortex, and hippocampus; Increased gadolinium
infiltration into various brain regions
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Highlights
•

Alkaline phosphatase activity in brain microvessels is diminished in early and late
sepsis.

•

Loss of alkaline phosphatase activity is coupled to the loss of barrier integrity.

•

Brain infiltration of myeloid and T-lymphoid cells persists in late sepsis.

•

Septic mice exhibit a novel anti-nociceptive phenotype.

•

Cortical astrogliosis and microgliosis persist in late sepsis.
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2.1 Abstract
Sepsis is a host response to systemic inflammation and infection that may lead to multiorgan dysfunction and eventual death. While acute brain dysfunction is common among all
sepsis patients, chronic neurological impairment is prevalent among sepsis survivors. The brain
microvasculature has emerged as a major determinant of sepsis-associated brain dysfunction,
yet the mechanisms that underlie its associated neuroimmune perturbations and behavioral
deficits are not well understood. An emerging body of data suggests that inhibition of tissuenonspecific alkaline phosphatase (TNAP) enzyme activity in cerebral microvessels may be
associated with changes in endothelial cell barrier integrity. The objective of this study was to
elucidate the connection between alterations in cerebrovascular TNAP enzyme activity and
brain microvascular dysfunction in late sepsis. We hypothesized that the disruption of TNAP
enzymatic activity in cerebral microvessels would be coupled to the sustained loss of brain
microvascular integrity, elevated neuroinflammatory responses, and behavioral deficits. Male
mice were subjected to cecal ligation and puncture (CLP), a model of experimental sepsis, and
assessed up to seven days post-sepsis. All mice were observed daily for sickness behavior and
underwent behavioral testing. Our results showed a significant decrease in brain microvascular
TNAP enzyme activity in the somatosensory cortex and spinal cord of septic mice but not in the
CA1 and CA3 hippocampal regions. Furthermore, we showed that loss of cerebrovascular
TNAP enzyme activity was coupled to a loss of claudin-5 and increased perivascular IgG
infiltration in the somatosensory cortex. Analyses of whole brain myeloid and T-lymphoid cell
populations also revealed a persistent elevation of infiltrating leukocytes, which included both
neutrophil and monocyte myeloid derived suppressor cells (MDSCs). Regional analyses of the
somatosensory cortex, hippocampus, and spinal cord revealed significant astrogliosis and
microgliosis in the cortex and spinal cord of septic mice that was accompanied by significant
microgliosis in the CA1 and CA3 hippocampal regions. Assessment of behavioral deficits
revealed no changes in learning and memory or evoked locomotion. However, the hot plate test
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uncovered a novel anti-nociceptive phenotype in our septic mice, and we speculate that this
phenotype may be a consequence of sustained GFAP astrogliosis and loss of TNAP activity in
the somatosensory cortex and spinal cord of septic mice. Taken together, these results
demonstrate that the loss of TNAP enzyme activity in cerebral microvessels during late sepsis is
coupled to sustained neuroimmune dysfunction which may underlie, in part, the chronic
neurological impairments observed in sepsis survivors.

Keywords: sepsis; cecal ligation and puncture; tissue non-specific alkaline phosphatase, bloodbrain barrier; nociception; astrogliosis; microgliosis; neuroimmune
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2.2 Introduction
Sepsis is a potentially fatal clinical syndrome that results from an excessive systemic
inflammatory response to an infection [1-3]. This syndrome accounts for 30 million cases
annually, and about 6 million deaths worldwide [4]. A unique feature of sepsis is that it is often
comorbid or may precipitate from other disease conditions such as stroke, cancer, or diabetes
[5-7]. It is anticipated that the rise in these chronic diseases will increase the global prevalence
of sepsis [8, 9]. Yet, therapeutic strategies to treat septic patients remain limited, as there are no
FDA-approved drugs to treat sepsis, and the primary treatments are largely limited to antimicrobial drugs, supportive fluids, and vasopressors [10]. In addition, the mechanisms
underlying the long-term consequences of sepsis on the brain and periphery remain elusive [11,
12].
Sepsis survivors are burdened with an increased risk of infections, sensorimotor
abnormalities, and cognitive decline [5, 12, 13]. The central nervous system (CNS), particularly
the brain, is severely affected in sepsis and sepsis-associated cognitive impairment is an
independent predictor of mortality [14]. Persistent peripheral inflammation in sepsis contributes
to a dysfunctional brain microvasculature and facilitates the trafficking of peripheral immune cell
populations, cytokines and neurotoxins into the brain which, collectively, promote
neuroinflammation and alter brain function [15, 16]. Short-term brain microvascular dysfunction
in murine models of experimental sepsis has been demonstrated by increased barrier
permeability and diminished tight junction [17] proteins 24 h post-sepsis [18, 19]. Thus, a better
understanding of the cellular and molecular mechanisms that contribute to brain microvascular
dysfunction in sepsis may provide insights to mitigate and improve long term neurological
outcomes in sepsis survivors.
We and others have shown that the ectoenzyme tissue-nonspecific alkaline
phosphatase (TNAP) may play a critical role in brain microvascular function and dysfunction [5,
20]. TNAP, also known as bone/liver/kidney alkaline phosphatase, is one of four alkaline
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phosphatase genes in the mammalian genome [21]. Peripheral TNAP enzymatic activity, most
likely generated within neutrophils, liver, and kidneys, has been shown to play an important role
in attenuating inflammation and improving survival in sepsis rodent models [22, 23]. TNAP
enzyme activity is also highly elevated in cerebral microvessels and has been used as a
histological marker of the brain microvasculature for nearly a century [24-26]. While a clearly
delineated physiological role for TNAP at the brain microvascular interface remains less
understood, recent studies suggest a role for TNAP in the maintenance of brain endothelial cell
integrity. An in vitro study demonstrated that inhibition of TNAP activity on brain endothelial cells
by levamisole, a pan-AP enzyme inhibitor, worsened barrier function and increased cellular
permeability [20]. In a recent in vivo study, we reported that brain TNAP enzyme activity is
decreased 24 h post-sepsis compared to sham-injured mice [5]. Taken together, both findings
suggest a plausible role for TNAP in maintaining brain microvascular barrier integrity during
inflammation. However, it remains unclear whether the observed decrease in TNAP’s enzyme
activity persists beyond 24 hours and whether the decrease in TNAP enzyme activity is coupled
to brain microvascular dysfunction in vivo. The delineation between early (£ 24 h) and late
sepsis (> 36 h) is particularly important considering that most sepsis-related deaths occur in the
late/hypo-inflammatory phase of sepsis [27].
The objective of this study was to determine the neuroimmune and behavioral changes
which paralleled the loss of TNAP in cerebral microvessels in late sepsis, i.e., up to seven days
post-sepsis. We incorporated an established a seven-day model of late sepsis, cecal ligation
and puncture (CLP) [28-30]. We assessed novel behavioral and neuroinflammatory outcomes in
late sepsis and coupled these outcomes to distinct alterations in the brain microvasculature and
integrity. Our results revealed a loss of TNAP enzymatic activity in cerebral microvessels,
diminished tight junctions and increased permeability, indicating a loss of barrier integrity.
Enhanced cortical astrogliosis and microgliosis was accompanied by sustained leukocyte
infiltration, and we also identified a novel cell population infiltrate with phenotypic characteristics
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of myeloid-derived suppressor cells (MDSCs). Assessment of behavioral deficits in late sepsis
uncovered a novel anti-nociceptive phenotype in the absence of an impairment in learning and
memory. Taken together, these results demonstrate that late sepsis is characterized by a novel
neuroimmune phenotype that embodies loss of sustained loss of cerebral microvascular TNAP
activity and persistent neuroinflammation.
2.3 Materials and Methods
2.3.1. Animals
All experiments were conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee at West Virginia University. Male wild-type
(WT; C57BL6/J) mice were bred in West Virginia University Health Sciences Center vivarium
facilities and used for experiments at 3-5 months old. All mice were generated from C57BL/6J
breeding pairs obtained from Jackson Labs (Bar Harbor, ME, Catalog # 000664). Mice were
group housed in environmentally controlled conditions with a reverse light cycle (12:12 h
light/dark cycle at 21 ± 1°C) and provided food and water ad libitum.

2.3.2. SBI-425 preparation
5-((5-chloro-2-methoxyphenyl) sulfonamido) nicotinamide (SBI-425) was synthesized as
previously described [31]. SBI-425 powder was dissolved in 100% dimethyl sulfoxide (DMSO,
Sigma-Aldrich, Milwaukee, WI), heated, sonicated, and stored at -80°C. The stock solution was
diluted to 1 mg/mL in a vehicle solution comprised of: 10% DMSO, 10% Tween-80 (SigmaAldrich, Milwaukee, WI), and 80% water.

2.3.3. Brain endothelial cell barrier function assays
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The human cerebral microvascular endothelial cell line (hCMEC/D3) is an immortalized
line that retains BBB characteristics in vitro [32]. hCMEC/D3 cells were seeded onto 3
independent collagen-coated 16-well E-Plate PET arrays (ACEA Biosciences, San Diego, CA)
at a concentration of 20,000 cells/well and loaded onto an xCelligence RTCA DP system (ACEA
Biosciences) enclosed in a tissue culture incubator. Once cells reached confluence ~ 24 h after
seeding, duplicate wells in each array were treated with 200 µl of the following: vehicle (DMSO,
0.3%), tissue-nonspecific alkaline phosphatase inhibitor (TNAPi 100 µM; Millipore, Temecula,
CA), lipopolysaccharide (LPS 100 ng/mL; Sigma-Aldrich, Milwaukee, WI), or LPS (100 ng/ml)
and TNAPi (100 µM). Cell index [20] was recorded continuously for 24 h and analyzed with
RTCA Software 2.0 (ACEA Biosciences). CI for all wells was normalized to a single timepoint,
i.e., ~1 h after treatment and reported as normalized CI.

2.3.4. Cecal ligation and puncture (CLP)
The cecal ligation and puncture (CLP) model of moderate polymicrobial sepsis was
employed as previously described [30]. Briefly, mice were anesthetized by the inhalation of 12% isoflurane. Abdominal access was obtained via a midline incision following topical
application of 2% lidocaine (Hospira, Lake Forest, IL). The cecum was isolated and ligated with
a 4-0 silk ligature below the ileocecal valve and then punctured twice with a 22 G needle
through and through. Fecal matter (approximately 1 mm) was extruded from the hole, and the
cecum was placed back into the abdominal cavity. The abdominal muscle layer was closed with
6-0 sutures (Ethilon, Cornelia, GA), while the abdominal skin layer was closed with 5-0 sutures
(Ethilon, Cornelia, GA). Sham-operated animals had their cecum isolated and then returned to
the peritoneal cavity without being ligated or punctured. One mL of sterile 0.9% saline was
administered subcutaneously after sepsis procedure for fluid resuscitation in sham- and CLPoperated mice. All mice were housed according to treatment group and placed on heating pads
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for three days following sepsis procedure. Mice were monitored for survival and sepsisassociated clinical signs twice daily for six days and underwent a series of behavioral
assessments. To assess the role of TNAP in maintaining brain endothelial cell barrier integrity in
vivo, a third cohort of septic mice was used for SBI-425 studies. Briefly, mice were injected
intraperitoneally with 25 mg/kg SBI-425 or vehicle 1 h following surgery and once daily for the
next six days; this dosage was derived from a previously published study [33]. Mice used for all
experiments were euthanized at day seven post-sepsis.

2.3.5. Modified murine sepsis score (MMSS) and average weight loss score
We modified a validated murine sepsis severity score (MSS) [34] to examine eight
sickness behavior components: appearance, weight loss, activity, response to stimulus, eyes,
posture, diarrhea, and respiratory rate, henceforth referred to as the modified murine sepsis
severity score (MMSS). Each component is scored from 0 (normal/no change) to 4 (severe
change), and the MMSS is a grand total of all eight aforementioned sickness behavior
components (i.e., 32 total points) collected each day post-sepsis over a 6-day period for each
animal. The average percent weight loss score was derived from the MMSS and defined on a
scale from 0 to 4 (i.e., a score of 0=0-5%, 1=5.1-10%, 2=10.1-15%, 3=15.1-20%, and 4=>20.1%
average percent weight loss). A score of 24 or greater on the MMSS represents a humane
endpoint for all animals used in our studies. Animals with a MMSS greater than 24 were
euthanized and excluded from behavioral assessments.

2.3.6. Tissue collecting and processing
Mice were deeply anesthetized with isoflurane and perfused intracardially with a
perfusion pump (Masterflex 7524-10, Cole-Parmer, Vernon Hills, IL) set to 5.0 mL/min. Blood
was removed with 25 mL of 0.9% saline followed by perfusion and fixation with 50 mL 4%
chilled paraformaldehyde (PFA, Fisher Scientific, Pittsburgh, PA). Perfused brains and spinal
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cords were removed from the skull and spinal canal, respectively, and post-fixed in 4% PFA
overnight at 4oC. On the following day, brains and spinal cords were rinsed in 0.01 M phosphate
buffered saline (PBS) and incubated sequentially in 10%, 20%, and 30% sucrose in PBS for 24
h each. Following successive incubations in sucrose, brains and spinal cords were coembedded in a 15% gelatin matrix in groups of twelve per matrix for simultaneous sectioning.
The gelatin block was processed sequentially through 4% PFA for 24 h, 15% sucrose for 24 h,
and 30% sucrose for 48 h. The block was trimmed and placed in a -80°C freezer for 30 min.
Sectioning was performed in the coronal plane at 30 µm on a sliding microtome (HM 450,
ThermoFisher Scientific, Waltham, MA) equipped with a 3x3 freezing stage (BFS-40MPA,
Physitemp, Clifton, NJ) at -20oC. Sections were collected into a series of six cups filled with
PBS/0.06% sodium azide. Adjacent cups were used for sequential histological staining or
immunostaining.

2.3.7. Immunohistochemistry
Following sequential cuts of the gelatin blocks on the microtome, sections were
immunostained using standard free-floating immunohistochemistry techniques as described
[35]. Briefly, all sections were blocked with 80 mL PBS, 10 mL of methanol (Fisher Scientific,
Pittsburgh, PA), and 10 mL of 30% hydrogen peroxide (Fisher Scientific, Pittsburgh, PA) and
incubated on a shaker (Model 55D, Reliable Scientific, Hernando, MS) for 15 min. Sections
were then washed three times and permeabilized for 30 min on a shaker with 1.83% lysine
(Fisher Scientific, Pittsburgh, PA) in 1% Triton (Sigma-Aldrich, St. Louis, MO), and 4% heatinactivated horse serum (Sigma-Aldrich, St. Louis, MO). Sections were then incubated for 24 h
with primary antibodies at room temperature, followed by a 2 h incubation with the appropriate
secondary antibody at room temperature. The following primary antibodies were used with
working dilutions and antibody identification indicated in parentheses: Iba-1 (Invitrogen (1:1000),
AB_2544912, Carlsbad, CA), GFAP (Agilent (1:10,000), AB_2811722, Santa Clara, CA),
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Claudin 5 (GeneTex (1:500), AB_2811720, Irvine, CA), TMEM 119 (Abcam (1:1000),
AB_2800343, Cambridge, MA), NeuN (Cell Signaling Technologies (1:500), AB_2651140,
Danvers, MA), and choline acetyltransferase [36] antibody (Abcam (1:1000), AB_2721842,
Cambridge, MA).

2.3.8. Tissue non-specific alkaline phosphatase (TNAP) enzyme histology
Brains and spinal cords and were evaluated for alkaline phosphatase enzyme activity
with the BCIP/NBT substrate kit (SK-5400, Vector Laboratories, Burlingame, CA) as previously
described [5]. Sections were rinsed in PBS twice for 5 min each, once in 0.1M Tris-HCl (pH =
9.5) for 5 min and incubated in the staining solution for 4 h at room temperature. Following three
rinses in 0.01 M PBS, the sections were mounted onto microscope slides (Unifrost+, Azer
Scientific, Morgantown, PA), air-dried overnight, dehydrated through a standard dehydration
series, and cover-slipped with Permount (Fisher Scientific, Pittsburgh, PA).

2.3.9. Image analysis
Sections were viewed on a Leica DM6B microscope (Leica Camera, Allendale, NJ) and
images were captured using Leica LASX software (Leica Microsystems, Buffalo Grove, IL). All
brain regions of interest i.e., the striatum, CA1, CA3, somatosensory cortex, and basal forebrain
(diagonal band of Broca and medial septum) were identified by referring to the Allen Institute
Brain Atlas (http://mouse.brain-map.org). Analysis of Iba-1 and TMEM 119 was conducted in the
somatosensory cortex (20X (TMEM119), and 20X and 40X (Iba-1) magnifications), CA1 (40X
(TMEM119 and Iba-1) magnification), and CA3 brain regions (40X (TMEM119 and Iba-1)
magnification). Analysis for GFAP was conducted in the somatosensory cortex (20X
magnification), CA1 (40X magnification), and CA3 (40X magnification). Cell counting analysis
for NeuN was conducted in the CA1 and CA3 hippocampal regions at 40X magnification.
Cholinergic (ChAT-positive) neurons were analyzed in the basal forebrain region at 40X
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magnification. Analysis for TNAP enzyme activity was conducted in the somatosensory cortex at
20X magnification. Three random images were collected per animal per brain region of interest.
Spinal cords were analyzed for GFAP, Iba-1, and TNAP. All collected images were converted to
an 8-bit image and quantified in FIJI/Image J version 2.0 software.

2.3.10. Flow cytometric sample preparation, gating strategy and analysis
Single cell suspensions were obtained as previously described using the Miltenyi adult
brain dissociation kit (Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instructions
[30, 37]. Briefly, mice were deeply anesthetized with isoflurane and were perfused intracardially
with a perfusion pump (Masterflex 7524-10, Cole-Parmer, Vernon Hills, IL) set to 5.0 ml/min.
Blood was removed with 25 mL 0.9% saline. Perfused whole brains were removed from the
skull and processed with the Adult Brain Dissociation Kit (Miltenyi Biotec, Auburn, CA)
according to manufacturer’s instructions. Briefly, brains were minced followed by mechanical
homogenization in a gentleMACS C tube with the gentleMACS Octo Dissociator (Miltenyi
Biotec). Following centrifugation, cells were further dissociated using a 70

m strainer to obtain

a single cell suspension. Myelin and other debris were removed, followed by red blood cell lysis
with ACK Lysis Buffer (Lonza, Walkersville, MD). CD45+ cells within the suspension were
isolated with mouse CD45 microbeads (Miltenyi Biotec) and magnetic separation with an
autoMACS separator (Miltenyi Biotec). Viability and total cell yield were determined by trypan
blue exclusion and cells were re-suspended to a final concentration of 2.5-3 × 106 cells/ml with
FACS buffer (0.01 M PBS, 5mM EDTA, 2% FBS). Cells were washed twice in cold 0.01M PBS
and stained with fixable viability dye eFluor780 (eBioscience, San Diego, USA) for 30 min at 4˚C
in the dark. Cells were then briefly washed with FACS buffer and blocked with Ultra-Leaf
purified anti-mouse CD16/32 (BioLegend, AB_2783156, San Diego, CA) for 20 min. Following
non-specific blocking, cells were stained with monoclonal antibodies for CD45-PE
(AB_2727965), CD11b-VioBlu (AB_2726322), CD11c-PerCp-Vio700 (AB_2660163), Ly6G-APC
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(AB_2660046), Ly6C-PE-Vio770 (AB_2660034) (Miltenyi Biotec, Auburn, CA) or CD4-FITC
(AB_464896), CD25-PE (AB_465607), CD19-PerCp-Cy5.5 (AB_1106999) and CD8a-eFluor450
(AB_1272198) (eBioscience, San Diego, USA) for 10 min at 4˚C. Appropriate single stained
controls were prepared for fluorophore compensation using compensation beads (Invitrogen,
Carlsbad, CA). For intracellular FOXP3 detection cells were fixed/permeabilized using a mouse
regulatory T cell staining kit (eBioscience) after staining the surface markers (CD4 or CD25,
Invitrogen, Carlsbad, CA) and stained with anti-FOXP3-PE-Cy5 (eBioscience, AB_468806, San
Diego, USA). Fluorescence was measured using a BD LSR Fortessa with FACS Diva software
(BD Biosciences, San Jose, CA). All data were compensated and spectral overlap was
minimized using automatic compensation method of BD FACS diva software (BD Biosciences,
San Jose, CA).
Further analyses were performed in FCS Express 6.0 (De Novo Software, Glendale,
CA). Single cells were identified by forward scatter and side scatter, and viable cells were gated
for further analysis of positive cell populations. Viable cells were gated for CD45+ populations
and then divided into T-lymphoid cells, which included cytotoxic T-cells (CD45hi, CD3+, CD8+),
helper T-cells (CD45hi, CD3+,CD4+), and T-regulatory cells (CD4+,CD25+, Foxp3+); myeloid cells,
which included neutrophils (CD45hi, CD11b+, Ly6C-, Ly6G+), monocytes (CD45hi, CD11c+,
Ly6C+, Ly6G-), polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) (CD45hi,
CD11b+, Ly6Clow, Ly6G+), and monocytic myeloid-derived suppressor cells (M-MDSCs) (CD45hi,
CD11b+, Ly6Chi, Ly6G-). The quantified results represent the percentage of positive cells from
the total CD45+ live cells.

2.3.11. Behavioral testing
2.3.11.1. Open field test [38]
The open field-testing paradigm was used to evaluate passive locomotor activity as
previously described [39] and was administered on day two post-sepsis. A white plastic box
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(60 cm × 60 cm × 15 cm) was placed upon a table accompanied by five 60-watt lamps that
provided indirect illumination. At the start of the trial, each mouse was placed at the center of
the box and received a 1 h session recorded over 5 min intervals. Locomotor activity was
recorded using a 4x8 photobeam activity system by San Diego Instruments (San Diego, CA).
The dependent variables are the total horizontal movements (x, y direction) and rearing
movements (z direction) over a 60 min period.

2.3.11.2. Accelerating rotarod (AR)
The accelerating rotarod test was used to evaluate evoked locomotor performance and
coordination as previously described [39] and was administered on day three post-sepsis. A
textured plastic horizontal rod (3 cm in diameter) was mounted 14.5 cm above a pressuresensitive base (Ugo Basile, Gemonio, Italy). For each trial, the mouse was placed on a moving
rod that accelerates from 4 rpm to 44 rpm when the operator hits the start button. Acceleration
is continued until the mouse fell onto the padded base or until 300 s elapsed. Latency to fall (s)
onto the padded base was the dependent variable. All mice received 4 trials on the rotarod.

2.3.11.3. Passive avoidance
The passive avoidance test is used to assess non-spatial aversive learning and memory
[40] and was administered days four and five post-sepsis. The test is performed using a twocompartment (illuminated and darkened) chamber connected by an automated door (Med
Associates, VT). All animals undergo 3 trials (120 s acquisition, 15 min immediate retention, and
24 h retention). During the 120 s acquisition, each animal is placed in the illuminated
compartment and receives a 0.3mA shock when it enters the darkened compartment. For the
300 s retention trials, the animal is placed in the illuminated chamber; however, no shock is
initiated upon entry into darkened compartment. The dependent variable is the latency to enter
the darkened compartment (s).
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2.3.11.4. Hot plate
The hot plate test is used to assess nociception [41] and was administered on day five
post-sepsis. Mice were individually placed on a preheated 55°C hot plate (IITC Life Science,
CA), inside an open-ended cylindrical Plexiglas tube with a diameter of 30 cm. The latency (s) to
respond to thermal stimuli and the total number of nociceptive behaviors (jumps as well as hind
limb-lick, flick or flexion) exhibited over a 30 s time frame were measured. To prevent tissue
damage, mice were removed from the hot plate after 30 s regardless of their response.

2.3.11.5. Two-day radial arm water maze (2D-RAWM)
The 2D-RAWM was used as previously described [42, 43] with minor modifications.
Briefly, a 6-arm maze is submerged in a pool of opaque water, and an invisible platform placed
at the end of 1 arm below the surface of the water. Each mouse received 15 trials per day for
two days and the start arm was changed on each trial, however, the goal arm remained the
same for all animals. Using static visual cues, the mouse learned the position of the platform.
The number of errors (incorrect arm entries) is counted across 1 min trials. If a mouse failed to
locate the platform in 1 min, the mouse was guided to the platform by the investigator and
allowed to stay on the platform for 15 s before returning the mouse to a heated cage. The
number of errors is averaged over two trials per block, resulting in five blocks (15 trials) per day
per animal, and a total of 10 blocks (30 trials) for the two-day period. The latency to get to the
platform (s) and the number of errors are the dependent variables measured. The 2D-RAWM
was performed on days five (acquisition) and six (retention) post-sepsis. It is important to note
that mice that participated in the hot plate test and the passive avoidance test did not participate
in the 2D-RAWM and vice versa due to the stressful impact of both tests on the mice. To avoid
any potential influence of aversive testing experience, a separate cohort of mice was used for
PA/HP testing than those that underwent 2D-RAWM.
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2.3.12. Experimental design and statistical analysis
All experiments were executed to enhance rigor and avoid experimenter bias according
to ARRIVE guidelines [44]. Only male mice were used for all experiments because males are
more susceptible to sepsis than females as previously published [45]. The use of male mice
also allows for comparisons with a number of published studies which address similar outcomes
[2, 16, 46]. Behavioral assays were conducted from the least aversive (i.e., open field) to most
aversive (i.e., 2D-RAWM). The investigator was blinded to the treatment groups for all behavior
tests and image analysis. Animals that died 24 h after a behavior test was conducted were
excluded from the study. See Figure 1 for an experimental timeline and outline of behavioral
assays performed. All statistical analyses were conducted in GraphPad Prism 8.1 (GraphPad
Software, La Jolla, CA). Results are expressed as mean ± SEM and p-values £0.05 were
considered significant. Survival was analyzed using a log-rank test. All other results were
analyzed using a two-tailed unpaired Student’s t-test, repeated two-way analysis of variance
(ANOVA), or two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons
post hoc test. Datasets that did not display a Gaussian distribution were subjected to a
comparable non-parametric analysis as indicated in the text and figure legends. All p-values and
n values are indicated in the text and figure legends.

2.4. Results
2.4.1. Survival analysis, sickness score, and average weight loss
The objective of our first set of experiments was to characterize our sepsis model by
investigating the detrimental effects of sepsis on mortality and sickness behavior. Septic mice
had a significantly increased mortality rate compared to sham mice (***p = 0.001, Log-rank)
(Fig. 2A). Thereafter, we examined sickness score and average weight loss using the modified
murine sepsis score (MMSS). Our results showed a significantly increased sickness score in
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septic mice compared to sham mice (F (1, 26) = 22.55, ****p < 0.0001, repeated measures twoway ANOVA) (Fig. 2B). Furthermore, septic mice had a significantly higher average weight loss
score compared to sham mice (U (104, 302) = 26, ***p = 0.0005, Mann-Whitney test) (Fig. 2C).
Due to the downward trend in the sickness score and an improvement in overall physical
appearance of septic animals after day five, we examined blood serum levels of inflammatory
cytokines interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) chemokine on
day seven in a terminal blood sample. Our results show that septic mice exhibit a persistent
peripheral inflammatory phenotype denoted by the significant increase in the levels of
inflammatory cytokines IL-6 (U (16, 62) = 1, **p = 0.005, Mann-Whitney test) and MCP-1 (U (11,
55) = 1, *p = 0.01, Mann-Whitney test) (Fig. 2D).

2.4.2. TNAP’s activity in brain microvascular endothelial cells is altered in early (24 h) and late
sepsis (7 days)
Earlier studies have demonstrated a strong evidence for BBB dysfunction in early sepsis
[47, 48]. Hence, we examined whether loss of TNAP activity was also present as early as 24 h
post-sepsis. Our results showed a significant loss of TNAP activity in the cerebral microvessels
of septic mice compared to sham septic mice at 24 h post-sepsis (Supplementary Fig. 1). We
next hypothesized that elevated levels of the serum pro-inflammatory cytokines, IL-6 and MCP1 (Fig. 2D), in late sepsis would support a sustained loss of TNAP enzyme activity in cerebral
microvessels. To investigate this, we co-immunolabelled cerebral microvessels with the
endothelial cell marker CD31 and subsequently quantified in vivo AP activity in the cerebral
microvessels within the same tissue. It is important to note that TNAP is the only AP isoform
found in microvessels of the brain and spinal cord [49, 50]. Therefore, assessment of total AP
activity is adequate to assess total TNAP activity in cerebral microvessels. Our in vivo results
demonstrated a significant decrease in TNAP enzyme activity in the somatosensory cortex (t =
2.8, *p = 0.02, unpaired t-test) (Fig. 3A, B) of septic mice. Parallel AP histology of the spinal
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cord also showed decreased TNAP enzyme activity in the spinal cords of septic mice
(Supplementary Fig. 2). Co-labeling of TNAP enzyme activity (purple) with cerebral
microvessels (CD31, brown) provides further support that the observed decrease in TNAP’s
enzyme activity is not the result of a loss of cerebral microvessels, and thus most likely
demonstrates that TNAP enzyme activity is reduced in cortical cerebral microvessels during late
sepsis (Fig. 3C). In contrast, we did not observe any significant differences in TNAP enzyme
activity in the hippocampal CA1 or CA3 region of septic and sham mice on day seven (data not
shown). Collectively, our findings reveal a sustained loss of cortical and spinal TNAP enzyme
activity in late sepsis.

2.4.3. TNAP is critical for maintaining cerebrovascular barrier integrity
Past studies by Deracinois et al. revealed that inhibition of TNAP enzyme activity with a
pan-AP inhibitor (levamisole) decreased barrier integrity in bovine capillary endothelial cells [20].
However, levamisole is a non-specific inhibitor of TNAP and is capable of decreasing the activity
of other phosphatases [31, 51, 52]. Likewise, it is not clear whether TNAP inhibition during
inflammation further exacerbates loss of barrier integrity. Therefore, we utilized a specific in vitro
inhibitor of TNAP (TNAPi) to examine the effect of TNAP inhibition in hCMEC/D3 cells under
basal conditions and during inflammation. Our results showed that treatment of hCMEC/D3 with
TNAPi (*p = 0.026, Tukey’s multiple comparison test, two-way ANOVA) or LPS (*p = 0.01,
Tukey’s multiple comparison test, two-way ANOVA) significantly decreased barrier integrity to
similar levels compared to DMSO treated cells. Furthermore, combination treatment of LPS and
TNAPi significantly decreased barrier integrity when compared to TNAPi only (****p < 0.0001,
Tukey’s multiple comparison test, two-way ANOVA), LPS only (****p < 0.0001, Tukey’s multiple
comparison test, two-way ANOVA), and DMSO (****p < 0.0001, Tukey’s multiple comparison
test, two-way ANOVA) treated hCMEC/D3 cells (Fig. 4A). As reported previously, the
expression of the tight junction [17] protein claudin-5 is decreased at 24 h following either CLP
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or LPS injection [53, 54]. We hypothesized that the sustained loss of TNAP enzyme activity in
the somatosensory cortex (Fig. 2D) would be coupled to a persistent loss of brain microvascular
integrity in late sepsis. To investigate this, we co-immunolabelled for the endothelial cell marker
CD31 (brown) and claudin-5 (red) in the somatosensory cortex. Our results showed that
claudin-5 expression around CD31-labelled microvasculature was decreased in the
somatosensory cortex of septic mice compared to sham mice (Fig. 4B). However, we did not
observe any differences in hippocampal claudin-5 expression between septic and sham mice
(data not shown). Since the TNAPI can only be used in vitro, we next used a highly specific in
vivo TNAP inhibitor (SBI-425) to investigate whether further inhibition of TNAP enzyme activity
exacerbates additional loss of cortical claudin-5 in septic mice. Our results showed that SBI425 treated septic mice exhibited an increased loss of cortical claudin-5 compared to vehicletreated septic mice and naïve mice (Fig. 4C). Furthermore, co-immunolabelling for
immunoglobulin G (IgG, brain permeability marker) and TNAP enzyme activity in the
somatosensory cortex revealed increased vascular (cyan arrow) and perivascular IgG
permeability (red arrow) in the brains of septic mice compared to sham mice (Fig. 4D). Our
results also showed that septic cortical microvascular brain regions with moderate TNAP
enzyme activity exhibited decreased IgG brain parenchymal infiltration (green arrow) compared
to cortical microvascular brains regions devoid of TNAP enzyme activity (red arrow) (Fig. 4D).
Together, our results demonstrate that modulation of TNAP enzyme activity during inflammation
may be critical for barrier maintenance. Thus, both in vitro and in vivo findings support TNAP’s
critical role in maintaining endothelial barrier integrity in normal physiology and during
inflammation.

2.4.4. Dysfunction of the neuroimmune axis post-sepsis
2.4.4.1. Sustained peripheral myeloid immune cell trafficking into brain parenchyma of septic
mice
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To investigate whether alterations in TNAP activity within cerebral microvessels (Fig.
3A, B) are coupled to trafficking of peripheral immune cells into the brain parenchyma at day
seven post-sepsis, we next characterized the percentage of myeloid cell populations in the
brains of septic and sham mice using flow cytometry. Myeloid cells are gated using the strategy
shown in Supplementary Figure 3. FCS express analyses of inflammatory myeloid cell
populations showed that neutrophils (CD45hi, CD11b+, Ly6C-, Ly6G+) (Fig. 5A, B) and
monocytes (CD45hi, CD11c+, Ly6C+, Ly6G-) (Fig. 5C, D) are significantly increased (U (15, 51) =
0, **p = 0.004, Mann-Whitney test) in the brains of septic compared to sham mice. Myeloid
derived suppressors cells (MDSCs) i.e., polymorphonuclear-MDSCs/PMN-MDCs (CD45hi,
CD11b+, Ly6Clo, Ly6G+) (Fig. 5E, F; U (15, 51) = 0, **p = 0.004, Mann-Whitney test) and
monocytic-MDSCs/M-MDSCs (CD45hi, CD11b+, Ly6Chi, Ly6G-) (Fig. 5E, G; U (15, 51) = 0, **p =
0.004, Mann-Whitney test) were also significantly increased in the brains of septic compared to
sham mice.

2.4.4.2. Sustained peripheral T-lymphoid immune cell trafficking into brain parenchyma of septic
mice
Next, we explored T-lymphoid immune cell trafficking post-sepsis using the gating
strategy for CD45hi live cells shown in Supplementary Figure 4. FCS express analyses of
CD8+ (CD45hi, CD3+, CD8+) (Fig. 6A, B; U (15, 51) = 0, **p = 0.004, Mann-Whitney test) and
CD4+ T-cells (CD45hi, CD3+, CD4+) (Fig. 6C, D; t = 2.3, *p = 0.046, unpaired t-test) revealed
increased populations of these cells in the brains of septic compared to sham mice. We also
assessed whether T-regulatory (Tregs) cells from the T-lymphoid lineage were similarly
increased in the brains of septic mice. To do this, CD4+ T-cells were gated further for Foxp3
and CD25 markers. Our results showed that Treg cells (CD4+, CD25+, Foxp3+) (Fig. 6E, F) are
significantly increased (t = 4.7, **p = 0.0011, unpaired t-test) in the brains of septic mice

57

compared to sham mice. Together both findings from Figures 5A-G and 6A-F demonstrate a
persistent dysfunction in the neuroimmune axis in septic mice.

2.4.5. Regional analyses of brain residential microglia populations in late sepsis
Our next step was to determine the effects of sepsis associated brain microvascular
dysfunction on residential microglia cell populations. For our analyses, we performed
immunohistochemistry and assessed microglia in three different brain regions (i.e.,
somatosensory cortex, CA1, and CA3) for the microglia/macrophage ionized calcium binding
adaptor molecule 1 (Iba-1). Iba-1 immunoreactive cells were significantly increased in the
somatosensory cortex (U (15, 51) = 0, **p = 0.004, Mann-Whitney test), and CA1 (t = 3.5, **p =
0.007, unpaired t-test) and CA3 (t = 3.9, **p = 0.004, unpaired t-test) hippocampal regions of the
brain (Fig. 7). Further analysis for Iba-1 positive cells in the spinal cords of septic mice were
increased compared to sham mice (Supplementary Figure 5A). To confirm whether the
stained Iba-1 positive cells were microglia and not macrophages, we stained for microglia using
a specific marker, TMEM119, which is not found on macrophages [55]. Contrary to the observed
increase in Iba-1 immunoreactive cells shown in Figures 7 A-F, there were no significant
differences in TMEM119 immunoreactive cells in the somatosensory cortex (t = 0.22, p = 0.13,
unpaired t-test), and the CA1 (t = 0.07, p = 0.94, unpaired t-test) and CA3 (t = 0.42, p = 0.68,
unpaired t-test) hippocampal regions (Supplementary Table 1). This suggests that these cells
are infiltrating monocytes rather than resident microglia.

2.4.6. Sustained astrogliosis in the somatosensory cortex of septic mice
Given the alterations in brain microglial/monocyte activation, we also assessed changes
in astrocyte proliferation and morphology post-sepsis. We performed glial fibrillary acidic protein
(GFAP) immunolabeling and quantified the proliferation of reactive astrocytes in the
somatosensory cortex, in hippocampal CA1 and CA3 and in the spinal cord. Our results
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demonstrate a significant increase in astrocyte proliferation in the somatosensory cortex (t =
3.5, **p = 0.006, unpaired t-test) of septic compared to sham mice (Fig. 8A, B). However, we
did not observe any significant differences in astrocyte proliferation in the CA1 (t = 0.5, p = 0.61,
unpaired t-test) and CA3 (t = 0.60, p = 0.56, unpaired t-test) hippocampal regions of the brain
(Fig. 8C-F). Parallel to the results observed in the somatosensory cortex of the brain, we
observed an increase in proliferative astrocytes in the spinal cords of septic mice compared to
sham mice (Supplementary Figure 5B). These results demonstrate that the somatosensory
cortex and the spinal cord exhibit sustained astrogliosis post-sepsis.

2.4.7. Septic mice displayed an impairment in spontaneous locomotion and exhibited a novel
anti-nociception phenotype
Septic and critically ill patients often experience long-term sensorimotor impairment [12,
13, 56]. Therefore, we implemented a series of behavioral assays on days two (open field
testing, OFT) and three (rotarod) to assess motor dysfunction and on day five (hot plate) to
assess sensory dysfunction in septic mice. The OFT was used to evaluate spontaneous motor
dysfunction while the rotarod was utilized to assess evoked motor dysfunction. Our results
showed that spontaneous locomotion in the horizontal (F (1, 24) = 20.51, ***p < 0.0001,
repeated measures two-way ANOVA) and vertical axes (F (1, 24) = 48.4, ***p < 0.0001,
repeated measures two-way ANOVA) were significantly decreased in septic compared to sham
mice on day two over a 60 min trial (Fig. 9A, B). However, we did not observe any differences
in evoked locomotion on the rotarod (F (1, 13) = 1.6, p = 0.23, repeated measures two-way
ANOVA) between septic and sham mice over four 300 s trials (Fig. 9C). Next, we utilized the
hot plate test to assess sensory dysfunction post-sepsis. Our results show that septic mice have
an increased latency to respond to thermal stimuli (t = 2.8, **p = 0.01, unpaired t-test) and
exhibit a decreased total number of nociceptive behaviors (hind limb-lick, flick, and jump) (t =
2.9, **p = 0.0096, unpaired t-test) compared to sham mice (Fig. 9D, E). From these findings, we
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report, for the first time, a discrepancy between two measurements of locomotion, OFT and
rotarod, in septic mice, and reveal a novel anti-nociceptive phenotype exhibited by septic mice.

2.4.8. Learning and memory is preserved seven days post-sepsis
To determine whether learning and memory deficits are evident during late sepsis, we
used the two-day radial arm water maze (2D-RAWM) to assess for spatial learning and memory
on days five and six, and the passive avoidance test to assess non-spatial learning and memory
on days four and five. Septic mice showed no difference in the number of errors (F (1, 20) =
0.76, p =0.39, repeated two-way ANOVA) or the latency to find the hidden platform (F (1, 20) =
0.87, p = 0.36, repeated two-way ANOVA) on day two of the retention trial compared to sham
mice (Fig. 10A, B). Assessment of non-spatial learning and memory with the use of the passive
avoidance test showed no difference in latency to enter the darkened compartment (F (1, 12) =
0.09, p = 0.77, repeated two-way ANOVA) between septic and sham mice at the 15 min and 24
h retention trials (Fig. 10C). Due to the absence of learning and memory impairments at these
timepoints, we assessed neuronal loss via NeuN immunolabeling in hippocampal regions CA1
and CA3. No apparent differences in neuronal loss were observed in these regions between
sham and septic mice (Supplementary Figure 6). To confirm that other brain regions involved
in memory consolidation were not affected by sepsis, we performed immunostaining for choline
acetyltransferase [36] in cholinergic neurons of the basal forebrain. Similarly, to results
observed in the hippocampus, there were no significant differences in the number of ChAT
positive neurons in the basal forebrain of septic mice compared to sham mice (Supplementary
Table 2). Taken together, the absence of neuronal loss in the hippocampus and cholinergic
neurons of the basal forebrain in septic mice further substantiated the results derived from the
2D-RAWM and passive avoidance behavioral tests (Fig. 10A-C).

2.5. Discussion
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Brain function in humans is significantly impaired in both early and late sepsis and is an
independent predictor of mortality [14]. An emerging hypothesis suggests that the pronounced
hyper-inflammatory phase seen in early sepsis disrupts brain microvascular function and barrier
integrity [57, 58]. The subsequent infiltration of peripheral immune cells and systemic proinflammatory molecules into the brain parenchyma that accompanies changes in brain
microvascular dysfunction may increase the likelihood of significant short-term and long-term
deficits in neurocognitive function [16, 59]. Therefore, a better understanding of brain
microvascular mechanisms that maintain barrier integrity may foster the development of
therapeutics to mitigate the neurological impairments seen in sepsis survivors. The results from
this study support a mechanism through which loss of TNAP activity is linked to brain
microvascular dysfunction. Our results demonstrate that TNAP is critically important for
maintenance of brain microvascular integrity in model of experimental sepsis and that perhaps
modulation of TNAP’s enzymatic activity may foster the development of new therapies that treat
long-term sepsis associated cognitive impairment.
We employed the cecal ligation and puncture model of experimental sepsis to identify
neuroimmune mechanisms and behavioral deficits that accompanied brain microvascular
dysfunction following a loss of TNAP enzyme activity in cerebral microvessels. Results from our
sepsis model closely align with previously reported findings in similar models of sepsis [2, 60].
However, a unique feature of our study involves our focus on the relationship between
suppressed TNAP enzyme activity to brain microvascular dysfunction, leukocyte trafficking, and
behavioral deficits in late sepsis. Very little is known about TNAP-associated functions and
signaling mechanisms outside of its well-characterized role in bone and mineral metabolism
[61]. The physiological importance of suppressed TNAP activity in brain endothelium was
suggested by an earlier in vitro study which showed that inhibition of TNAP with a nonspecific
pan-AP inhibitor (levamisole) worsened brain endothelial cell barrier integrity [20]. However, the
experiments in this study established a role for TNAP in basal endothelial cell permeability but
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did not address the effects of TNAP inhibition during inflammation or injury. Moreover,
levamisole is a nonspecific AP inhibitor that induces neurological deficits [31, 62]. Thus, we
carried out a series of in vitro and in vivo studies with highly specific TNAP inhibitors to further
investigate a putative role for TNAP in brain endothelium. Our findings in the current study
expand on previously published data showing that TNAP’s enzymatic activity is decreased in
septic mice 24 h post-sepsis [5], i.e., early sepsis, and we demonstrate that suppression of
TNAP’s enzymatic activity extends into late sepsis.
Results from the current study also reveal a mechanistic role for TNAP as an important
regulator of barrier function during inflammation. First, our in vitro results in hCMEC/D3 cells
demonstrated that inhibition of TNAP activity significantly suppressed barrier function in brain
endothelium over time. More importantly, TNAP inhibition combined with LPS treatment
synergistically worsened barrier function compared to LPS or TNAPi alone. Second, in vivo
results showed that a decrease in claudin-5 coupled with increased extravasation IgG in the
somatosensory cortex suggests that inhibition of TNAP is coupled to cerebral microvascular
dysfunction. Furthermore, in vivo inhibition of TNAP on cerebral microvessels of septic mice
with SBI-425 decreased claudin 5 immunolabeling in the somatosensory cortex. However, a
limitation of our SBI-425 studies is that because TNAP is expressed in numerous brain cell
types [63], and it is likely that SBI-425 crosses the BBB in sepsis. Therefore, we cannot discern
whether the effects SBI-425 on brain endothelial cell cells are direct or indirect due to crosstalk
with other brain resident cells that express TNAP, e.g., neurons, astrocytes. Of note, there was
no detectable loss of hippocampal TNAP enzyme activity or claudin-5 in this model. These
findings suggest that specific brain regions are more susceptible to sepsis-induced brain
dysfunction than others in late sepsis. Collectively, our experiments demonstrate that TNAP
modulation may be critical in attenuating the brain microvascular dysfunction described in many
published preclinical and clinical sepsis studies [57].
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Our experiments also addressed whether alterations in brain myeloid and lymphoid cell
populations paralleled the loss of brain microvascular integrity. While alterations in peripheral
myeloid and T-lymphoid cell populations have been described in numerous murine sepsis
studies [64, 65], few studies have addressed changes in brain immune cells populations and
trafficking peripheral leukocyte populations in late sepsis. Our results are consistent with
findings from Singer et al. who also showed that monocytes and neutrophils persist up to day 14
in septic rodent brains [15]. Importantly, our findings showed that elevated numbers of
leukocytes are present in the brain parenchyma post-sepsis in spite of a downward trend in
sickness score, physical appearance of animal, and cessation of additional mortality past day
five. Additionally, we also uncovered two novel findings that support a role for brain
immunosuppression in late sepsis. It has been demonstrated that sepsis-associated
immunosuppression in peripheral tissues contributes to poor recovery and long-term morbidity
post-sepsis [66, 67], but a role of brain immunosuppression in sepsis is less clear. There are no
reports, to our knowledge, that have investigated alterations in brain T-regulatory cell or MDSC
populations in sepsis, our observation that brain CD4+/CD25+/Foxp3+ T-regulatory cells (Tregs)
were elevated in septic mice suggests that dysregulation of peripheral Tregs may play a role in
generating the immunosuppressive phenotype associated with late sepsis [68-70]; however,
further studies are needed to substantiate this finding. While the role of MDSCs in
neuroinflammation is not well understood, a recent study in a mouse model of traumatic brain
injury showed that circulating PMN-MDSCs and M-MDSCs entered the brain shortly after injury
to suppress neuroinflammation; however, PMN-MDSCs declined thereafter while M-MDSCs
remained elevated in the brain [71]. In contrast, the results from our study suggest that both
PMN-MDSCs and M-MDSCs remain elevated in late sepsis. While MDSCs have been shown to
express an immunosuppressive phenotype, we did not perform a functional analysis of MDSC
populations and cannot determine whether this population contributes to sepsis-associated
immunosuppression.
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Due to a persistent presence of brain microvascular dysfunction post-sepsis, we also
investigated the impact of these changes on two key glial cell populations: microglia and
astrocytes. Prior studies that have utilized Iba-1 and CD11b as markers to assess alterations in
microglia populations have shown that microglia numbers are increased in the cortex and
hippocampus of septic mice [15, 72]. In agreement with prior reports, we found that Iba-1
positive cell populations were increased in cortex and hippocampus. It is important to note that
the Iba-1 and CD11b markers label microglia and/or infiltrating monocytes [72, 73]. Further
immunostaining with TMEM119, a marker for residential microglia, did not reveal any
differences between microglial populations in sham and septic mice. The observed differences
reflect the heterogeneity of the brain microglial/monocyte populations and emphasize their
importance in the pathophysiology of sepsis [74, 75]. These findings further suggest that the
resultant increase in Iba-1 positive cells may be attributed to infiltrating monocyte populations
that differentiate into macrophages expressing Iba-1.
Clinical studies have shown that elevated serum GFAP concentrations are associated
with a poor prognosis and quality of life post-sepsis [76]. Similarly, preclinical studies have
shown that GFAP-mediated astrogliosis is associated with brain microvascular dysfunction in
many neuroinflammatory conditions [3]. Therefore, we speculated that the presence of brain
microvascular dysfunction in late sepsis would support sustained astrogliosis in the
somatosensory cortex and spinal cord but not in the hippocampus because there were no
differences in hippocampal TNAP enzyme activity between sham and septic mice. Our results
confirmed prominent astrogliosis in the somatosensory cortex and spinal cord. Taken together,
our results demonstrate that brain microvascular dysfunction is also coupled to sustained
microgliosis and astrogliosis in late sepsis.
Since septic survivors are burdened with neurological impairments [12], we investigated
whether the neuroinflammatory findings in our sepsis model paralleled sensorimotor,
nociceptive, and learning and memory impairments. Importantly, we identified several novel
64

behavioral outcomes that are supported by findings in human sepsis survivors. We speculate
that the significant decrease in spontaneous locomotion we observed was due to a lack of
motivation to explore a novel environment post-sepsis; however, when septic mice were forced
to engage in motor activity using the rotarod test, this motor impairment disappeared. These
differences may be due to an effect of sepsis on motivation. Motivation is an affective behavior
that is difficult to quantify in mice [77], and sepsis-induced changes in motivation have been
observed following lipopolysaccharide injection [78]. Recent studies have also reported similar
neuropsychiatric disturbances in motivation in sepsis survivors [79, 80]. We also assessed
deficits in thermal sensory dysfunction using the hot plate test since altered pain perception has
previously been reported in sepsis patients [81]. Increased sensitivity to deep pain but not
cutaneous pain has been reported in studies of human experimental endotoxemia [82]. Our
results uncovered a novel anti-nociceptive phenotype in septic mice. The mechanism through
which the observed anti-nociceptive phenotype is unclear, but we speculate that this phenotype
may result from loss of TNAP enzyme activity observed in the somatosensory cortex and spinal
cord, as these regions are part of critical neural circuits involved pain perception and processing
biobehavioral pathways [83].
In contrast to previous studies, we did not observe any alterations in either spatial or
non-spatial learning and memory tests between septic and sham mice. The absence of
neuronal loss in the basal forebrain or the hippocampus supports these behavioral findings. It is
highly likely that the seven-day post-sepsis time frame was too early to detect cognitive
impairment, as other studies have shown that learning and memory are significantly altered at
one-month post-sepsis in mice and may be mediated via infiltration of CCR2+ monocytes and/or
increased levels of high mobility group box 1 protein (HMGBI) secreted by inflammatory cells
[16, 84]. Conceivably, activation of TNAP enzyme activity may limit the infiltration of CCR2+
monocytes and HMGBI into the brain and prevent the cognitive impairment seen one-month
post-sepsis. It is also plausible that TNAP activity may be suppressed in other brain regions,
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e.g., hippocampus, at later time points such as one-month post-sepsis when learning and
memory deficits typically become more apparent. Thus, a limitation of our behavioral studies is
that they spanned from day 2 (early sepsis) up to day six (late sepsis).
In summary, this study establishes that diminished TNAP enzyme activity in cerebral
microvessels is a consequence of the brain’s sustained response to systemic inflammation and
infection, i.e., sepsis. We propose a model in which TNAP functions as part of a dynamic
complex of barrier integrity proteins on the luminal and abluminal surfaces of cerebral
microvessels. Inhibition of TNAP activity disrupts this complex, thereby resulting in the loss of
tight junction proteins, e.g., claudin-5, elevated extravasation of circulating proteins, e g. IgG,
and increased leukocyte trafficking into the brain parenchyma. In turn, these events exacerbate
neuroinflammation and behavioral deficits in sepsis survivors. A better understanding of these
mechanisms will support the development of targeted therapies to mitigate chronic neurological
impairments in sepsis survivors. It is highly likely that this novel regulatory mechanism extends
beyond sepsis and encompasses a common mechanism of cerebral microvascular dysfunction
in both acute and chronic systemic inflammatory disorders that cause neurological impairment.
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Figure Legends
Figure 1: Experimental design and behavioral testing paradigm to study neuroimmune
and brain microvascular function in late sepsis. Animals in cohorts 1 and 2 were
randomized and underwent either sham or sepsis (cecal ligation and puncture, CLP) surgery. All
animals were subjected to a series of daily behavioral assays from day two to six. Mice were
euthanized on day seven and their brains were harvested for flow cytometry (cohort 1) or
immunohistochemistry (IHC), and alkaline phosphatase (AP) histology (cohort 2). Spinal cords
were used for IHC and AP histology (cohort 2). Animals in cohort 3 underwent sepsis surgery
alone and were injected with SBI-425 or vehicle intraperitoneally 1 h post-CLP and daily for six
days post-CLP. Mice in cohort 3 were euthanized on day seven post-sepsis and brains collected
for IHC.
Figure 2: Survival is decreased while longitudinal clinical scores and serum
proinflammatory cytokines are increased in sepsis. (A) A Kaplan-Meier log-rank survival
curve analysis of sham (n = 22) and septic (n = 38) mice from day 0 of surgery to euthanasia at
day seven showed that septic mice had a significant decrease in survival (***p = 0.001)
compared to sham mice. (B, C) Septic mice (n = 16) had significantly higher sickness scores
(****p < 0.0001, repeated two-way ANOVA) and average weight loss scores (***p = 0.0005,
Mann-Whitney test) compared to sham mice (n = 12). (D) Examination of blood serum
inflammatory cytokines at day seven revealed a persistent increase in IL-6 (**p = 0.005, MannWhitney test) and MCP-1 (*p = 0.01, Mann-Whitney test) in septic mice (n=7) compared to
sham mice (n = 4-5). * indicates p < 0.05, **p <0.01, ***p < 0.001, ****p < 0.0001, and is
considered significant. All data are presented as mean ± SEM.
Figure 3: Tissue nonspecific alkaline phosphatase (TNAP) enzyme activity in cerebral
microvessels is decreased in late sepsis. (A) Representative images of TNAP enzyme
activity on brain microvessels showed that TNAP’s enzyme activity in the somatosensory cortex
(20X magnification) of septic mice is decreased compared to sham mice. (B) Quantification of
TNAP enzyme activity on sections of the somatosensory cortex showed that TNAP enzyme
activity is significantly decreased (*p = 0.02, unpaired t-test) in septic (n = 6) compared to sham
treated mice (n = 5). (C) Co-labelling of TNAP enzyme activity (purple) with CD31 cerebral
microvessel marker (brown) in the somatosensory cortex (10X and 40X magnification) further
demonstrates that loss of TNAP’s enzyme activity in brain sections is due to a loss of TNAP
enzyme activity in cerebral microvessels rather than a loss of brain microvessels. * indicates p <
0.05, and is considered significant. All data are presented as mean ± SEM. 10X, 20X, and 40X
magnification scale bar = 160 µm, 80 µm, and 40 µm respectively.
Figure 4: Changes in claudin-5 expression and IgG permeability are consistent with
diminished tissue nonspecific alkaline phosphatase (TNAP) enzyme activity in cerebral
microvessels. (A) Normalized cell index is an impedance-based measure of barrier integrity.
Treatment of hCMEC/D3 cells with TNAPI significantly decreased barrier integrity (*p = 0.026,
Tukey’s multiple comparison test, two-way ANOVA) compared to DMSO treated hCMEC/D3
cells. Combination treatment of LPS and TNAPI significantly decreased barrier integrity
compared to TNAPI only (****p < 0.0001, Tukey’s multiple comparison test, two-way ANOVA),
LPS only (****p < 0.0001, Tukey’s multiple comparison test, two-way ANOVA), and DMSO
(****p < 0.0001, Tukey’s multiple comparison test, two-way ANOVA) treated hCMEC/D3 cells.
(B) Claudin-5 (red) expression surrounding CD31 (brown) labelled brain microvessels is
decreased in septic compared to sham mice (20X magnification). (C) Daily injections of SBI-425
up to day six post-sepsis dramatically reduced claudin-5 expression compared to vehicle (Veh)
treated septic mice or naïve mice. 20X and 40X magnification scale bar = 80 µm and 40 µm
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respectively. (D) Vascular (cyan arrow) and perivascular IgG permeability (red arrow) is
increased in septic brains compared to sham brains (white arrow) (40X magnification). Also,
note that cortical microvessels with slight TNAP enzyme activity (green arrow) in septic brains
showed reduced perivascular IgG permeability compared to areas without TNAP enzyme
activity (red arrow) (40X magnification). * indicates p < 0.05, ****p < 0.0001, and is considered
significant. All data are presented as mean ± SEM. 20X and 40X magnification scale bar = 80
µm and 40 µm respectively.
Figure 5: Brain infiltrating myeloid cell populations are elevated in late sepsis. (A-D)
Representative dot plot and quantification of inflammatory myeloid cells showed a significant
increase in neutrophil (**p = 0.004, Mann-Whitney test) and monocyte (**p = 0.004, MannWhitney test) cell populations in the brains of septic compared to sham mice. [85] Analyses of
myeloid derived suppressor cells (MDSCs) showed that septic brains have a significant increase
in polymorphonuclear-MDSC/PMN-MDSC (**p = 0.004, Mann-Whitney test) and monocyticMDSCs/M-MDSC (**p = 0.004, Mann-Whitney test) cell populations compared to sham mice.
Flow cytometric results are expressed as the percentage of an indicated cell type in total CD45+
live cells in septic mice (n = 6) or sham mice (n = 5). Analyzed population is indicated by the
encircled gating. ** indicates p < 0.01, and is considered significant. All data are presented as
mean ± SEM.
Figure 6: Multiple T-lymphoid cell populations are elevated in the brain during late
sepsis. (A-D) Representative dot plot and quantification of T-lymphoid cells revealed that septic
brains have a significant increase in CD8+ (**p = 0.004, Mann-Whitney test) and CD4+ T-cell
(*p = 0.046, unpaired t-test) populations compared to sham mice. (E, F) Further analyses of a
specific subset of CD4+ cells (T-regulatory cells, Tregs) using Foxp3 and CD25 markers
revealed a significant increase in the percentage of Tregs (**p = 0.0011, unpaired t-test) in the
brains of septic compared to sham mice. Quantification of flow cytometric results are expressed
as the percentage of an indicated cell type in total CD45+ live cells in septic mice (n = 6) or
sham mice (n = 5). The analyzed population is indicated by the encircled gating. * indicates p <
0.05, **p < 0.01, and is considered significant. All data are presented as mean ± SEM.
Figure 7: Late sepsis is characterized by increased microglia/infiltrating monocyte
populations. (A-F) Representative histological images (A, C, E) and quantification of Iba-1 (B,
D, F) showed an increased number of Iba-1 immunoreactive cells in the somatosensory cortex
(**p = 0.004, Mann-Whitney test), CA1 (**p = 0.007, unpaired t-test) and CA3 (**p = 0.004,
unpaired t-test) brain regions of septic (n = 6) compared to sham mice (n = 5). ** indicates p <
0.01, and is considered significant. All data are presented as mean ± SEM. 20X and 40X
magnification scale bar = 80 µm, and 40 µm respectively.
Figure 8: Sustained astrogliosis in the somatosensory cortex of septic mice. (A-F)
Representative glial fibrillary acidic protein (GFAP) astrocyte histological images and
quantification of astrogliosis (astrocyte proliferation) in the somatosensory cortex, CA1, and CA3
brain regions of septic and sham mice. (B) Quantification of GFAP astrocytes showed a
sustained significant increase in astrocyte proliferation in the somatosensory cortex (**p =
0.006, unpaired t-test) of septic (n = 6) compared to sham mice (n = 5). (D, F) However, no
differences in astrocyte proliferation were seen between septic (n = 6) and sham mice (n = 6) in
the hippocampal brain regions CA1 (p = 0.61, unpaired t-test) and CA3 (p = 0.56, unpaired ttest). ** indicates p < 0.01, and is considered significant. All data are presented as mean ± SEM.
20X and 40X magnification scale bar = 80 µm, and 40 µm respectively.
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Figure 9: Spontaneous sensorimotor activity and nociceptive functions are impaired in
septic mice. (A, B) Open field testing of spontaneous locomotion on day two showed that septic
mice (n = 14) had a significant decrease in horizontal (***p < 0.0001, repeated two-way ANOVA)
and vertical (***p < 0.0001, repeated two-way ANOVA) spontaneous locomotion compared to
sham mice (n = 10). (C) Rotarod assessment of evoked locomotion on day three showed no
difference (p = 0.23, repeated two-way ANOVA) between septic mice (n = 8) and sham mice (n
= 7). (D, E) Evaluation of sensory dysfunction with the hot plate test revealed a novel
antinociceptive behavior in septic mice i.e., septic mice exhibited a significant increase in the
latency to respond to thermal stimuli (**p = 0.01, unpaired t-test) and a significant decrease in
the total number of nociceptive behaviors (hind limb - lick, flick, and jump) (**p = 0.0096,
unpaired t-test). ** indicates p < 0.01, ****p < 0.0001, and is considered significant. All data are
presented as mean ± SEM.
Figure 10: Absence of spatial and non-spatial learning and memory behavioral deficits in
late sepsis. (A, B) Mice underwent two-day radial arm water maze (2D-RAWM) testing to
assess spatial learning and memory deficits on days five and six post-sepsis. Septic mice (n =
12) showed no difference in the number of errors (p = 0.39, repeated two-way ANOVA) or the
latency to find the hidden platform (p = 0.36, repeated two-way ANOVA) on day two of the
retention trial compared to sham mice (n = 10). (C) The passive avoidance assessed nonspatial learning and memory on days four and five post-sepsis. Septic mice (n = 7) showed no
difference in latency to enter the darkened compartment (p = 0.77, repeated two-way ANOVA)
compared to sham mice (n = 7). All data are presented as mean ± SEM.

80

Supplementary Tables:
Supplementary Table 1
Quantification of TMEM 119 positive brain microglia populations sham (n = 5) and septic mice (n
= 6)
2

Area of stained TMEM119 microglia/μm
Treatment
Brain region

Sham (mean ± SEM)

Sepsis (mean ± SEM)

p-value

Cortex

17634 ± 2313

27110 ± 4924

0.13

CA1

16152 ± 1138

16006 ± 1609

0.94

CA3

11837 ± 2436

10475 ± 2103

0.68

All data are presented as mean ± SEM, unpaired t-test.

Supplementary Table 2
Quantification of cholinergic ChAT positive neurons in the basal forebrain of sham (n = 5) and
septic mice (n = 6)
# of ChAT positive neurons
Treatment
Brain region

Sham (mean ± SEM)

Sepsis (mean ± SEM)

p-value

Basal forebrain

24 ± 2.63

19.4 ± 3.04

0.28

All data are presented as mean ± SEM, unpaired t-test.
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Supplemental Figures:
Supplemental Figure 1.
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Supplementary Figure 2.
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Supplementary Figure 3.
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Supplementary Figure 4.
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Supplementary Figure 5.
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Supplementary Figure 6.
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Supplementary Figure Legends
Supplementary Figure 1.
TNAP activity in the brain 24 h post-sepsis. (A) Histological staining for TNAP activity shows
decreased TNAP enzyme activity in the cortex of septic male mice subjected to the cecal
ligation and puncture (CLP) model of experimental sepsis. C57BL/6J mice were subjected to
CLP or a sham injury and brains were harvested 24 hours later. (B) Graph shows the
quantification of cortical AP enzyme activity in CLP (n = 3, 52.49 ± 0.1094) versus sham (n = 3,
53 ± 0.1142) mice (sections = 3 per mouse; data represented as mean ± SEM, *P < .05, t
(4) = 3.384, unpaired Student’s t-test, scale bar = 115 µm).
Supplementary Figure 2.
Tissue non-specific alkaline phosphatase (TNAP) enzyme activity in the spinal cord.
Representative alkaline phosphatase (AP) histology shows that TNAP’s enzyme activity is
decreased in the spinal cord of septic mice compared to sham mice (20X magnification). 20X
magnification scale bar = 80 µm.
Supplementary Figure 3.
Gating strategy for brain myeloid populations. (A) Representative live cell gating strategy.
Neutrophil (B), monocytes (C), and MDSCs (C) were gating under the parent gate CD45hi prior
to being organized into precise cell types using the following specific markers: CD11b, CD11c,
Ly6G, and Ly6C. SSC = side scatter, FSC = forward scatter, A = area, H = height, VB = viability,
M = monocytic MDSCs, and PMN = polymorphonuclear MDSCs. Analyzed population is
indicated by the encircled gating.
Supplementary Figure 4.
Gating strategy for brain lymphoid populations. (A) Representative live cell gating strategy.
CD4, CD8, and regulatory T-cells were gating under the parent gate CD45hi prior to being
organized into precise cell types using the following specific markers: CD3, CD4, CD8, CD25,
and Foxp3. SSC = side scatter, FSC = forward scatter, A = area, H = height, and VB = viability.
Analyzed population is indicated by the encircled gating.
Supplementary Figure 5.
Iba-1 positive microglia and GFAP positive astrocyte immunohistochemistry in the spinal
cord of septic and sham mice. (A) Iba-1 positive cells are increased in the spinal cords of
septic mice compared to sham mice. (B) GFAP positive cells are increased in the spinal cords
of septic mice compared to sham mice (20X magnification). 20X magnification scale bar = 80
µm.
Supplementary Figure 6.
NeuN positive immunohistochemistry for neuronal loss in the CA1 and CA3 hippocampal
regions. Representative histology for NeuN immunolabelling shows no apparent differences in
neuronal loss in the (A) CA1 or (C) CA3 between septic and sham mice (40X magnification).
40X magnification scale bar = 40 µm.
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3.1. Abstract
Blood-brain barrier (BBB) dysfunction is a key feature in many neuroinflammatory
diseases. Yet, no therapies exist to effectively mitigate BBB dysfunction. A strategy to bridge
this knowledge gap requires an examination of proteins localized to brain microvascular
endothelial cells (BMECs) and evaluating their role in preserving barrier integrity. Tissuenonspecific alkaline phosphatase (TNAP) is highly abundant in brain microvascular endothelial
cells (BMECs); however, its function in BMECs remains unclear. We hypothesized that a loss or
inhibition of TNAP activity on BMECs would impair barrier integrity through increased
cytoskeletal remodeling driven by the Rho-associated protein kinase [1] pathway. First, we
examined barrier integrity (measured as impedance) in hCMEC/D3 cells treated with a TNAP
inhibitor (TNAPi) and in primary BMECs (pBMECs) via the conditional deletion of TNAP in
endothelial cells. Our results showed that both pharmacological inhibition and genetic
conditional loss of TNAP significantly worsened endothelial barrier impedance compared to
controls. Next, we examined the mechanisms through which TNAP activity exerts a protective
phenotype on BMECs. Our results showed that hCMEC/D3 cells treated with TNAPi displayed
remarkable phalloidin and vimentin cytoskeletal remodeling compared to control. We then
examined the role of ROCK, a key player in cytoskeletal remodeling. Our results showed that
TNAPi increased the expression of ROCK 1/2. Furthermore, inhibition of ROCK 1/2 with fasudil
mitigated TNAPi-induced and VE-cKO barrier dysfunction. Collectively, our results support a
novel mechanism through which loss of TNAP activity results in cerebrovascular dysfunction,
and selective modulation of TNAP activity in BMECs may be a therapeutic strategy to improve
BBB function.

Keywords: Tissue-nonspecific alkaline phosphatase; Alpl; Barrier integrity; ROCK; Brain
microvasculature; Cytoskeleton
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3.2. Introduction
The blood-brain barrier (BBB) is a dynamic vascular interface that separates the brain
parenchyma from systemic circulation [2]. The brain’s microvasculature differs from the
peripheral vasculature due to its unique composition of brain capillary endothelial cells linked
tightly together by junctional proteins, surrounding pericytes, basal lamina, and astrocyte endfoot processes [3]. At the BBB, brain capillary endothelial cell-cell junctions are critical for
maintaining the integrity of the BBB via paracellular transport size selective restriction of
molecules, toxin, and cells [4]. Furthermore, the expression of specific proteins, enzymes, and
transporters on luminal and abluminal surfaces of brain capillary endothelial cells help to
regulate blood-to-brain trafficking of certain molecules [5]. One example of these important
proteins is the endothelial sphingosine-1-receptor-1 (S1Pr1). Yanagida et al., showed that
conditional endothelial knockout of S1Pr1 led to a size selective BBB leakiness to fluorescent
tracers less than 3 kDa. Furthermore, BBB leakiness in the S1Pr1 endothelial knockout mice
was coupled to altered subcellular distribution of junctional proteins [6]. Thus, a crossexamination of specific proteins, enzymes, and transporters localized to brain capillary
endothelial cells may provide therapeutic insight that may mitigate BBB dysfunction and the
consequential long-term cognitive impairment seen across many neuroinflammatory conditions
[3, 7].
Alkaline phosphatases [8] are found in numerous tissues, and are thought to play an
important role in regulating inflammation [9]. There are four AP isozymes in humans (gene
name in italics): placental alkaline phosphatase (PLAP; ALPP), germ cell alkaline phosphatase
(GCAP; ALPPL2), intestinal alkaline phosphatase (IAP; ALPI), and tissue-nonspecific alkaline
phosphatase (TNAP; ALPL; also known as Akp2 or Alpl in mouse) [10]. Of the four AP
isozymes, only TNAP is expressed in the brain tissue of humans and rodents [11]. Moreover,
biochemical and histological studies have shown that brain microvessels are abundantly rich in
TNAP [12, 13]. Several studies have demonstrated a role for APs in catalyzing the hydrolysis of
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nucleotides (ATP, ADP, and AMP) to free adenosine and inorganic phosphates [14]. Similarly,
APs are able to dephosphorylate inflammatory molecules such as lipopolysaccharide (LPS),
damage-associated molecular patterns (DAMPs), and pathogen-associated molecular patterns
(PAMPs) [15-17]. Free adenosine and dephosphorylation of LPS (dLPS) are suggested to
support the anti-inflammatory role for APs in disease [14, 18-20]. However, the molecular
mechanisms through which APs maintain homeostasis via its putative anti-inflammatory function
remain unclear. Earlier investigations from our group revealed that brain microvascular TNAP
activity is decreased as early as 24 h post-sepsis, and this decrease is sustained up to 7 days
post-sepsis. Furthermore, the decrease in brain microvascular TNAP activity at 7-days postsepsis was coupled to increased immunoglobulin G [21] permeability and sustained
neuroinflammation. Moreover, treatment of septic animals with a specific TNAP inhibitor
decreased brain endothelial junctional protein claudin-5 expression compared to vehicle treated
septic and naïve mice [3, 22]. These results suggest a putative role for microvascular TNAP
activity in maintaining vascular barrier integrity at the endothelium. Therefore, in this study we
elucidated the mechanistic role for TNAP at the brain endothelium and examined the molecular
and cellular pathways targeted by TNAP.
Investigating the role of brain endothelial TNAP has been challenging for decades due to
TNAP’s ubiquitous expression in other tissue types such as the liver, kidney, spleen, lung, bone,
and diverse brain cell types [10, 23]. Furthermore, mice with a global knockout of TNAP (Alpl-/-)
die within days after birth from seizures and rickets characteristics of hypophosphatasia [24].
Newly generated pharmacological agents such as the TNAP inhibitor (TNAPi) probe and the
pharmacological derivative 5-((5-chloro-2-methoxyphenyl) sulfonamido) nicotinamide (SBI-425)
have advanced our knowledge on TNAP function in recent years [25, 26]; however, the use of
these drugs in vivo makes it difficult to delineate brain endothelial TNAP function as opposed to
other cell types. The availability of the Alpl floxed mouse allowed for a targeted approach to
delineate cell-specific function by Cre-lox recombination [27]. We utilized both pharmacological
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(using TNAP inhibitor (TNAPi)) and genetic TNAP deletion on endothelial cells (i.e., VE-cKO
mice), to demonstrate a mechanistic role for brain endothelial TNAP in maintaining barrier
integrity (measured as impedance) in vitro and ex vivo. Taken together, our results suggest that
TNAP plays a critical role in maintaining in vitro barrier impedance via Rho-associated protein
kinase mediated by cytoskeletal reorganization.

3.3. Methods
3.3.1. Cell lines
The hCMEC/D3 human cerebral microvascular endothelial cell line (D3 cells) is an
immortalized endothelial line that retains BBB characteristics in vitro [28]. The cell line was
purchased from Cedarlane Labs (Burlington, NC).

3.3.2. Animals
All experiments were conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee at West Virginia University. Male wild-type
(WT; C57BL6/J; Bar Harbor, ME, Catalog # 000664) mice were bred in West Virginia University
Health Sciences Center vivarium facilities and used for sepsis and stroke experiments at 3-5
months old. Floxed Alpl (Alplfl/fl) mice on a C57BL/6J genetic background were obtained from
Dr. José Luis Millán at the Sanford-Burnham Prebys Medical Discovery Institute and crossed
with B6.FVB-Tg(Cdh5-cre)7Mlia/J (VE-Cadherin Cre, Bar Harbor, ME, Catalog # 006137) mice
obtained from Jackson Labs. Creation of Alplfl/fl mice is described in [27] and creation of VECadherin Cre mice is described in [29]. VE-Cadherin Cre and Alplfl/fl mice were crossed to
ultimately produce mice with a conditional deletion of Alpl in the endothelium (VE-cKO) and
littermate control mice (Alplfl/fl). For genotyping, DNA was extracted from ear snips using the
Purelink Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA), and PCR products were
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amplified by using a Veriti 96-well Thermal Cycler (Applied Biosystems, ThermoFisher
Scientific, Waltham, MA) under the following conditions: 94 °C for 1 min, [(94 °C for 30 sec,
60 °C for 30 sec, 72 °C for 45 sec) × 40 cycles], then 72 °C for 1 min. VE-Cadherin Cre
specificity was determined by the presence of a 700 bp product using the following primers;
ACRE_F: 5’- GAACCTGATGGACATGTTCAGGGA -3’, and ACRE_R: 5’CAGAGTCATCCTTAGCGCCGTAAA -3’ [29]. Confirmation of floxed Alpl sites was determined
by the presence of a 263 bp product using the following primer set; Alplflox_F: 5’GTTGCGATGTGTGAAGATGTCCTCG -3’, and Alplflox_R: 5’CTTGGGCTTGCTGTCGCCAGTAAC -3’. An additional strain was employed. Red fluorescent
protein (RFP) B6.Cg-Gt[30]26Sor (Ai9) mice under a genetic C57BL/6J background were
obtained from Dr. Eric Tucker in the Department of Neuroscience at West Virginia University;
generation of these mice is described in [31]. All mice were group housed in environmentally
controlled conditions with a reverse light cycle (12:12 h light/dark cycle at 21 ± 1°C) and
provided food and water ad libitum.

3.3.3. Cecal Ligation and Puncture (CLP)
The cecal ligation and puncture (CLP) model of polymicrobial sepsis was employed as
previously described [22, 32]. Briefly, C57BL/6J mice were anesthetized by the inhalation of 12% isoflurane and abdominal access was obtained via a midline incision. The cecum was
ligated below the ileocecal valve, punctured twice with a 22 G needle through and through, and
placed back into the abdominal cavity. The abdominal muscle and skin layer were closed with 60 and 5-0 sutures (Ethilon, Cornelia, GA) respectively. Sham-operated animals had their cecum
isolated and then returned to the peritoneal cavity without being ligated or punctured. One mL of
sterile 0.9% saline was administered subcutaneously (s.c.) for fluid resuscitation in all
experimental groups. Mice used for all experiments were euthanized at seven days post-CLP.
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3.3.4. Transient Middle Cerebral Artery Occlusion (tMCAO)
tMCAO surgery was performed under isofluorane anesthesia as previously described
[33]. Briefly, male C57BL/6J mice were subjected to 60 min tMCAO using silicon coated sutures
(Cat. #702334, Doccol Corporation, MA) followed by reperfusion. Body temperatures were
controlled at 37 ± 0.5 °C during occlusion. Occlusion and reperfusion were verified in each
animal by a Laser Speckle Imager (Moor Instruments, England). Bupivacaine (2 mg/kg, s.c.)
was administered to relieve pain after surgery. Mice were followed for seven days post-stroke
and euthanized.

3.3.5. Tissue Collecting and Processing
Mice were deeply anesthetized with isoflurane and transcardially perfused (Masterflex
7524-10, Cole-Parmer, Vernon Hills, IL) as described previously [22]. Briefly, blood was
removed with 0.9% saline followed by perfusion and fixation with 4% chilled paraformaldehyde
(PFA, Fisher Scientific, Pittsburgh, PA). Perfused brains were post-fixed in 4% PFA overnight at
4oC. On the following day, brains were rinsed in 0.01 M phosphate buffered saline (PBS) and
incubated sequentially in 15% and 30% sucrose in PBS for 24 h each. Next, brains were coembedded in 15% gelatin for sectioning. The gelatin block was processed sequentially through
4% PFA for 24 h, 15% sucrose for 48 h, and 30% sucrose for 48 h. The block was trimmed and
placed in a -80°C freezer for 1 h. Sectioning was performed in the coronal plane at 35 µm on a
sliding microtome (HM 450, ThermoFisher Scientific).

3.3.6. Primary Brain Microvascular Endothelial Cell (pBMEC) Culture
Brain microvascular endothelial cells (BMECs) were cultured from male and female mice
as previously described [32]. Briefly, 6-8 weeks old Alplfl/fl (n = 5) and VE-cKO (n = 5) were
perfused with 0.01 M PBS. Cortices were dissected, homogenized, digested in papain and
DNase I (Worthington Biochemical Corp, Lakewood, NJ) at 37 °C for 1 h. The homogenate was
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then centrifuged (1360 × g) for 10 minutes, followed by myelin removal. The cell pellet was
resuspended in endothelial cell growth medium (ECGM: F12 medium with 10% fetal bovine
serum (FBS), endothelial growth supplement, ascorbate (2.5 µg/ml), L-glutamine (4 mM), and
heparin (10 µg/ml)), and plated into four collagen-coated wells (calf skin collagen, SigmaAldrich) of a six-well plate. Cultures were treated with fresh ECGM medium the next day
followed by treatment with puromycin hydrochloride (4 μg/ml) with EGCM + FBS for 2.5 days.
Cultures reached confluency after 5–7 days and were used for barrier function assays.

3.3.7. Brain Endothelial Cell Barrier Function Assays
Barrier function assays were carried out as previously described for hCMEC/D3 cells
[22] and in pBMECs [32]. Briefly, hCMEC/D3 cells were seeded onto 3 independent collagencoated 16-well E-Plate PET arrays (ACEA Biosciences, San Diego, CA) at a concentration of
20,000 cells/well and loaded onto an xCelligence RTCA DP system (ACEA Biosciences)
enclosed in a cell culture incubator. Once hCMEC/D3 cells reached confluence ~ 24 h after
seeding, triplicate wells in each array were treated with 200 μl of the following: 0.3% dimethyl
sulfoxide (DMSO), tissue-nonspecific alkaline phosphatase inhibitor (TNAPi 100 μM; Millipore,
Temecula, CA), or tumor necrosis factor-alpha and interferon-gamma (TNF-α and IFN-γ; 10
ng/mL; Sigma-Aldrich, Milwaukee, WI). In a second set of experiments hCMEC/D3 cells in
triplicate wells were treated with 200 μl of the following: 0.3% DMSO, TNAPi (100 μM), fasudil
(10 μM; Selleckchem, Houston, TX), or TNAPi (100 μM) and fasudil (10 μM). Barrier function
assays were also performed in pBMECs cultures isolated from Alplfl/fl and VE-cKO mice. Barrier
function of pBMEC cultures was recorded both with and without treatments. Alplfl/fl and VE-cKO
endothelial cell cultures were treated with vehicle or 10 μM fasudil (i.e., Alplfl/fl untreated, Alplfl/fl
fasudil, VE-cKO untreated, and VE-cKO fasudil). Cell impedance or normalized cell impedance
was recorded and analyzed with RTCA Software 2.0 (ACEA Biosciences). Normalized cell
impedance is calculated by dividing cell impedance at the normalized time (i.e., when cells are
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treated) by the original cell impedance. Untreated for all experiments refers to cells treated with
vehicle (i.e., ECGM medium for pBMECs and endothelial cell growth basal medium-2 (EBM-2)
for hCMEC/D3 cells).

3.3.8. In-Cell Western (ICW) Assay
The ICW assay was performed using the Odyssey Imaging System (LI-COR
Biosciences, Lincoln, NE) as previously described [34]. Briefly, hCMEC/D3 cell cultures were
grown in 96-well plates until they reached confluency. Thereafter, hCMEC/D3 cells were treated
with vehicle, 0.3% DMSO, or TNAPi (100 µM) for 24 h. The following day, cells were fixed with
4% PFA then permeabilized with 0.5% Triton X-100 for 15 min at room temperature and blocked
with LI-COR Odyssey Blocking Solution (LI-COR Biosciences) for 1 h. The cells were then
incubated overnight at 4°C with primary antibodies. The following primary antibodies were used:
ROCK1 (Invitrogen (1:1000), AB_11155392), ROCK2 (Invitrogen (1:1000), AB_11157047), and
RhoA (Abcam (1:1000), AB_10675086, Cambridge, MA). The next day, the cells were washed
three times with PBS and incubated with the appropriate secondary IgG IRDye™ 800/680
antibody (1:10,000 dilution, LI-COR Biosciences) at room temperature for 2 h. The 96-well
plates were scanned with the Odyssey CLx Infrared Imaging System (LI-COR Biosciences), and
the integrated fluorescence intensities representing the protein expression levels were acquired
using the Odyssey software (Odyssey Software Version 3.0, LI-COR Biosciences). The relative
amount of the protein of interest was obtained by normalizing to total cell number (CellTag700
stain) in all experiments.

3.3.9 Alkaline Phosphatase Activity Assay Using Homogenized Brain Tissue
Measurement of alkaline phosphatase activity, quantified as area under the curve [1],
from homogenized brain tissue was performed as previously described [32]. Briefly, perfused
mouse brains were homogenized in 500 ul assay buffer (comprised of 1 M Tris-HCl, 1 M MgCl2,
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50 mM ZnCl2, and deionized water), centrifuged to remove insoluble material, aliquoted, and
frozen at -80°C until analysis. On the day of the assay, brain samples were thawed and diluted
1:10 using assay buffer. Sample wells given assay buffer containing para-nitrophenylphosphate
(pNPP; Millipore Sigma, Billerica, MA) for measurement of enzyme activity, were matched to a
background control well containing the same buffer as sample wells with the addition of 5%
sodium orthovanadate (BeanTown Chemical, Hudson, NH). This assay was performed in a 384well plate and read kinetically, every 10 mins for 5 hours, on a plate reader at OD380 using Gen5
Version 2.01.14 software (BioTek Instruments, Inc., Winooski, VT). To compare total enzyme
activity over time between genotypes, quantification of AUCs was applied.

3.3.10. Tissue-Nonspecific Alkaline Phosphatase (TNAP) Enzyme Activity Histology
Brain tissue section and cell cultures were evaluated for alkaline phosphatase enzyme
activity with the BCIP/NBT substrate kit (SK-5400, Vector Laboratories, Burlingame, CA) as
previously described [22, 32]. Tissue sections and cells were rinsed three times in 0.1M TrisHCl (pH = 9.5) for 5 min and incubated in BCIP/NBT staining solution for 4 h at room
temperature. Following incubation, sections were rinsed in 0.01 M PBS and mounted onto
microscope slides (Unifrost+, Azer Scientific, Morgantown, PA), air-dried overnight, dehydrated
through a standard dehydration series, and cover-slipped with Permount (Fisher Scientific,
Pittsburgh, PA).

3.3.11. Immunohistochemistry
Brain sections and cell cultures were immunostained using standard
immunohistochemistry techniques [22, 32]. Briefly, tissue sections and cells were washed three
times, permeabilized, and blocked for 30 min on a shaker. Tissue sections and cells were then
incubated for 24 h with primary antibodies or 1 h in Alexa 594 phalloidin dye at room
temperature, followed by a 2 h incubation with the appropriate secondary antibody at room
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temperature. The following primary antibodies were used with working dilutions and antibody
identification indicated in parentheses: CD31 (RnD Systems (1:500), AB_1026192, Minneapolis,
MN), Phalloidin (Invitrogen (1:1000), AB_2315633, Carlsbad, CA), Claudin-5 (Invitrogen (1:200),
AB_2806730), and Vimentin (Cell Signaling Technologies (1:500), AB_10695459, Danvers,
MA).

3.3.12. Image Analysis
Sections were viewed on a Leica DM6B microscope (Leica Camera, Allendale, NJ) and
images were captured using Leica LASX software (Leica Microsystems, Buffalo Grove, IL). Cell
culture images were captured on the EVOS FL Auto 2 microscope (ThermoFisher Scientific).
The cortex, striatum, and hippocampus were identified by referring to the Allen Institute Brain
Atlas (http://mouse.brain-map.org). TNAP and/or CD31 images were captured in the cortex,
striatum, and hippocampus (40X magnification). 6 fields from 2 sections per animal were
collected for the quantification of regional TNAP enzyme activity. CD31 and RFP images were
captured in the cortex at 20X magnification. 30 images/cell culture well [35] were used for the
quantification of phalloidin, vimentin, and TNAP enzyme activity stains. Images were quantified
using the FIJI/Image J version 2.0 software.

3.3.13. Statistical Analysis
All experiments were executed to enhance rigor and avoid experimenter bias.
Investigators were blinded to the experimental groups for all image analyses.
Immunohistochemistry and in-cell western images were analyzed using a one-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparisons post hoc test. The hCMEC/D3 cell
barrier function assay was analyzed using a one-way repeated measure analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons post hoc test. The pBMECs (i.e., Alplfl/fl
versus VE-cKO) barrier function assay was analyzed using a two-way repeated measure
103

analysis of variance (ANOVA). Whole brain AP activity assay in Alplfl/fl versus VE-cKO was
analyzed using a two-tailed unpaired Student’s t-test. Barrier function assay for the fasudil
treated pBMECs was analyzed using linear mixed modeling with repeated subject set to cell line
and covariance matrix set to compound symmetry. The model effects included the time block
(pre-treatment, fasudil treatment, and 48 h post-fasudil treatment), group (Alplfl/fl untreated,
Alplfl/fl fasudil, VE-cKO untreated, and VE-cKO fasudil), and time block by group interaction.
Comparisons within time blocks were made across groups on the least square means (LS
means) with Tukey-Kramer adjustments. All analyses were conducted using SAS 9.4 (SAS
software, Cary, NC) and GraphPad Prism 8.1 (GraphPad Software, La Jolla, CA). All p-values
and n values are indicated in the figure legends. Results were expressed as means ± SEM and
p-values <0.05 were considered significant.

3.4. Results
3.4.1. Brain Microvascular TNAP Activity is in Models of Cerebrovascular Dysfunction
We have previously shown that brain microvascular TNAP activity is decreased at 24 h
post-sepsis, and this decrease in TNAP activity is sustained up to 7 days post-sepsis [3, 22].
Therefore, we examined whether the decrease in brain microvascular TNAP activity post-sepsis
(Fig. 1a) extends to other neuroinflammatory conditions such as stroke. Cortex and striatum
were examined because these regions revealed increased microvascular TNAP activity
compared to other regions like the hippocampus in mice (Supplementary Fig. 1). Our results
showed that following transient middle cerebral artery occlusion, the penumbra in the ipsilateral
cortex and striatum exhibited decreased TNAP activity compared to the contralateral cortex and
striatum (Fig. 1b). These results are consistent with an earlier study from our group showing that
the loss of brain microvascular TNAP activity post-sepsis did not result from the loss of brain
microvessels (Supplementary Fig. 2a) [22]. Similarly, CD31 and TNAP activity double-label
histology in the penumbra of stroke tissue (striatum shown) revealed a loss of brain
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microvascular TNAP activity that is independent of CD31 positive vessel loss (Supplementary
Fig. 2b). The loss of TNAP activity on CD31 positive microvessels after stroke and sepsis led us
to speculate that TNAP may play an important role in cerebrovascular inflammation.

3.4.2. TNAP Inhibition in Brain Microvascular hCMEC/D3 Endothelial Cells Promotes Loss of
Barrier Impedance
Brain microvascular endothelial cells are a key component of cerebral microvessels and
play an important role in maintaining barrier integrity [36]. Next, we investigated whether a
decrease in TNAP activity in brain endothelial cells promotes barrier dysfunction. Brain
microvascular hCMEC/D3 endothelial cells were treated with TNAPi alone, TNF-α and IFN-γ, or
TNF-α and IFN-γ combined with TNAPi. Our results showed that treatment of hCMEC/D3
endothelial cells with TNAPi (p = 0.01) and TNF-α and IFN-γ (p = 0.0005) significantly
decreased endothelial TNAP activity compared to appropriate controls (Tukey’s multiple
comparisons test, one-way ANOVA). Furthermore, a combined treatment of TNAPi and TNF-α
and IFN-γ significantly decreased (p < 0.0001) endothelial TNAP activity compared to TNAPi
alone (Tukey’s multiple comparisons test, one-way ANOVA) (Fig. 2a, b). We then examined
whether the loss of TNAP activity in hCMEC/D3 endothelial cells following treatment with TNAPi
or TNF-α and IFN-γ resulted in a loss of barrier function. Our results showed that both TNAPi (p
< 0.0001) and TNF-α and IFN-γ (p < 0.0001) significantly decreased barrier integrity
(impedance) compared to control (Tukey’s multiple comparisons test, one-way ANOVA) (Fig.
2c).

3.4.3. Inhibition of Brain Endothelial TNAP Activity Induces Cytoskeletal Remodeling
The next studies sought to explore the mechanisms responsible for TNAPi-induced
barrier dysfunction shown in Figure 2. Earlier studies by Deracinois et al. with a panphosphatase inhibitor (levamisole) suggested that the TNAP-dependent loss of barrier integrity
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in bovine capillary endothelial cells was associated with cytoskeleton remodeling [37]. However,
levamisole is a non-specific inhibitor of TNAP and is capable of decreasing the activity of other
phosphatases [26, 38]. Hence, we examined cytoskeletal remodeling by using a specific TNAP
inhibitor. To do this, we treated hCMEC/D3 endothelial cells with TNAPi alone, TNF-α and IFNγ, or TNF-α and IFN-γ combined with TNAPi. Thereafter, we immunostained for F-actin using
phalloidin and intermediate filaments using vimentin 24 h following treatment. Our results
showed that treatment of hCMEC/D3 endothelial cells with TNAPi alone (p = 0.0008) and TNF-α
and IFN-γ (p < 0.002) significantly decreased F-actin fluorescence intensity compared to
appropriate controls (Tukey’s multiple comparisons test, one-way ANOVA). Furthermore,
combined treatment of TNF-α and IFN-γ with TNAPi significantly decreased F-actin
fluorescence intensity compared to TNAPi alone (p < 0.006) or TNF-α and IFN-γ (p = 0.0001;
Tukey’s multiple comparisons test, one-way ANOVA). Moreover, we observed increased cell
detachment (white arrows) in the TNAPi alone, TNF-α and IFN-γ, and TNF-α and IFN-γ
combined with TNAPi groups compared to controls (i.e., DMSO or untreated) (Fig. 3a, b).
Likewise, intermediate filament (vimentin) fluorescence intensity was significantly decreased in
the TNAPi alone (p = 0.03) and TNF-α and IFN-γ combined with TNAPi (p = 0.008) when
compared to DMSO control (Tukey’s multiple comparisons test, one-way ANOVA). However,
treatment with TNF-α and IFN-γ alone did not appear to significantly alter the fluorescence
intensity of vimentin (Fig. 3c, d).

3.4.4. ROCK Protein Expression is Increased Following TNAP Inhibition in Endothelial Cells
Numerous studies have implicated the Rho/ROCK pathway as a critical mediator
involved in endothelial cytoskeletal remodeling [39]. From the results derived in Figure 3, we
employed in-cell westerns (ICW) to examine the implications of TNAP inhibition on RhoA,
ROCK 1, and ROCK 2 endothelial protein expression. Although RhoA expression increased
relative to the appropriate control (DMSO) following treatment with TNAPi; however, this
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increase was not significant (Fig. 4a, b). Next, we examined downstream proteins (i.e., ROCK 1
and ROCK 2) involved in the Rho/ROCK pathway. Our results showed that ROCK 2 (p =
0.0003) and ROCK 1 (p = 0.02) protein expression was significantly increased following TNAPi
treatment compared to DMSO control (Tukey’s multiple comparisons test, one-way ANOVA)
(Fig. 4c-f). Interestingly, DMSO, the vehicle for TNAPi, significantly increased (p = 0.02)
ROCK1 protein expression relative to untreated endothelial cells (Tukey’s multiple comparisons
test, one-way ANOVA). This finding was not uncommon since DMSO has been shown to induce
slight inflammation [40].

3.4.5. A ROCK Inhibitor Mitigates Loss of Barrier Impedance Following TNAP Inhibition
Fasudil is a potent competitive inhibitor of ROCK 1 and ROCK 2 [41]. Therefore, we
examined whether fasudil alleviates TNAPi-induced barrier dysfunction. To do this, hCMEC/D3
endothelial cells were treated with TNAPi, fasudil, and TNAPi and fasudil. Following treatment,
barrier impedance was measured over a 48-h period. Our results showed that TNAPi treatment
significantly decreased (p < 0.0001, Tukey’s multiple comparisons test, repeated one-way
ANOVA) barrier impedance compared to DMSO control. A combination treatment of fasudil and
TNAPi revealed a significantly improved (p < 0.0001, Tukey’s multiple comparisons test,
repeated one-way ANOVA) barrier impedance relative to TNAPi alone (Fig. 5). These results
implicate ROCK proteins as downstream mediators of TNAP inhibition.

3.4.6. Conditional Deletion of TNAP in Primary Brain Microvascular Endothelial Cells Reduces
Barrier Impedance
To further establish an important role for endothelial TNAP in barrier maintenance, we
generated a mouse model with a conditional deletion of endothelial Alpl - the gene that encodes
TNAP – in endothelial cells [42]. To do this, we bred a Cdh5-Cre driver mouse with the
previously published Alpl floxed mouse [27]. Cdh5 encodes VE-cadherin, a marker of
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endothelial cells. First, we verified that Cre expression was specific for vascular endothelial cells
by crossing the Cdh5-Cre mice with Ai9 RFP promoter mice (Supplementary Figure 3). Then,
we measured whole brain AP activity in offspring littermates. VE-cKO (endothelial TNAP
knockouts) mice revealed a significantly decreased (t = 5.4, p = 0.006, unpaired t-test) whole
brain AP activity compared to Alplfl/fl mice (littermate control) (Fig. 6a). To further demonstrate
the loss of TNAP in endothelial cells, we isolated and cultured primary brain microvascular
endothelial cells (pBMECs) from Alplfl/fl and VE-cKO mice. Our results revealed an absence of
TNAP activity in VE-cKO pBMECs compared to Alplfl/fl pBMECs (Fig. 6b). Additionally, VE-cKO
endothelial cells revealed increased cell-cell detachment and loss of junction protein – claudin-5
compared to Alplfl/fl endothelial cells (Supplementary Figure 5). Consequently, we assessed
whether the loss of TNAP on VE-cKO pBMECs were comparable to the barrier assay results
derived with TNAPi in hCMEC/D3 endothelial cells. Our results revealed a significant loss of
barrier impedance (p < 0.0001) in VE-cKO pBMECs compared to Alplfl/fl pBMECs (Tukey’s
multiple comparisons test, repeated two-way ANOVA) (Fig. 6c).

3.4.7. Fasudil Rescues Loss of Barrier Impedance in VE-cKO Endothelial Cells
Next, we assessed whether ROCK inhibition would mitigate the loss of barrier
impedance shown in Figure 6c. Barrier impedance data was collected at three timepoints: pretreatment, fasudil treatment, and 48 h post-fasudil treatment (i.e., drug elimination). Our results
shown in Figure 7a (pre-treatment) paralleled the results derived in Figure 6c as expected (i.e.,
VE-cKO pBMECs demonstrated a significant loss of barrier impedance (p = 0.0009) compared
to Alplfl/fl pBMECs (repeated three-way ANOVA). Following treatment with fasudil, barrier
impedance in VE-cKO pBMECs significantly improved (p < 0.0001) compared to untreated VEcKO pBMECs (Tukey-Kramer comparisons test, linear mixed modeling). Interestingly, the
improvement of barrier impedance in fasudil treated VE-cKO pBMECs was comparable (p =
0.89) to untreated Alplfl/fl pBMECs (Tukey-Kramer comparisons test, linear mixed modeling)
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(Fig. 7b). 48 h post-fasudil treatment, barrier impedance in fasudil treated VE-cKO pBMECs
declined and became comparable (p = 0.52) to untreated VE-cKO pBMECs (Tukey-Kramer
comparisons test, linear mixed modeling) (Fig. 7c).

3.5. Discussion
In the present study, we sought to elucidate the mechanistic role of an AP isozyme,
TNAP, in brain microvascular endothelial cells. We have shown previously that microvascular
TNAP activity is decreased as early as 24 h post-sepsis and sustained up to 7 days post-sepsis
in the brains of mice [3, 22]. In addition, we showed that the decrease in TNAP activity in brain
microvessels extrapolates to other acute inflammatory conditions such as stroke. The
observation of a loss microvascular TNAP activity in late (7 days) sepsis and ischemic stroke
highlights a putative role for TNAP at the brain’s vasculature. Our results demonstrate an
important mechanistic role for endothelial TNAP in maintaining barrier integrity (measured as
impedance) by preventing the ROCK-mediated disruption of the cytoskeleton. Of note, it
remains unclear how TNAP’s action on ROCK proteins converge into the well-known function of
TNAP involving the dephosphorylation of nucleotides, LPS, DAMPs, and PAMPs [15-17].
Inflammatory molecules such as LPS have been shown in other models to increase ROCK
protein expression and cause endothelial barrier integrity loss [43-45]; hence, it is likely that the
action of LPS, DAMPs, and PAMPs are upstream relative to the novel mechanistic findings
shown in this study. Future studies will address the convergence of these pathways.
Circulating levels of pro-inflammatory cytokines such as TNF-a and IFN-g have been
shown to be increased in neuroinflammatory conditions like sepsis and stroke [21, 46-48]. Our
laboratory has previously shown that there is a sustained increase in pro-inflammatory cytokines
up to 7 days post-sepsis, and this increase is coupled to a loss of TNAP activity in brain
microvessels [22]; therefore, we examined whether treatment with TNF-a and IFN-g decreased
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endothelial TNAP activity similar to TNAPi. Our results showed that treatment of the brain
microvascular D3 endothelial cells with TNF-a and IFN-g sufficiently decreased TNAP activity
similarly to TNAPi treatment alone. This finding demonstrates that pro-inflammatory cytokines
may, in part, be responsible for the initial loss of brain microvascular TNAP activity seen in
sepsis and stroke. Furthermore, we showed that the decrease in endothelial TNAP activity or
the conditional loss of TNAP worsened endothelial cell barrier impedance. Owing to these
findings, we propose that impaired BBB function seen in sepsis and stroke pathogenesis
originates from endothelial cell damage, and the loss of endothelial TNAP activity contributes to
BBB dysfunction.
The overall findings from our pharmacological and genetic studies have identified a
novel molecular mechanism through which brain endothelial cell TNAP regulates BBB
impedance. Importantly, our results substantially extend the findings from a previous study
which showed that treatment of bovine capillary endothelial cells with a pan-AP inhibitor, i.e.
levamisole, induced the retraction of endothelial cells [37]. Endothelial cell retraction and
detachment are prototypical indicators of cytoskeletal reorganization and have been shown to
accompany BBB dysfunction and increase cellular permeability [49, 50]. We observed that
treatment of BMECs with TNF-α and IFN-γ combined with inhibition of TNAP enzymatic activity
disrupted the actin cytoskeleton. More importantly, the reorganization of the BMEC actin
cytoskeleton was accompanied by increased cell detachment between adjacent endothelial
cells, which represents reduced cell-cell junctional protein contact and adhesion. Junctional
proteins such as claudin-5 are connected to the actin cytoskeleton via scaffold proteins and
have been shown to play an important role in maintaining paracellular barrier permeability [51].
Therefore, it becomes plausible that the observed TNAPi-induced loss of endothelial barrier
impedance shown in this study originates from the inability of brain endothelial cells to form
proper cell-cell tight junctions. Therefore, we propose that the observed TNAPi-induced loss of
endothelial barrier impedance shown in this study originates from the inability of brain
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endothelial cells to form proper cell-cell adhesion. This is supported by a previous in vivo study
from our laboratory which showed that the junctional protein claudin-5 is decreased in the brains
of septic mice treated intraperitoneally with an in vivo TNAP inhibitor, SBI-425, compared to
vehicle treated septic mice [22]. In addition, morphological analyses of endothelial TNAP
conditional knockout cell cultures with the AP activity stain revealed endothelial retraction and
cellular detachment similar to TNAPi treated microvascular D3 endothelial cells (data not
shown).
Intermediate filaments have been shown to directly and indirectly interact with actin [52,
53]. This interaction is demonstrated by studies which showed that actin disruption affected
intermediate filament sub-localization networks in cells [54-56]. We observed that the disruption
of actin following TNAP enzyme inhibition disrupted the intermediate filament. Vimentin is one of
the major intermediate filaments shown to provide a structural support for cells [57].
Interestingly, we only observed diminished vimentin fluorescence intensity following inhibition of
TNAP activity, but not with TNF-α and IFN-γ treatment. In contrast, other studies that employed
different cell types, human umbilical vein endothelial cells (HUVECs) or astrocytes, have
demonstrated that TNF-α treatment increased vimentin protein expression [58, 59]. We suggest
that the properties of individual cell types, the dosage used, and use of TNF-α alone instead of
TNF-α and IFN-γ are responsible for this discrepancy. Taken together, our results suggest that
the sustained loss of microvascular TNAP activity induced by the presence of pro-inflammatory
cytokines may be detrimental to the actin cytoskeleton and intermediate filaments. However, it
remains unclear whether the loss of actin initiates vimentin disruption following TNAPi treatment
or vice versa.
ROCK protein expression has been shown to play a role in regulating cytoskeletal
proteins such as vimentin and actin by initiating F-actin contraction/retraction and cellular
detachment [39, 41, 49]. Upstream of ROCK is the RhoA protein, one of many proteins that
drives the activation of ROCK, and the Rho-ROCK pathway has been shown to play an
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important role in endothelial cell function Based on our cytoskeletal findings, we addressed
whether the Rho/ROCK pathway was implicated in TNAP signaling. Our results showed that
ROCK (1/2) protein expression was significantly increased following TNAPi treatment, along
with a trending decrease in RhoA. protein levels. This finding indicates that TNAP-mediated
signaling mechanism which suppresses ROCK activation is likely mediated by at least one
separate pathway in addition to the canonical RhoA pathway. We speculate that the drastic
effect of TNAP inhibition on ROCK 2 compared to ROCK 1 protein expression arises from the
increased expression of ROCK 2 in brain tissue compared to ROCK 1 [41]. Furthermore, it is
also likely that ROCK 1 and ROCK 2 may play independent effector roles downstream. For
example, Shi et el., showed that ROCK 1 regulates the actin cytoskeleton through myosin light
chain 2 (MLC2) phosphorylation while ROCK 2 regulates the actin cytoskeleton through cofilin
phosphorylation in mouse embryonic fibroblast (MEF) cells [60]. Finally, we utilized a ROCK1/2
inhibitor [61] to further demonstrate the involvement of ROCK proteins in a novel TNAP
signaling pathway in both D3 cells and pBMECs. These results contribute a novel mechanism in
support of the neuroprotective and anti-inflammatory benefit of fasudil treatment established in
preclinical models of sepsis and stroke [61-64].
BBB dysfunction is a common feature in many neuroinflammatory disorders [5].
Diminished BBB function is characterized by increased loss of junctional proteins, increased
paracellular permeability of molecules and immune cells into the brain parenchyma, and
endothelial cell transcytosis of immune cells into the parenchyma [3]. To our knowledge, this is
the first study to describe the novel role played by endothelial TNAP in maintaining paracellular
barrier impedance since our barrier assays can only assess this parameter. Our results suggest
that endothelial TNAP exerts an inhibitory function on the activity of endothelial ROCK proteins
in health and this function is dysregulated during acute injury as suggested by our septic and
stroke studies. We propose a working model (Fig. 8) in which TNAP inhibition or loss prevents
the contraction/retraction of endothelial cells and junctional protein disruption. During
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inflammation and/or acute injury, the rapid increase in pro-inflammatory cytokines leads to a
reduction in endothelial TNAP activity on microvessels. The sustained loss of TNAP activity
leads to cytoskeletal remodeling indicated by endothelial contraction and junctional protein
detachment, which then permits the paracellular infiltration of pro-inflammatory molecules and
immune cells that promote astrogliosis and microglial activation.
Despite the current advances discussed in this study, some limitations exist. Since the
experiments were carried out using in vitro and ex vivo methods, the contribution of astrocytes
or pericytes is not clear and will be addressed in future studies. Since D3 cells were generated
from a female donor and mixed sex pBMECs were used in the ex vivo experiments, we were
unable to delineate sex-specific pathways. Future studies will address the role of sex on brain
endothelial TNAP function. Furthermore, the barrier assay used in this study was unable to
delineate how endothelial TNAP may affect transcellular permeability or alter the physiological
and metabolic functions of brain endothelial cells. These mechanisms will also be addressed in
future studies. In summary, our results support a novel role for TNAP signaling in maintaining
BMEC barrier integrity. Therapeutic strategies that modulate the endothelial TNAP activity may
be beneficial for the treatment of BBB dysfunction or temporal - targeted drug delivery for
various neurological disorders such as brain tumors, ischemic stroke, or Alzheimer’s disease.
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Figure Legends
Figure 1: TNAP activity is decreased in sepsis and stroke (AD). (A-B) Representative
images showed that TNAP activity in the cortex and striatum is decreased in sepsis (7 days
post-sepsis) and stroke (7 days post-stroke) compared to appropriate controls. Images taken at
20X magnification and scale bar = 75 µm.
Figure 2: Inhibition of brain hCMEC/D3 endothelial TNAP promotes barrier dysfunction.
(A, B) TNAPi (p = 0.01, Tukey’s multiple comparisons test, one-way ANOVA) and TNF-a and
IFN-g (p = 0.0005, Tukey’s multiple comparisons test, one-way ANOVA) significantly decreased
brain endothelial TNAP activity compared to appropriate controls (DMSO or untreated).
Moreover, combined treatment of TNAPi, TNF-a and IFN-g significantly decreased (p < 0.0001,
Tukey’s multiple comparisons test, one-way ANOVA) brain endothelial TNAP activity compared
to TNAPi alone. (C) TNAPi (p < 0.0001, Tukey’s multiple comparisons test, repeated one-way
ANOVA) and TNF-a and IFN-g (p < 0.0001, Tukey’s multiple comparisons test, repeated oneway ANOVA) significantly decreased barrier integrity (impedance) compared to DMSO control. *
indicates p < 0.05, **p < 0.01 ***p < 0.001, and ****p < 0.0001, and is considered significant. All
data presented as mean ± SEM. Images taken at 10X magnification and scale bar = 1000 µm. n
= 3-5 wells/treatment group, ns = not significant.
Figure 3: TNAPi induces cytoskeletal remodeling in hCMEC/D3 brain endothelial cells. (A,
B) TNAPi (p = 0.0008, Tukey’s multiple comparisons test, one-way ANOVA) and TNF-a and
IFN-g (p < 0.002, Tukey’s multiple comparisons test, one-way ANOVA) significantly decreased
phalloidin (F-actin) fluorescence intensity compared to appropriate controls (DMSO or
untreated). Furthermore, combined treatment of TNAPi, TNF-a and IFN-g significantly
exacerbated the decrease in phalloidin fluorescence intensity compared to TNAPi (p < 0.006,
Tukey’s multiple comparisons test, one-way ANOVA) or TNF-a and IFN-g alone (p = 0.0001,
Tukey’s multiple comparisons test, one-way ANOVA). Increased endothelial cell detachment
(gaps, white arrows) accompanied the decrease in phalloidin fluorescence intensity. (C, D)
TNAPi (p = 0.03, Tukey’s multiple comparisons test, one-way ANOVA) and combined treatment
of TNAPi, TNF-a and IFN-g (p = 0.008, Tukey’s multiple comparisons test, one-way ANOVA)
significantly decreased vimentin fluorescence intensity compared to DMSO control.
Interestingly, TNF-a and IFN-g alone did not alter vimentin fluorescence intensity. * indicates p <
0.05, **p < 0.01 ***p < 0.001, and ****p < 0.0001, and is considered significant. All data
presented as mean ± SEM. Images taken at 20X magnification and scale bar = 200 µm. n = 3-6
wells/treatment group, ns = not significant.
Figure 4: ROCK isoforms are increased following TNAPi treatment in hCMEC/D3 brain
endothelial cells. (A, B) Rho protein was increased following treatment with TNAPi; however,
this increase was not significant (p = 0.34, Tukey’s multiple comparisons test, one-way
ANOVA). (C-F) Treatment with TNAPi increased ROCK 2 (p = 0.0003, Tukey’s multiple
comparisons test, one-way ANOVA) and ROCK 1 (p = 0.02, Tukey’s multiple comparisons test,
one-way ANOVA) protein expression compared to DMSO control. Fluorescence signal was
normalized to total cell number for each respective well. * indicates p < 0.05 and ***p < 0.001,
and is considered significant. All data presented as mean ± SEM. Average n = 10
wells/treatment group, ns = not significant
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Figure 5: Fasudil mitigates TNAPi-induced barrier dysfunction in hCMEC/D3 brain
endothelial cells. TNAPi alone significantly decreased (p < 0.0001, Tukey’s multiple
comparisons test, repeated one-way ANOVA) barrier impedance compared to DMSO control.
Combined treatment of TNAPi and fasudil significantly (p < 0.0001, Tukey’s multiple
comparisons test, repeated one-way ANOVA) rescues TNAPi-induced barrier dysfunction. ****
indicates p < 0.001, and is considered significant. All data presented as mean ± SEM. n = 3
wells/treatment group.
Figure 6: Conditional loss of endothelial TNAP worsens barrier impedance. (A) Whole
brain AP activity is significantly increased (p = 0.006, unpaired t-test) in Alplfl/fl (n = 2, littermate
control) mice compared to VE-cKO (n = 4, endothelial TNAP knockout) pBMECs. (B) VE-cKO
pBMECs were absent of TNAP activity stain (purple) compared to Alplfl/fl pBMECs. (C) Barrier
impedance in VE-cKO pBMECs was significantly decreased (p < 0.0001, Tukey’s multiple
comparisons test, repeated two-way ANOVA) compared to Alplfl/fl pBMECs. ** indicates p < 0.01
and ****p < 0.0001, and is considered significant. All data presented as mean ± SEM. Images
taken at 40X magnification and scale bar = 100 µm. n = 4 wells/treatment group.
Figure 7: Fasudil mitigates barrier impedance loss in VE-cKO pBMECs. (A) Barrier
impedance was significantly decreased (p = 0.0009, repeated three-way ANOVA) in VE-cKO
pBMECs compared to Alplfl/fl pBMECs before fasudil treatment. (B) Fasudil treatment
significantly mitigated (p < 0.0001, Tukey-Kramer comparisons test, linear mixed modeling) loss
of barrier impedance in fasudil treated VE-cKO pBMECs compared untreated VE-cKO pBMECs.
(C) 48 h post-fasudil treatment (i.e., drug elimination) barrier impedance in fasudil treated VEcKO pBMECs was comparable (p = 0.52, Tukey-Kramer comparisons test, linear mixed
modeling) to untreated VE-cKO pBMECs. *** indicates p < 0.001, and ****p < 0.0001, and is
considered significant. All data presented as mean ± SEM. n = 3 wells/treatment group.
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Supplementary Figure Legends
Supplementary Figure 1: Expression of brain microvascular TNAP activity is region
specific in mice. (A) Representative images of brain microvascular TNAP activity expression in
the cortex, striatum, and hippocampus (CA3 shown) of WT mice (n = 5). (B) Quantification of
brain microvascular TNAP activity expression revealed that TNAP activity is most significantly
expressed in the striatum (p < 0.0001, Tukey’s multiple comparisons test, one-way ANOVA) and
cortex (p = 0.0002, Tukey’s multiple comparisons test, one-way ANOVA) relative to the
hippocampus. Interestingly, TNAP activity in the striatum was significantly increased (p = 0.03)
when compared to the cortex. * indicates p < 0.05, ***p < 0.001, and ****p < 0.0001, and is
considered significant. All data are presented as mean ± SEM. Images taken at 20X
magnification and scale bar = 200 µm.
Supplementary Figure 2: Loss of TNAP activity on brain microvessels. (A) Representative
images showed loss of TNAP activity on CD31 positive (black arrow) brain microvessels 7 days
post-sepsis. (B) Similarly, TNAP activity on CD31 positive brain microvessels decreased in the
ipsilateral striatal penumbra (stroke hemisphere) compared to the contralateral striatum (nonstroke hemisphere) 7 days post-stroke. Images taken at 20X magnification and scale bar = 250
µm.
Supplementary Figure 3: VE-Cadherin Cre is specific for microvessels. Red fluorescent
protein (RFP) signal colocalizes with CD31 vascular endothelial marker. Cortex, striatum, and
thalamus are shown. Images taken at 20X magnification and scale bar = 75 µm
Supplementary Figure 4: pBMEC morphology and junctional protein expression. (A)
Representative images showed increased cell detachment and endothelial retraction (black
arrows) in VE-cKO pBMECs compared to Alplfl/fl pBMECs. (B) Claudin-5 junctional protein
expression is decreased in VE-cKO pBMECs compared to Alplfl/fl pBMECs. Images taken at 20X
magnification and scale bar = 200 µm (A); Images taken at 40X magnification and scale bar =
100 µm (B).
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4.1 Abstract
Blood-brain barrier (BBB) dysfunction is a key feature seen across many
neuroinflammatory conditions. Recent studies suggest that BBB dysfunction precedes long-term
cognitive impairment seen across many neuroinflammatory diseases. Yet, no therapies exist to
effectively mitigate BBB dysfunction. Preliminary evidence suggests that tissue-nonspecific
alkaline phosphatase (TNAP), an ectoenzyme localized to cerebral microvessels, may play an
important role in maintaining barrier integrity. In a recent study, we demonstrated that loss of
TNAP in primary microvascular endothelial cell (pBMEC) cultures worsened barrier integrity.
However, it remained unclear whether these findings translate in vivo. In the present study, we
sought to investigate the role of BMEC TNAP in maintaining BBB integrity in health and during
sepsis. We hypothesized that a conditional loss of brain endothelial TNAP in cerebral
microvessels would exacerbate BBB permeability to fluorescent molecules in naïve VE-cKO
mice. Our results revealed that naïve VE-cKO demonstrated a size selective increased
permeability to small molecules such as Rhodamine 123 (380 Da) but not to Texas red (625
Da). More importantly, when sepsis or stroke is initiated in VE-cKO mice, BBB permeability is
significantly increased. Taken together, we demonstrate a novel role for BMEC TNAP in
maintaining barrier integrity in health and during systemic inflammation.

Keywords: Tissue-nonspecific alkaline phosphatase; Alpl; Blood-brain barrier, BBB
Permeability; Brain microvascular endothelial cell; Sepsis
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4.2. Introduction
The blood-brain barrier (BBB) is a selective vascular interface composed of brain
microvascular endothelial cells (BMECs), pericytes, basement membrane, and astrocyte endfeet processes [1, 2]. BBB dysfunction is a key neuropathological feature seen in many
neuroinflammatory diseases [3]. Yet, therapies that mitigate BBB dysfunction remain to be
elucidated despite recent studies suggesting that BBB dysfunction may be responsible for longterm cognitive impairment [4-6]. To elucidate the role of the BBB in disease progression, it is
imperative that researchers examine protein/enzymes localized to cells that comprise the BBB
such as the BMEC.
Tissue-nonspecific alkaline phosphatase (TNAP) is one of many proteins localized to
BMECs, and is highly abundant in human and rodent cerebral microvessels [7]. Recent studies
from our group have demonstrated that following sepsis, TNAP activity was decreased in
cerebral microvessels and this decrease in TNAP activity was coupled to increased BBB
permeability to immunoglobulin G [8] [9]. Furthermore, we showed that pharmacological
inhibition of TNAP activity in hCMEC/D3 cells or conditional loss of brain endothelial TNAP (VEcKO) in primary cultures diminished paracellular barrier integrity using in vitro and ex vivo
barrier assays [10]. However, it is not clear whether the findings of diminished barrier seen in
VE-cKO primary brain microvascular endothelial cell (pBMECs) culture translate in vivo (i.e., in
the context of the BBB) given that endothelial cell solo-cultures lose their BBB properties and
characteristics [11].
The objective of this study was to examine the role of brain endothelial TNAP in health
and sepsis. We hypothesized that a conditional loss of brain endothelial TNAP in cerebral
microvessels would exacerbate BBB permeability to fluorescent molecules in VE-cKO naïve and
septic mice. First, we assessed permeability of the BBB in naïve VE-cKO mice using fluorescent
dyes of different sizes. Thereafter, we initiated sepsis in our mice via the cecal ligation and
puncture (CLP) model of sepsis, and then assessed BBB permeability to fluorescent dyes 24 h
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post-sepsis. Furthermore, we examined whether VE-cKO stroke mice exhibit worsened BBB
dysfunction and neuroinflammation compared to Alplfl/fl stroke mice. Taken together, our results
demonstrate that loss of brain endothelial TNAP in vivo resulted in a size selective whole brain
permeability in naïve VE-cKO mice that is exacerbated in septic and stroke. Moreover, our
finding provides preclinical evidence for the use of TNAP therapeutics to mitigate BBB
dysfunction seen in sepsis and stroke.

4.3. Methods
4.3.1. Animals
Experiments were conducted in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care
and Use Committee at West Virginia University. Creation of Alplfl/fl mice is described in [12] and
creation of VE-Cadherin Cre mice is described in [13]. Floxed Alpl (Alplfl/fl) mice on a C57BL/6J
genetic were crossed with B6.FVB-Tg (Cdh5-cre)7Mlia/J (VE-Cadherin Cre, Bar Harbor, ME,
Catalog # 006137) to ultimately produce mice with a conditional deletion of Alpl in the
endothelium (VE-cKO) and littermate control mice (Alplfl/fl). Genotyping was performed as
described previously [10]. Briefly, DNA was extracted from ear snips using the Purelink
Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA), and PCR products were amplified by
using a Veriti 96-well Thermal Cycler (Applied Biosystems, ThermoFisher Scientific, Waltham,
MA) under the following conditions: 94 °C for 1 min, [(94 °C for 30 sec, 60 °C for 30 sec, 72 °C
for 45 sec) × cycles], then 72 °C for 1 min. VE-Cadherin Cre specificity was determined by the
presence of a 700 bp product using the following primers; ACRE_F: 5’GAACCTGATGGACATGTTCAGGGA -3’, and ACRE_R: 5’CAGAGTCATCCTTAGCGCCGTAAA -3’ [13]. Confirmation of floxed Alpl sites was determined
by the presence of a 263 bp product using the following primer set; Alplflox_F: 5’GTTGCGATGTGTGAAGATGTCCTCG -3’, and Alplflox_R: 5’136

CTTGGGCTTGCTGTCGCCAGTAAC -3’. All mice were group housed in environmentally
controlled conditions with a reverse light cycle (12:12 h light/dark cycle at 21 ± 1°C) and
provided food and water ad libitum. Male and female wild-type mice were bred in West Virginia
University Health Sciences Center vivarium facilities and both sexes were used in all
experiments. Mice 3-4 months old were used for naïve and stroke experiments while 11-12
months old were used for sepsis experiments. Aged mice were used in the septic experiments
due to prior studies demonstrating that middle aged and elderly individuals are at a higher risk
for sepsis mortality and morbidity [14-16].

4.3.2. Cecal Ligation and Puncture (CLP)
The cecal ligation and puncture (CLP) model of polymicrobial sepsis was employed as
previously described [9, 17]. Briefly, Alplfl/fl and VE-cKO mice were anesthetized by the
inhalation of 1-2% isoflurane and abdominal access was obtained via a midline incision. The
cecum was ligated below the ileocecal valve, punctured twice with a 22 G needle through and
through, and placed back into the abdominal cavity. The abdominal muscle and skin layer were
closed with 6-0 and 5-0 sutures (Ethilon, Cornelia, GA) respectively. Sham-operated animals
had their cecum isolated and then returned to the peritoneal cavity without being ligated or
punctured. One mL of sterile 0.9% saline was administered subcutaneously (s.c.) for fluid
resuscitation in all experimental groups. Mice used for all experiments were euthanized at 24 h
post-sepsis surgery for permeability studies.

4.3.3. Permanent Middle Cerebral Artery Occlusion (pMCAO)
pMCAO surgery was performed under isoflurane anesthesia as previously described
[18]. Briefly, Alplfl/fl and VE-cKO mice were subjected to pMCAO using silicon coated sutures
(Cat. #702334, Doccol Corporation, MA) followed by reperfusion. Body temperatures were
controlled at 37 ± 0.5 °C during occlusion. Occlusion was verified in each animal by a Laser
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Speckle Imager (Moor Instruments, England). Bupivacaine (2 mg/kg, s.c.) was administered to
relieve pain after surgery. Mice were euthanized 6h following pMCAO surgery.

4.3.4. BBB Permeability Assay, Perfusion, and Tissue Collection
Rhodamine 123 (Invitrogen, Carlsbad, CA) and Texas red (Invitrogen) fluorescent dyes
were used to measure permeability as described previously [19]. Briefly, both dyes were coinjected at a concentration of 2 mM intravenously via the retro-orbital vein. Following retroorbital injection, the dyes were allowed to circulate for 15 mins prior to euthanasia. Mice were
then deeply anesthetized with isoflurane after 15 mins of dye circulation and transcardially
perfused (Masterflex 7524-10, Cole-Parmer, Vernon Hills, IL) with 0.9% saline to remove blood.
Thereafter, brains were removed from the skull with the olfactory bulbs and cerebellum carefully
dissected out and discarded. The right cerebrum and left cerebrum were quickly separated. The
left cerebrum was immediately frozen in -80oC isopentane for 1 min and then stored at -20oC
until further processing. The right cerebrum was weighed (grams) and placed in microcentrifuge
tubes (VWR, Bridgeport, NJ) containing 300 µL of phosphate buffered saline (PBS) for
homogenization. Following homogenization, samples were then centrifuged at 15000 g, 20
mins, at 4oC. Supernatants were transferred into a new microcentrifuge tube (see Figure 1A). A
similar experimental paradigm as shown in Figure 1A was carried out for sham and septic
experiments, however, cascade blue-3 kDa dextran dye (Invitrogen) was utilized in addition to
the Rhodamine 123 and Texas red fluorescent. Furthermore, dyes were allowed to circulate for
1 h instead of 15 mins.

4.3.5 BBB permeability quantification
4.3.5.1 Spatial permeability
Spatial/regional permeability was assessed in the left cerebrum of naive animals as
previously described [19]. Frozen brains were sectioned at 20 µ on a Leica CM30505 cryostat
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(Leica Biosystems, Buffalo Grove, IL). Regions such as the cortex, striatum, hippocampus, and
thalamus were identified using the Allen Institute Brain Atlas (http://mouse.brain-map.org). 3
sections per brain region from each animal were used for all image analyses. Fluorescence
intensity was measured on the Olympus MVS10 stereomicroscope (Olympus, Japan) using a
2X objective and an optical zoom 0.63 to 6.3X. Rhodamine 123 and Texas red
excitation/emission filters (470/525 nm and 560/645 nm respectively) were used to acquire
fluorescence intensity.

4.3.5.2 Whole cerebrum (brain) permeability
Whole brain permeability was assessed in the right cerebrum of naïve and septic
animals as previously described [19]. Briefly, 50 µL triplicates of tissue supernatant from the
right cerebrum was pipetted into a 96-well plate. The 96-well plate was inserted into a plate
reader (BioTek, Winooski, VT) and fluorescence was measured using respective
excitation/emission filters for Rhodamine (488/525 nm), Texas red (461/605 nm), and cascade
blue-3 kDa dextran (360/450 nm) dyes. Relative fluorescence intensity was normalized to the
weight of the right cerebrum.

4.3.6. Stroke brain collection, immunohistochemistry, and image analysis
Mice were deeply anesthetized with isoflurane and transcardially perfused as described
previously [9]. Briefly, blood was removed with 0.9% saline followed by perfusion and fixation
with 4% chilled paraformaldehyde (PFA, Fisher Scientific, Pittsburgh, PA). Perfused brains were
post-fixed in 4% PFA overnight at 4oC. On the following day, brains were rinsed in 0.01 M PBS
and incubated sequentially in 15% and 30% sucrose in PBS for 24 h each. Brains were
sectioned at 35 µm on a sliding microtome (HM 450, ThermoFisher Scientific). Brain sections
were washed three times, permeabilized, and blocked for 30 min on a shaker. Brain sections
were then incubated overnight with primary antibodies, followed by a 2 h incubation with the
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appropriate secondary antibody at room temperature. The following primary antibodies were
used with working dilutions and antibody identification indicated in parentheses: GFAP (Agilent
(1:10,000), AB_2811722, Santa Clara, CA) and Fibrinogen (Abcam (1:500), (AB_732367),
Cambridge, MA). Sections were viewed on a Leica DM6B microscope (Leica Camera,
Allendale, NJ) and images were captured using Leica LASX software (Leica Microsystems,
Buffalo Grove, IL). Cortex was identified by referring to the Allen Institute Brain Atlas
(http://mouse.brain-map.org). Three random images were collected per animal per brain region
of interest. All collected images were converted to an 8-bit image and quantified in FIJI/Image J
version 2.0 software as percent area.

4.3.7. Statistical Analysis
Experiments were executed to enhance rigor and avoid experimenter bias according to
ARRIVE guidelines [20]. Animals whose brain did not perfuse well were removed from the study
as described in [19]. All statistical analyses were performed in GraphPad Prism 9.0 (GraphPad
Software, La Jolla, CA). Results are expressed as mean ± SEM and p-values ≤0.05 were
considered significant. Data was analyzed using a two-tailed unpaired Student’s t-test, repeated
two-way analysis of variance (ANOVA), or two-way analysis of variance followed by Tukey’s
multiple comparisons post hoc test. Datasets that did not display a Gaussian distribution were
subjected to a comparable non-parametric analysis (Mann-Whitney test). All p-values and n
values are indicated in the figure legends. Outliers were removed using the GraphPad prism
Grubbs outlier test.

4.4. Results
4.4.1. Naïve VE-cKO mice whole brain demonstrated a size selective permeability to
Rhodamine 123 (380 Da) but not to Texas red (625 Da).
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First, we assessed whether the loss of brain endothelial TNAP would increase BBB
permeability to fluorescent dyes of different sizes. Our results showed that VE-cKO mice
revealed no difference in Rhodamine 123 or Texas red spatial permeability in the cortex.
striatum, hippocampus, and thalamus when compared to Alplfl/fl mice (Fig. 1B-G; Supplementary
Fig.1). Next, we assessed whether VE-cKO mice would demonstrate increased whole brain
permeability when compared to Alplfl/fl mice. Our results showed that VE-cKO mice revealed a
significantly increased permeability to Rhodamine 123 but (p = 0.03) not to Texas red (p = 0.24)
(Fig. 2). Taken together, our results suggest that loss of brain endothelial TNAP results in a size
selective loss of whole brain BBB integrity.
4.4.2. Loss of brain endothelial TNAP worsened BBB permeability to fluorescent dyes postsepsis
Next, we assessed whether the increase in whole brain permeability to small molecules
seen in naïve VE-cKO mice would be exacerbated in early sepsis (24 h). Paradoxically,
Rhodamine 123 permeability was significantly decreased (main effect: p = 0.003) in the brains
of VE-cKO and Alplfl/fl septic mice (Fig. 3A). Post hoc analyses revealed that the decrease in
Rhodamine 123 permeability post-sepsis was only significant between Alplfl/fl sham and Alplfl/fl
septic mice (p = 0.0028) but not between VE-cKO sham and VE-cKO septic mice (p = 0.32).
Sepsis significantly increased permeability to Texas red (main effect: p < 0.0005) and cascade
blue-3 kDa dextran (main effect: p < 0.0021) dyes for both VE-cKO and Alplfl/fl mice. Post-hoc
analyses revealed that VE-cKO septic mice when compared to VE-cKO sham mice
demonstrated a significantly increased permeability to Texas red (p = 0.0022) and cascade
blue-3 kDa dextran (p = 0.03). However, no differences in permeability to Texas red (p = 0.33)
and cascade blue-3 kDa dextran (p = 0.24) were seen between male Alplfl/fl sham and Alplfl/fl
septic mice. More importantly, comparisons between VE-cKO sham and Alplfl/fl sham mice
revealed no difference in Texas red (p = 0.99) or cascade blue (p = 0.99) permeability (Fig. 3 B,
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C). These results suggest a plausible role for TNAP in maintaining BBB permeability during
systemic inflammation.
4.4.3. VE-cKO stroke mice displayed increased fibrinogen extravasation and astrocyte
proliferation
Thereafter, we examined whether VE-cKO mice subjected to 6 h pMCAO would exhibit a
worsened BBB integrity compared to Alplfl/fl stroke mice. Our results showed that VE-ckO stroke
mice demonstrated a significant increase (p = 0.050) in brain parenchymal fibrinogen deposition
compared to Alplfl/fl stroke mice. Furthermore, the increase in fibrinogen brain deposition (p =
0.046) was coupled to significant astrogliosis in VE-cKO (Fig. 4).
4.5. Discussion
TNAP activity is abundantly expressed in cerebral microvessels, however, its function on
cerebral microvessels has been vastly unexplored until lately. We recently demonstrated that
inhibition of TNAP activity in an immortalized human endothelial cell line (hCMEC/D3) or a
conditional loss of TNAP in pBMECs resulted in a loss of barrier integrity [10]. Though these
results have advanced our knowledge on the function of TNAP in BMECs, it remained unclear
whether the observed in vitro findings of diminished barrier integrity would persist in vivo.
In the present study, we sought to examine whether conditional loss of BMEC TNAP in
vivo would exacerbate BBB permeability in naïve and septic mice. We showed here that whole
brain BBB permeability following a loss of BMEC TNAP was increased to smaller molecules
(~380 Da) but not to molecules greater or equal to 625 Da. The findings from this study
resemble the deletion of junctional protein claudin-5 in mice which led to a size selective
permeability to small molecules <800 Da [21]. Interestingly, both TNAP and claudin-5 global
knockouts die immediately after birth which further highlights the critical role played by both
proteins in normal physiology [21, 22]. Furthermore, a recent study showed that size selective
permeability to small molecules in the early phase of ischemic brain injury is attributed to actin
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cytoskeletal re-organization [23]. We have previously shown that inhibition of BMEC TNAP led
to actin cytoskeletal re-organization via the ROCK pathway [10]. Thus, it is likely that loss of
BMEC TNAP in vivo and the resultant size selective permeability to small molecules may be
mediated through actin cytoskeletal re-organization.
Spatial permeability was also assessed in naïve mice; however, no differences were
observed indicating that whole brain rather than regional permeability needs to be taken into
account when studying BMEC TNAP function in vivo. It is unclear whether BBB permeability to
very small molecules like Rhodamine 123 (380 Da) holds any biological significance in healthy
mice. Future studies will need to address whether naïve VE-cKO mice exhibit cognitive decline
in young and aged mice. Additionally, whole brain selective permeability to only small molecules
in naïve mice suggest that other cell types of the BBB may compensate for BMEC TNAP loss
through molecular cross-talk via signaling molecules. For instance, co-cultures of BMECs and
mixed glial cells in vitro has been shown to drastically increase TNAP protein, activity, and
mRNA expression in BMECs compared to solo-cultures [24-26]. More importantly, astrocyte
end-feet processes and pericytes have been shown to express TNAP activity [27-29]. Hence, it
becomes plausible that the loss of cerebral microvascular TNAP activity seen in sepsis may
have resulted from a combined loss of TNAP activity in pericytes or astrocytes rather than
BMECs alone. Future studies are warranted to examine how TNAP expression in other cell
types of the BBB work together with BMEC TNAP to maintain precise cerebral homeostasis.
Since naïve mice demonstrated a size selective permeability to smaller molecules, we
examined the implications of this size selective permeability in the context of systemic
inflammation (i.e., sepsis). Not surprising, there was a significant main effect of treatment
(sepsis) that led to an increased permeability of fluorescent dyes in VE-cKO and Alplfl/fl septic
mice compared to controls. These findings are corroborated by other septic studies which have
shown increased BBB dysfunction post-sepsis [30, 31]. Interestingly, post-hoc analyses
revealed that VE-cKO septic mouse exhibited a significantly increased permeability to Texas red
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(625 Da) and cascade blue-3 kDa dextran when compared to VE-cKO sham mice. However, no
significant differences in permeability were seen between Alplfl/fl sham and Alplfl/fl septic mice
when compared. Next, we examined the loss of BMEC in a model of stroke. As expected, VEcKO stroke mice exhibited a worsened barrier integrity denoted by increased fibrinogen
extravasation into the brain parenchyma. Therefore, our results suggest that the size selective
permeability seen in naïve VE-cKO mice is worsened when sepsis or stroke is superimposed on
an already leaky BBB.
Paradoxically, Rhodamine 123 was decreased in the brains of septic mice compared to
sham mice. We speculate that the decrease in Rhodamine 123 in the brains of septic mice likely
resulted from the 1 h dye circulatory period prior to euthanasia. Furthermore, inflammatory
molecules have been shown to increase P-glycoprotein (P-gp) efflux transporter expression in
the kidney, pulmonary, and intestinal tissue [32, 33]. Given that Rhodamine 123 is a P-gp
substrate [34], it is likely that this dye would be rapidly removed from the brain by the P-gp efflux
transporter if allowed to circulate for longer periods (> 15 mins) post-sepsis. Interestingly, posthoc analyses revealed that the significant decrease in Rhodamine 123 is only present between
Alplfl/fl sham and Alplfl/fl septic mice but not VE-cKO sham and VE-cKO septic mouse. These
findings suggest that P-gp efflux transporter function may be dysfunctional in VE-cKO mice
following sepsis.
In summary, our results demonstrate a novel role for BMEC TNAP in maintaining barrier
integrity in vivo that corroborates our recent in vitro findings [10]. Furthermore, we have
demonstrated a plausible role for the P-gp efflux transporter post-sepsis, which may yield
therapeutic consideration when selecting drugs to treat sepsis associated brain dysfunction.
Further investigations that examine the contribution of other BBB TNAP expressing cell types
such as astrocytes and pericytes in maintaining BBB integrity are needed to fully elucidate the
role of TNAP in cerebral microvessels.
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Figure Legends
Figure 1: Naïve VE-cKO mice displayed no differences in spatial BBB permeability. (A)
Experimental design for the naïve BBB permeability study. (B-G) Cortex (ctx), striatum (str),
hippocampus (hip), and thalamus (thal) revealed no differences in spatial permeability to
Rhodamine 123 (p > 0.05) or Texas red (p > 0.05) fluorescent dyes between naive VE-cKO and
Alplfl/fl mice. A two-tailed unpaired Student’s t-test was used for all analyses. All data presented
as mean ± SEM. Images taken at 1.5X magnification and scale bar = 1 mm. n = 6/mice group.
Figure 2: Naïve VE-cKO mice demonstrate a whole brain size selective permeability to
Rhodamine 123. (A) Rhodamine 123 (380 Da) whole brain permeability was significantly
increased (p = 0.03; two-tailed unpaired Student’s t-test) in VE-cKO mice compared to Alplfl/fl
mice. (B) Texas red (625 Da) permeability showed no significant differences (p > 0.05; MannWhitney test) between naive VE-cKO and Alplfl/fl mice. * indicates p < 0.05 and is considered
significant. All data presented as mean ± SEM. n = 6/mice group.
Figure 3: Sepsis exacerbates VE-cKO size selective permeability. (A) Rhodamine 123
permeability was significantly decreased (main treatment effect: p = 0.003; two-way ANOVA) in
the brains of VE-cKO and Alplfl/fl septic mice. Tukey’s multiple comparisons test revealed that
the decrease in Rhodamine 123 permeability post-sepsis was only significant (p = 0.0028)
between Alplfl/fl sham and Alplfl/fl septic mice. (B-C) Sepsis significantly increased permeability to
Texas red (main treatment effect: p < 0.0005; two-way ANOVA) and cascade blue-3 kDa
dextran (main treatment effect: p < 0.0021; two-way ANOVA) dyes for both VE-cKO and Alplfl/fl
mice. Tukey’s multiple comparisons test revealed that VE-cKO septic mice when compared to
VE-cKO sham mice demonstrated a significantly increased permeability to Texas red (p =
0.0022) and cascade blue-3 kDa dextran (p = 0.03). Alplfl/fl sham and Alplfl/fl septic mice Tukey’s
multiple comparisons revealed no significant differences in permeability to Texas red (p = 0.33)
and cascade blue (p = 0.24) dyes. * indicates p < 0.05, **p < 0.01 ***p < 0.001, and is
considered significant. All data presented as mean ± SEM. n = 13-20/mice group. ns = not
significant.
Figure 4: VE-cKO stroke mice displayed BBB dysfunction and astrogliosis. Brains of VEcKO stroke mice exhibited a significant increase in astrogliosis (p = 0.046) and fibrinogen (p=
0.05) deposition compared to Alplfl/fl mice. Scale bar = 75 µm. A two-tailed unpaired Student’s ttest was used for all analyses All data presented as mean ± SEM. n = 2/mice group.
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Supplementary Figure
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Supplementary Figure Legends
Supplemental Figure 1 VE-cKO mice displayed no differences in spatial BBB
permeability. 10X magnified images further demonstrated that Cortex, striatum, hippocampus
(CA3 shown), and thalamus revealed no differences in spatial permeability to Rhodamine 123 or
Texas red fluorescent dyes between naive VE-cKO and Alplfl/fl mice. Scale bar = 100 µm.
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Brain microvascular endothelial cells (BMECs) are a key cellular component of the
blood-brain barrier (BBB) that provide a stringent, yet, dynamic interface between systemic
circulation and the brain parenchyma [1, 2]. BMECs are characterized by a non-fenestrated
continuous endothelium linked together by tight junction [3] proteins that confer high resistance
to paracellular transport between adjacent endothelial cells [4-6]. BMEC dysfunction is seen
across several neuroinflammatory diseases including sepsis, stroke, multiple sclerosis (MS),
and Alzheimer’s disease (AD). Elegant studies have shown that BBB dysfunction precedes
cognitive decline or disease activity in AD, MS, and aging [7-12]. TNAP is one of many proteins
localized to BMECs, and is highly abundant in human and rodent cerebral microvessels [13].
Despite the high expression of TNAP on cerebral microvessels, the role of TNAP in the brain
microvascular endothelium remained unclear until recently [13-17]. The overarching objective of
this dissertation was to elucidate the role played by BMEC TNAP in preserving BBB integrity in
normal physiology and in sepsis. Three sets of studies were designed to address the knowledge
gaps associated with understanding the function of TNAP in cerebral microvessels – specifically
BMECs. We proposed a central hypothesis that BMEC TNAP is critical for maintenance of
BBB integrity in normal physiology and in sepsis through molecular mechanisms that
preserve BMEC structure and function.
In this body of work, we showed that BMEC TNAP activity plays a critical role in
maintaining paracellular barrier integrity in health and in disease (sepsis and stroke). Prior to
this work, the role for BMEC TNAP in cerebral microvessel was vastly unexplored. Previous
studies from decades ago had suggested that the appearance of TNAP activity in cerebral
microvessels during development correlated with a functional BBB [13]. However, these studies
did not examine how TNAP contributed to proper BBB integrity and function. A critical question
in the field that remained unanswered was whether the loss of TNAP activity seen in disease
coupled BBB dysfunction. Indeed, we showed in Chapters 2 and 3 that TNAP activity was
coupled to BBB dysfunction in sepsis and stroke. Furthermore, we provided substantial
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evidence in Chapter 2 that pro-inflammatory cytokines may be responsible for the decrease in
BMEC TNAP activity seen in sepsis and stroke. More importantly, our studies in Chapter 3
significantly contributed to the field by mechanistically delineating a molecular target of TNAP ROCK. Lastly, we investigated the role of BMEC TNAP in vivo in sepsis and stroke. We showed
that loss of BMEC TNAP in sepsis and stroke worsened BBB dysfunction. This is the first in vivo
study to provide preliminary evidence for TNAP as a therapeutic target to treat cerebral injury.
One of the many challenges in studying organ specific TNAP function arises from the
fact that life expectancy of mice with a global genetic deletion of the Alpl gene (Alpl-/-) averages
3-5 weeks due to hypophosphatasia (HPP) and neurological deficits such as seizures [18, 19].
However, development of the Alpl floxed mice by Dr. Jose Luis Millan and VE-Cadherin Cre
mice by Alva et el. have aided our understanding of TNAP in BMECs [20-23]. The data
described in this dissertation demonstrates the utility of the VE-cKO mice as a mouse model
that could be used to investigate BMEC TNAP function in future studies.

I. A novel anti-inflammatory role for TNAP in cerebral microvessels
Historically, TNAP activity has been used as a histological marker for the presence or
absence of cerebral vessels in disease without much attention given to why the loss of TNAP
activity was occurring, and how this loss might affect disease progression [13]. This perspective
is exemplified in an earlier study utilizing TNAP activity to examine vascular density [24]. Briefly,
Brown et al. investigated brain arteriolar and capillary density in 12 patients with leukoaraisosis
(LA; age-related white matter degenerative disease) and 9 age-matched control patients using
TNAP activity. The authors conclude that vascular density is significantly decreased in LA when
compared to control patients [24]. However, it was not evident from the study why TNAP activity
was decreased in patients with LA compared to controls. It was also not clear if the loss of
TNAP activity in LA was due to the loss of cerebral microvessels since the study did not utilize
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appropriate markers for the vasculature such as CD31, CD34, or collagen type IV [25]. Owing to
these findings, several important questions were raised for future investigations:

1) Is the loss of TNAP activity on cerebral microvessels specific to a unitary disease state?
2) Does the loss of TNAP activity equate to the loss of cerebral microvessels?
3) Does the loss of TNAP in cerebral microvessels couple the loss of barrier integrity?
4) What are the relevant long-term neuroinflammatory and behavioral implications of brain
microvascular TNAP loss?

The results derived in chapter 2 of this dissertation sought to answer these critical
questions. A significant number of studies have demonstrated a role for peripheral endothelial
TNAP activity in disease [26-29], however, there is a paucity of data on the function of cerebral
microvascular TNAP activity in disease. To elucidate whether TNAP activity was altered in
disease, we utilized the cecal ligation and puncture (CLP) model of sepsis to examine how
TNAP activity changed in early sepsis and whether this changed was sustained long-term (7
days). Our results showed that loss of TNAP activity is present as early as 24 h post-sepsis [30]
and this loss was sustained up to 7 days post-sepsis [15]. However, it was unclear whether the
resultant loss of TNAP activity was due to cerebral microvessel loss as stated in the Brown et al.
LA study [24]. Therefore, we co-labelled for cerebral microvessel using CD31 and TNAP
activity. Our results showed that indeed the loss of TNAP activity was not due to a loss of brain
microvessels. This finding refutes the utility of brain microvascular TNAP activity as a measure
of vascular density since this activity changes with disease. More importantly, we showed that
the loss of TNAP activity on cerebral microvessels coupled a loss of junctional protein claudin-5,
microglial activation, astrocyte proliferation, and the infiltration of an endogenous permeability
marker, immunoglobulin G [31], into the brain [15]. To further demonstrate a role for brain
microvascular TNAP in disease, we intraperitoneally injected septic mice with SBI-425 (an in
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vivo TNAP inhibitor) or vehicle (DMSO) and examined junctional protein claudin-5 expression.
Our results showed that claudin-5 expression was decreased in SBI-425 treated septic mice
compared to vehicle treated septic mice.
Sepsis survivors are burdened with long-term cognitive impairments [32], hence, we
examined whether the loss of TNAP in cerebral microvessels coupled behavioral deficits at 7
days post-sepsis. We showed that our septic mice displayed an impaired sensorimotor
phenotype but had no alterations in memory. We speculate that the impairment in sensorimotor
dysfunction likely results from the loss of TNAP in the cortex, striatum, and spinal cord,
whereas, no differences in memory were observed because hippocampal TNAP activity at 7day post-sepsis revealed no differences between sham and septic animals [15]. Nevertheless, it
remains unclear whether hippocampal TNAP activity may be altered at later timepoints (>7
days) when memory loss has been shown to occur in other septic studies [33, 34]. Taken
together, the data discussed in Chapter 2 of this dissertation provided a novel role for TNAP
activity in cerebral microvessels (Fig. 1). Despite these advancements in understanding the role
of TNAP activity in cerebral microvessels, it remains unclear what parts of the brain’s vascular
tree (arteries, capillaries, or veins) may be critical for BBB maintenance relating to TNAP
function.
The cerebral vasculature is heterogenous and displays an arteriovenous hierarchy
similar to peripheral vascular beds. Moreover, the expression of a single protein or molecule
differs across the cerebral arteriovenous vascular bed. For example, a recent study
demonstrated that the expression of von Willebrand Factor (VWF) is increased in venous
BMECs compared to brain arterial and capillary BMECs, whereas, major facilitator super family
domain containing 2a (Mfsd2a) protein is highly abundant in capillary BMECs compared to brain
arterial and venous BMECs [35]. The localization of TNAP activity in the brain endothelium has
been explored in an earlier study. Vorbrodt et al. showed that adult mouse capillary and arterial
BMECs express strong TNAP activity, however, venules showed a complete lack of TNAP
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activity. Importantly, despite brain arterioles and capillaries sharing a strong TNAP activity
expression, electron microscopy revealed that capillaries express TNAP activity on the luminal
surface, whereas, arterioles express TNAP activity on the luminal and abluminal surfaces of
BMECs [36]. Intriguingly, a recent study utilizing single-cell RNA sequencing demonstrated that
TNAP protein (i.e., Alpl) is also present in the cerebral venous endothelium. Furthermore, this
same study also demonstrated that Alpl is highly abundant in brain endothelial cells compared
to astrocytes, pericytes, neuron, microglia, and oligodendrocytes [17]. It is unclear whether this
new finding contradicts the earlier findings from the Vorbrodt et al. study, which showed an
absence of TNAP activity on the venous endothelium using electron microscopy, or rather
demonstrates that the protein is present on the venous endothelium but its activity is absent.
Spatial/regional brain microvascular expression of TNAP activity was examined in this
dissertation. We showed that TNAP activity is highly expressed in striatum (highest TNAP
expression) and cortex compared to the hippocampal cerebral microvessels [16].
Future studies, will need to utilize multiphoton imaging, optical tissue clearing, and
electron microscopy methods to examine TNAP brain zonation in arterioles, venules, and
capillaries given that these vascular regions are morphologically and functionally different [37].
For example, arteriolar vessels have been shown to regulate blood-flow in the cerebral
microvasculature via smooth muscle actin, and this regulation is known as neurovascular
coupling [38, 39]. On the other hand, brain capillaries are importance sites of molecular and
nutrient transport [37], whereas, post-capillary venules have been shown to play an important
role in immune cell transmigration [40]. It remains unclear how a loss of BMEC TNAP may affect
the function of these different vessel types in health and disease. The availability of the VE-cKO
mice along with specific pharmacological inhibitors (TNAPi and SBI-425) could help answer
these new questions. For example, VE-cKO mice would be injected via the retroorbital vein with
LysM green fluorescent protein (GFP) monocytes or CD4-GFP T-cells, thereafter, multiphoton in
vivo live imaging could be used to examine immune cell extravasation at the post-capillary
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venules in naïve VE-cKO and septic VE-cKO mice. Alternatively, flow cytometric methods could
be used to assess whole brain immune cell populations in naïve VE-cKO and septic VE-cKO
mice.

II. TNAP-mediated signaling pathways in brain endothelium: a mechanism to explain the
repercussions of diminished cerebral microvascular TNAP activity
Alkaline phosphatases such as TNAP have been previously shown to detoxify toxic
molecules such as lipopolysaccharide (LPS) [41]. Other known substrate for TNAP under
healthy conditions include: inorganic pyrophosphates (PPi), vitamin B6, adenosine triphosphate
(ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), and
phosphoethanolamine (PEA) [42, 43]. Despite the intriguing findings of a loss of brain
microvascular TNAP coupled to BBB dysfunction in sepsis as shown in Chapter 2, it was not
apparent on what factors or molecules induced brain microvascular TNAP loss following sepsis,
and whether this loss could be seen in other acute neuroinflammatory conditions such as
stroke. These new questions were answered in Chapter 3, which showed that the loss of TNAP
activity in cerebral microvessels during sepsis manifests similarly in the cortical and striatal
penumbra following transient ischemic stroke in mice [16]. Sepsis and stroke animal models
have been shown to exhibit a rapid increase in systemic and cerebral pro-inflammatory
cytokines [31, 44-46], therefore, we hypothesized that the presence of pro-inflammatory
cytokines would decrease BMEC TNAP activity. As expected, treatment of hCMEC/D3 with
TNF-α and interferon-gamma (IFN-g) significantly decreased BMEC TNAP activity to similar
levels as the use of TNAPi. More importantly, we showed that the decrease in TNAP activity
was coupled to a loss of paracellular barrier integrity. Thereafter, we delineated the mechanisms
through which the loss of paracellular barrier integrity occurred in hCMEC/D3 cells.
BMEC TNAP was studied in this dissertation as opposed to other BBB cell types
because BMECs have been shown to express abundant TNAP protein compared to astrocytes
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and pericytes [17]. In the brain, the molecular mechanisms through which TNAP operates are
well studied in neurons but not well elucidated in brain endothelial cells. For an in-depth
discussion on neuronal TNAP function, the reader is directed towards these excellent reviews
[47-49]. Preliminary evidence from the Deracinois et al. group was the first study to show that
inhibition of TNAP using a pan-AP inhibitor (levamisole) in bovine capillary endothelial cells
(BCECs) increased barrier permeability to Lucifer Yellow (PeLY) [50]. Our data in Chapter 3
corroborates this finding. In Chapter 3, we utilized the Real Time Cell Analysis Dual Plate
instrument (RTCA DP) that measures cell impedance as a function of cell viability, cell
morphology, and degree of adhesion. The presence of cells in the wells act as an insulator and
alters the ionic environment. Therefore, adhesive cells exhibit higher cell impedance values,
whereas, non-adhesive cells should theoretically exhibit a lower cell impedance (see RTCA DP
instrument manual: http://www.cytometrie-imagerie-saint
antoine.org/media/4046/RTCA_DP_System_Operator_Manual_v3.pdf). Pharmacological
inhibition of TNAP with a specific TNAP inhibitor (TNAPi) in an appropriate human BBB
endothelial cell line model (hCMEC/D3 cells) demonstrated worsened paracellular barrier
impedance. Furthermore, primary BMECs (pBMECs) cultured from 6-8 weeks old mice with a
conditional deletion of endothelial TNAP (VE-cKO) demonstrated a worsened paracellular
barrier impedance. Together, these results suggest that BMEC TNAP activity plays an important
role in maintaining barrier integrity, however, the mechanisms through which this occurred
remained unclear.
Next, we showed that the loss in barrier impedance resulted from cytoskeletal
remodeling denoted by cellular detachment and loss of fluorescence intensity of actin and
vimentin. Rho-associated protein kinase [51] proteins belong to a family of serine/threonine
kinases and are often downstream targets of Rho GTPases. Following activation, ROCK inhibits
the phosphorylation of myosin II regulatory light chain (MLC) and MLC phosphatase (MLCP)
which are both important for cellular relaxation, inhibition of stress fiber formation, and
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prevention of cell-cell detachment [52]. More importantly, increased ROCK protein expression
has been implicated in many neurodegenerative diseases including amyotrophic lateral
sclerosis [53], Huntington’s disease (HD), AD, and Parkinson’s disease (PD) [54]. Thus, we
explored the role of the ROCK pathway in mediating cytoskeletal remodeling following TNAPi
treatment. Our results showed that TNAPi increased BMEC expression of ROCK 1 and 2
proteins. Interestingly, TNAPi did not significantly increase Ras homolog family member A
(RhoA; an Upstream target of ROCK) protein expression. This indicates that TNAP activity may
decrease ROCK expression through another pathway that is independent of RhoA. Future
studies will need to examine what additional proteins are involved in TNAP-induced
downregulation of ROCK protein expression.
In a final set of experiments, we utilized a pan-ROCK inhibitor to demonstrate that
ROCK inhibition mitigated the worsened barrier integrity seen in TNAPi-treated hCMEC/D3 cells
or VE-cKO pBMECs [16]. These results elucidated a novel mechanism through which TNAP is
able to maintain barrier integrity in brain endothelial cells (Fig. 2A-C), and demonstrates why
drugs like fasudil have shown some therapeutic efficacy in preclinical models of stroke [55-57].
For example, Fukuta et al. showed that co-administration of fasudil liposomes and tissue
plasminogen activator (t-PA) significantly decreased brain endothelial damage and improved
motor scores [56]. However, there is a paucity of data on the utility of fasudil to improve sepsis
associated mortality and neurological impairment. Pilot data from our laboratory suggest that
fasudil treatment alone for 6 days following sepsis initiation decreased microglia activation
(amoeboid morphology; see arrows) and astrocyte proliferation in the dentate gyrus of the
hippocampus in mice (Fig. 2D). Future studies will address whether fasudil alone or combined
treatment of fasudil and AP-based drugs is able to improve survival, BBB dysfunction, and
neurological impairment post-sepsis.

III. Deciphering the role of BMEC TNAP at the neurovascular unit in vivo
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A. A Potential role for TNAP in the regulation of BBB permeability
In Chapter 4, we sought to elucidate the role of BMEC TNAP in vivo given that our in
vitro and ex vivo data shown in Chapter 3 supported a role for BMEC in maintaining paracellular
integrity. Furthermore, the data in Chapter 4 expanded on the limitations of the study conducted
in Chapter 3. We showed that naïve VE-cKO mice demonstrated a whole brain size selective
permeability to small molecules (~ 380 Da). Interestingly, we did not observe any differences in
spatial permeability between naïve VE-cKO and Alplfl/fl mice. Three plausible explanation may
be responsible for this finding: 1) The tissues collected for quantification were not sufficient
enough to observe the size selective permeability we saw in the whole brain permeability study
2) The dyes used were sensitive to the tissue processing procedure and 3) The imaging
modality was not sensitive enough to detect the size selective permeability in tissue sections. To
address this issues, ongoing studies will utilize multiphoton live animal imaging to elucidate
spatial permeability in naïve VE-cKO mice. Alpl (TNAP protein) has been shown in a recent
study to regulate caveolin mediated transcytosis (transcellular transport) [17]. Future studies
utilizing electron microscopy, Mfsd2a (a marker for transcytosis [58]) immunohistochemistry,
and albumin permeability assays will address the role of BMEC TNAP in regulating transcellular
barrier integrity.
Next, we explored whether the size selective permeability seen in naïve VE-cKO mice
was worsened in sepsis. Our data demonstrated that VE-cKO mice were more susceptible to
significant BBB dysfunction 24 h post-sepsis compared to Alplfl/fl septic mice. Despite this
intriguing finding, we had expected that VE-cKO mice should have exhibited a remarkable loss
of barrier integrity in normal physiology and sepsis, given the data derived from Chapters 2 and
3. Upon examining the literature, we found that other cell types that comprise the BBB such as
astrocyte end-feet processes and pericytes also expressed TNAP activity [59-61]. Furthermore,
co-culture of BMECs with mixed glial cells in vitro has been shown to drastically increase TNAP
protein, activity, and mRNA expression in BMECs compared to solo-cultures [50, 62, 63]. In
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another study, Tio et al. used conditioned medium to demonstrate that secreted products from
astrocytes were capable of inducing an increase in TNAP activity expression in endothelial cells
[64]. Owing to the finding from these studies, we examined whether naïve VE-cKO mice still
expressed TNAP activity in cerebral microvessels. We demonstrated in Chapter 3 that pBMEC
cultures from VE-cKO mice did not show any TNAP activity compared to controls. Therefore, if
TNAP activity remained present in cerebral microvessels of VE-cKO mice, it is likely that this
activity originates from other BBB cell types such as astrocytes and pericytes. We showed here
that indeed TNAP activity was still present in cerebral microvessels of VE-cKO mice (Fig. 3A).
More importantly, cerebral microvascular TNAP activity colocalized with aquaporin-4 (AQP4), a
marker for astrocyte end-feet processes (Fig. 3B) [65]. Therefore, it is plausible that the
continued presence of TNAP activity in cerebral microvessels may be responsible for the small
size selective BBB permeability seen in naïve VE-cKO mice. This suggestion is supported by
the Deracinois et al. study which showed that BCECs co-cultured with mixed glial cells did not
exhibit increase permeability to PeLY (> 380 Da) following levamisole (pan-AP inhibitor)
treatment [50]. Consequently, future studies will need to address the contributions of these cells
with widely available astrocyte and pericyte Cre-driver mouse (Aldh1l1-Cre/ERT2 and PDGFRβP2A-CreERT2 respectively) [66, 67]. Furthermore, we demonstrated in Chapter 4 that the
magnitude of BBB dysfunction in VE-cKO mice may become apparent in severe disease
conditions such as stroke. In summary, these studies support a role for TNAP in maintaining
BBB integrity in disease.

B. Emerging roles for brain microvascular TNAP in aging, Alzheimer’s disease, and Alzheimer’s
disease related dementia’s (ADRD)
Aging increases susceptibility of brain endothelial cells to injury or toxins [68]. Preclinical
studies utilizing plasma substitution therapies from aged mice into young mice have been able
to show the significant effects of aging on brain endothelial cell function and zonation [69, 70].
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The role for BMEC TNAP in aging is poorly understood, however, recent data suggest that brain
microvascular TNAP protein (i.e., Alpl) expression is decreased in the hippocampus of aged
mice (20 months old) compared to young mice (3 months) [70]. Given the observation of
increased TNAP protein expression with aging, we examined whether brain microvascular
TNAP activity also increased with aging. As shown in Figure 4A, TNAP activity increased in
cerebral microvessels of the cortex, striatum, and hippocampus (CA3 shown) in 14-month-old
mice (middle aged) compared to 4-month-old mice (young mice). These results suggest a
dichotomy in brain microvascular TNAP function whereby following injury TNAP activity is
diminished while in aging TNAP activity increases in cerebral microvessels. The implications of
the increased brain microvascular TNAP protein expression were further explored in a new
report which showed that inhibition of brain microvascular TNAP in aged mice enhanced
transcytosis of plasma proteins into the brain parenchyma [17]. To our knowledge, these are the
only studies that have investigated a role of brain microvascular TNAP in aging. Notably, a
recent transcriptome study demonstrating that each vessel segment (i.e., arteries, capillaries,
and venules) age differently emphasizes the need to consider differential functions of the
vascular tree when studying BMEC TNAP function [70]. Likewise, the role of sex-specific BMEC
TNAP function in aging remains to be elucidated.
Aging is a risk factor for dementia and AD. However, no studies have examined the role
of BMEC TNAP or cerebral microvascular TNAP in AD pathogenesis and progression. We
present here for the first time preliminary evidence suggesting that brain microvascular TNAP is
decreased in a model of AD (APPSwDI/Nos2-/- or CVN-AD [71]) compared to wild-type mice
(Figure 4B). This finding contrast neuronal TNAP studies which demonstrated that neuronal
TNAP exacerbates tau toxicity in AD through its dephosphorylation mechanism [72]. We had
previously shown that 8-month-old female CVN-AD mice displayed AD associated
neuropathology which coupled sleep, metabolic, and sensorimotor dysfunction [73]. Female
mice were used due to a higher prevalence of AD in females than males [74]. In an unpublished
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study, we examined whether sepsis would exacerbate AD progression in 8-month-old CVN-AD
female mice. Our results showed that sepsis worsened memory retention on the radial arm
water maze (RAWM). Interestingly, memory loss in AD septic mice coupled to IgG infiltration
and loss of cerebral microvascular TNAP activity (Figure 4C). These findings suggest a role for
TNAP in AD pathogenesis. Future studies are needed to assess the role of cerebral
microvascular TNAP in AD pathogenesis and progression. Experimental paradigms that involve
chronic treatment of AD animals with TNAPi prior to the development of AD neuropathology
would help bridge this knowledge gap. Given the preliminary data discussed here, we speculate
that AD animals treated with TNAPi would demonstrate worsened AD neuropathology and
cognitive outcomes. Data from this dissertation as described in Chapter 3 supports the use of
fasudil alone or combined treatment of fasudil and AP-based drugs as a therapy for AD. This
suggestion is corroborated by a recent study showing that AD mice treated with fasudil exhibited
decreased neuroinflammation (activation of microglia and astrocytes) and improved memory
and learning [75].

IV. Restoring AP activity as therapy to treat neuroinflammatory diseases
To date, there are few pharmaceuticals available for exogenous treatment to restore AP
activity. However, some AP-based therapeutic agents have been investigated in both preclinical
and clinical studies. Recombinant human TNAP (rhTNAP) purified from rabbit transgenic milk
samples and administered to LPS-infected mice resulted in increased survival [76]. Clinical trials
using bovine intestinal AP (bIAP) have shown functional improvement in patients with sepsis
and ulcerative colitis [77-80]. However, due to bIAP side effects, a human recombinant AP
(recAP), which encompasses the stability afforded from placental AP and catalytic viability of
IAP, was created and has been promising in preclinical trials for treatment of sepsis-induced
acute kidney injury (sepsis-AKI) [81, 82]. One drawback is that recAP administration did not
affect pulmonary inflammation or endothelial and epithelial dysfunction in rats [83], and it failed
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to improve short-term kidney function in patients with sepsis-associated acute kidney injury [84].
This compound is currently in a Phase III clinical trials that has enrolled patients in European
and North American hospitals. The data in this dissertation provide preclinical evidence to
support the use of rhTNAP or recAP to treat sepsis and stroke patients. Future studies will need
to assess whether rhTNAP or recAP are able to mitigate BBB dysfunction and long-term
cognitive impairment seen in sepsis survivors.

V. A plausible role for the hypothalamic-pituitary-adrenal axis (HPA) in regulating
endothelial TNAP activity
A. The HPA axis
The HPA axis collectively comprises the organs and secretions whose activation results
in the release of corticosteroid (CORT) hormones from the adrenal glands. Physiological actions
of CORT are primarily regulatory and are involved in the establishment and maintenance of
homeostasis. At the cellular level, corticosteroids interact with two types of steroid hormone
receptors: mineralocorticoid receptors (MR), which bind CORT and aldosterone (ALD), and
glucocorticoid receptors (GR), which bind CORT [85, 86]. MR has a 10-fold higher affinity for
CORT than GR resulting in high receptor occupation at normally low circulating levels of
hormone [87]. GR occupancy increases as a result of elevated levels of hormone during stress,
and the peaks of fluctuating hormone levels linked to circadian or ultradian rhythms [88]. This
occupancy profile suggests the majority of corticosteroid-regulated effects are mediated through
GR. CORT modulates a number of systems and processes such as immunity, inflammation,
metabolism, and energy balance in a variety of cell types [89]. Importantly, CORT has been
shown to regulate the stability of the BBB [90]. In the brain, MR expression is restricted to the
neurons of limbic brain regions including the hippocampus, lateral septum, amygdala, and
prefrontal cortex [91]. GR expression is more ubiquitous among cells in all tissue types, and
especially in neurons, endothelial cells, and glia of the brain [92].
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B. Glucocorticoid regulation of the BBB in health and systemic inflammation
Glucocorticoids (GCs) are a class of CORT with strong anti-inflammatory properties [93].
Experimental studies have shown an upregulation of TJ proteins, increased electrical
resistance, and reduction in vascular permeability following treatment with synthetic GCs [9496]. GC treatment in pathology and physiological conditions has been shown to reduce
leukocyte infiltration, enhance transendothelial electrical resistance (TEER), and increase the
expression of efflux transporters [97-99]. Administration of GC inhibits the translocation of brain
endothelial pro-inflammatory signals like NF-kβ and reduces the binding of GATA and AP-1 to
DNA elements [100]. The summative effect of blocking NF-kβ endothelial translocation and
other pro-inflammatory signals via GC treatment is a reduction in several inflammatory cytokines
and chemokines (IL-6, CXCL8, CCL2, etc.), decreased immune cell trafficking across the BBB,
increased MMP inhibitors (TIMP-1, TIMP-3, etc.), and downregulation of endothelial integrins
(ICAM-1, VCAM-1, etc.) [101-105].
The TJ protein, occludin, is important to the electrical resistance of the junction and
contributes to the formation of aqueous pores within the junction [106]. Occludin transcription is
positively regulated by glucocorticoid response elements (GREs) [107]. Claudin is another TJ
protein regulated by GCs. The claudin family consists of at least 24 conserved proteins, several
of which play a role in maintenance of the BBB, including claudin-1, -3, -5, and -12 [108-110].
The 5’ promoter region of claudin-5 has been shown to contain several putative GREs that
confer increased claudin-5 transcription following GC treatment [111, 112].
GCs also have direct effects on enzymes localized to the endothelium such as TNAP.
Adams and Melnykovych showed that bovine aortic endothelial cells treated with
dexamethasone demonstrated an elevated increase in TNAP activity [113]. Despite these
intriguing results, it is unclear till date whether these findings extrapolate to BMECs. We
speculate that the BMECs treated with dexamethasone would demonstrate an increase in
TNAP activity that is coupled to an increase in barrier impedance (integrity). This speculation is
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not unwarranted since several studies have shown that dexamethasone improved barrier
integrity in several models [114].
More importantly, other molecules such as retinol, cyclic AMP (cAMP), transforming
growth factor-beta (TGF-β), interleukin-6 (IL-6), and basic fibroblast growth factor (bFGF) are
known to modulate TNAP activity [13]. While retinol, cyclic cAMP, IL-6, and bFGF have been
shown in previous studies to increase TNAP activity [113, 115-117], TGF-β has been shown to
suppress TNAP activity in brain ECs [117]. The mechanisms through which GCs and the
aforementioned molecules modulate TNAP activity remain to be elucidated. Likewise, it remains
unclear how the presence of TNAP activity on BMECs influences targeted downstream
pathways associated with these molecules.

VI. Concluding remarks
The results discussed in this dissertation demonstrate a novel role for TNAP in
maintaining BBB integrity and adds to the only existing scientific literature which had previously
examined TNAP’s role in maintaining barrier function [13]. Furthermore, the contributions from
our study highlight the emerging importance of TNAP in other neuroinflammatory and
neurodegenerative diseases. Most importantly, our study lends support for TNAP as a
therapeutic target to mitigate the long-term cognitive impairment symptoms seen in septic,
stroke and AD patients via the maintenance of BBB integrity. Conversely, TNAP activity could
be manipulated to allow pharmacological therapies to penetrate the brain and target cancerous
cells. Nevertheless, we must stress that much research is needed to fully elucidate additional
mechanisms and signaling pathways through which TNAP is able to maintain barrier integrity.
Additional studies are also needed to understand how other TNAP expressing cell types
communicate with brain endothelial cells to preserve BBB integrity in the face of injury.
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Figure Legends
Figure 1: Schema for TNAP’s role at the BBB during acute systemic inflammation. (A)
Under physiologic conditions, the BMEC is enriched with TNAP activity (shown in purple), and
this activity is required to maintain precise cerebral homeostasis. (B) Key brain regions (cortex
depicted) become susceptible to loss of TNAP activity (i.e., purple stain) in septic compared to
sham mice. The loss of TNAP activity on CD31+ (brown) cerebral microvessels is sustained up
to 7 days post-sepsis. (C) Following a loss of TNAP activity in BMECs, junctional protein
disruption occurs and promotes the infiltration of peripheral pro-inflammatory cytokines and
leukocytes into the brain parenchyma. Infiltrating cytokines increase the number of activated
microglia and reactive astrocytes. Activated microglia and reactive astrocytes contribute to a
state of sustained neuroinflammation which promotes long-term cognitive impairment,
sensorimotor dysfunction, and increased mortality and morbidity. BMECs: brain microvascular
endothelial cells; TNAP: tissue-nonspecific alkaline phosphatase; BBB: blood-brain barrier.
Images were taken at 10X magnification, scale bar = 100 µm. Image credit: Biorender
Figure 2: ROCK proteins in BMEC TNAP function and fasudil utility as therapeutic for
sepsis. (A) In health, BMECs are enriched with TNAP activity. We propose that abundant
BMEC TNAP activity decreases ROCK (1/2) protein expression, which maintains the endothelial
cytoskeleton by ensuring that brain endothelial cells are in a relaxed state. (B) However, during
inflammation, BMEC TNAP activity decreases substantially, and this decrease promotes
increased ROCK (1/2) protein expression. Increased ROCK (1/2) protein expression leads to
BMEC cytoskeletal contraction and ultimately alters paracellular barrier integrity. Disruption of
the BMEC paracellular barrier allows for the infiltration of cytokines and immune cells into the
brain parenchyma. (C) Therapeutic injection of fasudil (ROCK inhibitor) during inflammation
decreases ROCK (1/2) protein expression, thereby allowing for a maintenance of paracellular
barrier integrity despite the loss of BMEC TNAP activity. (D) Mice were injected with fasudil or
vehicle for 6 days post-sepsis. On day 8, mice were euthanized and brains collected for
assessment of neuroinflammation using Iba-1 (microglia marker) and GFAP (astrocyte marker).
Microglia activation (amoeboid morphology; see arrows) is increased in the dentate gyrus of
septic mice treated with vehicle (sep + veh) compared to septic mice treated with fasudil (sep +
fas) or sham mice. Astrocyte proliferation is also increased in the dentate gyrus of septic mice
treated with vehicle compared to septic mice treated with fasudil or sham mice. BMEC: Brain
microvascular endothelial cells; TNAP: tissue-nonspecific alkaline phosphatase; ROCK: rhoassociated protein kinase; Iba-1: ionized calcium binding adaptor molecule 1; GFAP: glial
fibrillary acidic protein. Images were taken at 40X magnification, scale bar = 75 µm. Image
credit: Biorender
Figure 3: Astrocyte end-feet and cerebral microvascular TNAP activity colocalization. (A)
Despite a knockout of BMEC TNAP in cerebral microvessels, TNAP activity is still present in
naïve VE-cKO mice. Scale bar = 75 µm (B) Bright field image and 3D reconstruction showed
that astrocyte end-feet processes visualized with AQP4 (green; 3D resconstruction) colocalized
(cyan; 3D reconstruction) with TNAP activity in cerebral microvessels (purple). Scale bar = 25
µm. TNAP: Tissue-nonspecific alkaline phosphatase; 3D: 3-dimension.
Figure 5: Brain microvascular TNAP activity in aging and in a mouse model of AD. (A)
The striatum (p = 0.004) and hippocampal CA3 (p = 0.02) regions revealed a significant
increase in brain microvascular TNAP activity in aged male mice (14 months old) compared to
young male mice (4 months old). The cortex also revealed an increase in TNAP activity in aged
mice, however, this increase was not statistically significant (p = 0.20). Images taken at 20X
magnification and scale bar = 100 µm. (B) Preliminary data from male CVN-AD mice showed a
175

decrease in cerebral microvascular TNAP activity in the cortex and striatum compared to WT
(C57BL/6J) mice. (C) Female AD sepsis mice exhibited loss of memory in the RAWM retention
test (D) Female AD sepsis mice also exhibited increased microvascular infiltration of IgG which
was coupled to a loss of brain microvascular TNAP activity. Images taken at 20X magnification
and scale bar = 75 µm. TNAP: Tissue-nonspecific alkaline phosphatase; AD: Alzheimer’s
disease; WT: Wild-type; and RAWM: radial-arm water maze. * indicates p < 0.05 and **p < 0.01.
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